A	O	O
further	O	O
major	O	O
contribution	O	O
to	O	O
improving	O	O
K	O	O
(	O	O
i	O	O
)	O	O
values	O	O
and	O	O
inhibition	O	O
strength	O	O
was	O	O
the	O	O
hydrophobic	O	O
natures	O	O
and	O	O
structures	O	O
of	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
substituents	B-MODIFIER	B-MODIFIER
.	O	O
Compared	O	O
with	O	O
their	O	O
non	O	O
-	O	O
fluorinated	O	O
parent	O	O
compounds	O	O
,	O	O
the	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
were	O	O
all	O	O
approximately	O	O
2	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
as	O	O
TS	O	O
inhibitors	O	O
.	O	O
A	O	O
new	O	O
series	O	O
of	O	O
thyrotropin	O	O
-	O	O
releasing	O	O
hormone	O	O
(	O	O
TRH	O	O
)	O	O
analogues	O	B-MODIFIER
,	O	O
obtained	O	O
by	O	O
further	O	O
modifications	O	O
of	O	O
our	O	O
most	O	O
potent	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
stimulating	O	O
neutral	O	O
tripeptides	O	O
at	O	O
both	O	O
termini	O	O
,	O	O
were	O	O
synthesized	O	O
by	O	O
the	O	O
pentafluorophenyl	O	O
ester	O	O
method	O	O
and	O	O
tested	O	O
for	O	O
CNS	O	O
and	O	O
thyrotropin	O	O
(	O	O
TSH	O	O
)	O	O
releasing	O	O
activity	O	O
.	O	O
When	O	O
the	O	O
4'	O	O
-	O	O
F	O	O
groups	O	O
of	O	O
compounds	O	O
5	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
2.94	O	O
nM	O	O
)	O	O
and	O	O
8	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
6.87	O	O
nM	O	O
)	O	O
were	O	O
replaced	O	O
with	O	O
4'	O	O
-	O	O
Cl	O	O
in	O	O
the	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboalkoxy	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
,	O	O
DAT	O	O
binding	O	O
affinities	O	O
were	O	O
slightly	O	O
reduced	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
12.6	O	O
and	O	O
14.6	O	O
nM	O	O
for	O	O
6	O	O
and	O	O
7	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
yet	O	O
inhibition	O	O
of	O	O
dopamine	O	O
uptake	O	O
potency	O	O
remained	O	O
comparably	O	O
high	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
range	O	O
=	O	O
1.5-2.5	O	O
nM	O	O
)	O	O
.	O	O
(	O	O
S	O	O
)	O	O
-	O	O
11b	O	O
was	O	O
evaluated	O	O
as	O	O
an	O	O
enzyme	O	O
-	O	O
activated	O	O
irreversible	O	O
inhibitor	O	O
of	O	O
murine	O	O
liver	O	O
AADC	O	O
and	O	O
determined	O	O
to	O	O
have	O	O
a	O	O
KI	O	O
of	O	O
24.3	O	O
+	O	O
/	O	O
-	O	O
3.01	O	O
microM	O	O
and	O	O
a	O	O
k2	O	O
of	O	O
2.26	O	O
+	O	O
/	O	O
-	O	O
0.44	O	O
min	O	O
-	O	O
1	O	O
.	O	O
In	O	O
order	O	O
to	O	O
study	O	O
the	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
of	O	O
L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxathiolanyl	I-IUPAC	I-IUPAC
nucleosides	B-MODIFIER	B-MODIFIER
as	O	O
potential	O	O
anti	O	O
-	O	O
HIV	O	O
agents	O	O
,	O	O
a	O	O
series	O	O
of	O	O
enantiomerically	O	O
pure	O	O
L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxathiolanyl	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
and	O	O
purine	O	O
nucleosides	O	O
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
anti	O	O
-	O	O
HIV	O	O
-	O	O
1	O	O
activity	O	O
in	O	O
human	O	O
peripheral	O	O
blood	O	O
mononuclear	O	O
(	O	O
PBM	O	O
)	O	O
cells	O	O
.	O	O
Minimum	O	O
-	O	O
energy	O	O
conformations	O	O
of	O	O
pirenzepine	O	O
and	O	O
II	O	O
were	O	O
calculated	O	O
by	O	O
using	O	O
the	O	O
program	O	O
MacroModel	O	O
(	O	O
version	O	O
2.0	O	O
)	O	O
.	O	O
Isolated	O	O
[	O	O
D	O	O
-	O	O
Trp	O	O
(	O	O
Boc	O	O
)	O	O
4	O	O
,	O	O
Lys	O	O
(	O	O
Boc	O	O
)	O	O
5	O	O
,	O	O
Thr	O	O
(	O	O
tBu	O	O
)	O	O
6	O	O
]	O	O
octreotide	O	O
had	O	O
the	O	O
correct	O	O
molecular	O	O
mass	O	O
(	O	O
[	O	O
M+	O	O
H	O	O
]	O	O
+	O	O
=	O	O
1275	O	O
Da	O	O
)	O	O
and	O	O
sequence	O	O
and	O	O
was	O	O
obtained	O	O
in	O	O
14%	O	O
yield	O	O
at	O	O
&	O	O
gt	O	O
;	O	O
98%	O	O
purity	O	O
.	O	O
Selected	O	O
compounds	O	O
were	O	O
additionally	O	O
investigated	O	O
in	O	O
binding	O	O
assays	O	O
at	O	O
recombinant	O	O
A	O	O
(	O	O
3	O	O
)	O	O
ARs	O	O
.	O	O
Compound	O	O
10	O	O
provided	O	O
approximately	O	O
50%	O	O
protection	O	O
against	O	O
HIV	O	O
at	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
M	O	O
concentrations	O	O
.	O	O
Several	O	O
compounds	O	O
protected	O	O
mice	O	O
from	O	O
lethal	O	O
intraperitoneal	O	O
(	O	O
ip	O	O
)	O	O
infections	O	O
with	O	O
S	O	O
.	O	O
[	O	O
18F	O	O
]	O	O
FCWAY	O	O
(	O	O
[	O	O
18F	O	O
]	O	O
4d	O	O
)	O	O
gave	O	O
half	O	O
-	O	O
lives	O	O
and	O	O
intercepts	O	O
comparable	O	O
to	O	O
[	O	O
carbonyl	O	O
-	O	O
11C	O	O
]	O	O
4a	O	O
in	O	O
the	O	O
brain	O	O
,	O	O
but	O	O
the	O	O
blood	O	O
clearance	O	O
was	O	O
faster	O	O
.	O	O
In	O	O
addition	O	O
to	O	O
being	O	O
excreted	O	O
in	O	O
urine	O	O
unchanged	O	O
,	O	O
tolazamide	O	O
was	O	O
metabolized	O	O
to	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hexahydroazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carboxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfonylurea	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
toluenesulfonamide	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hexahydroazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfonylurea	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyhexahydroazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tolylsulfonylurea	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
and	O	O
a	O	O
labile	O	O
,	O	O
unidentified	O	O
metabolite	O	O
6	O	O
by	O	O
man	O	O
.	O	O
Methyl	O	B-IUPAC
5	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyribofuranose	I-IUPAC	I-IUPAC
was	O	O
oxidized	O	O
and	O	O
the	O	O
mixture	O	O
of	O	O
the	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
keto	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
was	O	O
separated	O	O
into	O	O
the	O	O
alpha	O	O
-	O	O
and	O	O
beta	O	O
-	O	O
anomers	O	O
.	O	O
B	O	O
.	O	O
The	O	O
Pu	O	O
complexes	O	O
of	O	O
the	O	O
CAM	O	O
-	O	O
HOPO	O	O
ligands	O	O
are	O	O
to	O	O
some	O	O
degree	O	O
unstable	O	O
at	O	O
pH	O	O
&	O	O
lt	O	O
;	O	O
7.4	O	O
,	O	O
as	O	O
judged	O	O
by	O	O
Pu	O	O
residues	O	O
in	O	O
kidneys	O	O
in	O	O
excess	O	O
of	O	O
24	O	O
-	O	O
h	O	O
Pu	O	O
-	O	O
injected	O	O
controls	O	O
.	O	O
By	O	O
contrast	O	O
,	O	O
alpha	O	O
-	O	O
chymotrypsin	O	O
inactivated	O	O
with	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Phe	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
epoxypropyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
then	O	O
subjected	O	O
to	O	O
amino	O	O
acid	O	O
analysis	O	O
showed	O	O
no	O	O
change	O	O
in	O	O
the	O	O
content	O	O
of	O	O
any	O	O
amino	O	O
acid	O	O
that	O	O
would	O	O
serve	O	O
as	O	O
a	O	O
potential	O	O
nucleophile	O	O
to	O	O
the	O	O
inhibitor	O	O
.	O	O
The	O	O
enantiomers	O	O
of	O	O
9	O	O
were	O	O
prepared	O	O
analogously	O	O
from	O	O
the	O	O
secondary	O	O
amine	O	O
27	O	O
.	O	O
The	O	O
GAELs	O	O
differ	O	O
from	O	O
1	O	O
in	O	O
having	O	O
the	O	O
sn	B-IUPAC	O
-	I-IUPAC	O
3	I-IUPAC	O
-	I-IUPAC	O
phosphocholine	I-IUPAC	O
residue	O	O
replaced	O	O
by	O	O
one	O	O
of	O	O
the	O	O
following	O	O
monosaccharide	O	O
residues	O	O
:	O	O
beta	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arabino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexopyranosyl	I-IUPAC	I-IUPAC
,	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mannopyranosyl	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glucopyranosyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mannopyranosyl	I-IUPAC	I-IUPAC
.	O	O
Selective	O	O
cleavage	O	O
of	O	O
the	O	O
Cbz	O	O
group	O	O
by	O	O
H2	O	O
/	O	O
Pd	O	O
gave	O	O
the	O	O
key	O	O
intermediate	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminopropionate	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
,	O	O
which	O	O
was	O	O
acylated	O	O
,	O	O
via	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxysuccinimide	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
,	O	O
with	O	O
bromoacetic	B-IUPAC	O
acid	I-IUPAC	O
,	O	O
dichloroacetic	O	O
acid	O	O
,	O	O
and	O	O
fumaric	B-IUPAC	O
acid	I-IUPAC	O
monoethyl	I-IUPAC	O
ester	I-IUPAC	O
to	O	O
give	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromoacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionate	I-IUPAC	I-IUPAC
(	O	O
6a	O	O
)	O	O
,	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichloroacetamido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionate	I-IUPAC	I-IUPAC
(	O	O
6b	O	O
)	O	O
,	O	O
and	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acrylamido	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propionate	I-IUPAC	I-IUPAC
(	O	O
6c	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
Conformational	O	O
factors	O	O
appear	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
inability	O	O
of	O	O
the	O	O
trans	O	B-IUPAC
-	O	I-IUPAC
C1	O	I-IUPAC
-	O	I-IUPAC
methyl	O	I-IUPAC
-	O	O
substituted	O	B-MODIFIER
derivative	O	B-MODIFIER
of	O	O
1	O	O
to	O	O
activate	O	O
5	O	O
-	O	O
HT	O	O
receptors	O	O
.	O	O
The	O	O
analogues	O	O
I	O	O
-	O	O
V	O	O
caused	O	O
an	O	O
initial	O	O
rise	O	O
in	O	O
blood	O	O
pressure	O	O
(	O	O
30	O	O
min	O	O
of	O	O
infusion	O	O
,	O	O
250	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
in	O	O
vagotomized	O	O
ganglion	O	O
-	O	O
blocked	O	O
rats	O	O
)	O	O
of	O	O
8.05	O	O
,	O	O
11.7	O	O
,	O	O
3.50	O	O
,	O	O
4.5	O	O
,	O	O
and	O	O
11.16	O	O
mmHg	O	O
.	O	O
Xanthine	O	O
derivatives	O	O
with	O	O
several	O	O
functional	O	O
groups	O	O
at	O	O
the	O	O
1	O	O
-	O	O
or	O	O
7	O	O
-	O	O
position	O	O
were	O	O
synthesized	O	O
,	O	O
and	O	O
their	O	O
pharmacological	O	O
activities	O	O
in	O	O
guinea	O	O
pigs	O	O
were	O	O
studied	O	O
.	O	O
MD	O	O
simulations	O	O
revealed	O	O
that	O	O
several	O	O
mutations	O	O
,	O	O
including	O	O
Pro11	O	O
-	O	O
-	O	O
&	O	O
gt	O	O
;	O	O
Gly	O	O
,	O	O
Leu21	O	O
-	O	O
-	O	O
&	O	O
gt	O	O
;	O	O
Gly	O	O
,	O	O
Leu24	O	O
-	O	O
-	O	O
&	O	O
gt	O	O
;	O	O
Gly	O	O
,	O	O
and	O	O
Gln27	O	O
-	O	O
-	O	O
&	O	O
gt	O	O
;	O	O
Gly	O	O
,	O	O
cause	O	O
a	O	O
rather	O	O
large	O	O
conformational	O	O
alteration	O	O
to	O	O
the	O	O
PKC	O	O
binding	O	O
site	O	O
and	O	O
,	O	O
in	O	O
some	O	O
cases	O	O
,	O	O
to	O	O
the	O	O
overall	O	O
structure	O	O
of	O	O
the	O	O
protein	O	O
.	O	O
Compounds	O	O
3	O	O
and	O	O
4	O	O
were	O	O
likewise	O	O
found	O	O
to	O	O
be	O	O
inactive	O	O
and	O	O
only	O	O
marginal	O	O
activity	O	O
was	O	O
exhibited	O	O
by	O	O
5	O	O
.	O	O
A	O	O
is	O	O
our	O	O
previously	O	O
reported	O	O
potent	O	O
and	O	O
selective	O	O
antagonist	O	O
of	O	O
the	O	O
vasopressor	O	O
(	O	O
V1	O	O
receptor	O	O
)	O	O
responses	O	O
to	O	O
arginine	O	O
-	O	O
vasopressin	O	O
(	O	O
AVP	O	O
)	O	O
/	O	O
weak	O	O
oxytocin	O	O
antagonist	O	O
,	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercapto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentamethylenepropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyltyrosine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
arginine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
vasopressin	I-IUPAC	I-IUPAC
(	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
]	O	O
AVP	O	O
.	O	O
A	O	O
minor	O	O
product	O	O
formed	O	O
in	O	O
both	O	O
cases	O	O
was	O	O
a	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
in	O	O
which	O	O
the	O	O
nucleoside	O	O
5'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
had	O	O
been	O	O
replaced	O	O
by	O	O
chlorine	O	O
(	O	O
6	O	O
and	O	O
8	O	O
)	O	O
.	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Methyl	I-IUPAC	I-IUPAC
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
substitution	B-MODIFIER	B-MODIFIER
was	O	O
also	O	O
favorable	O	O
,	O	O
with	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
being	O	O
2	O	O
.	O	O
Among	O	O
the	O	O
latter	O	O
compounds	O	O
,	O	O
the	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkylamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	O	O
11a	O	O
)	O	O
showed	O	O
a	O	O
clear	O	O
selectivity	O	O
for	O	O
the	O	O
vascular	O	O
smooth	O	O
muscle	O	O
tissue	O	O
.	O	O
The	O	O
T	O	O
.	O	O
Variations	O	O
of	O	O
the	O	O
1	O	O
-	O	O
substituent	O	O
at	O	O
the	O	O
indole	O	O
and	O	O
of	O	O
the	O	O
chain	O	O
length	O	O
of	O	O
the	O	O
alkylene	O	O
spacer	O	O
group	O	O
were	O	O
studied	O	O
.	O	O
Cyclic	O	O
depsipeptide	O	O
cyclo	O	O
-	O	O
[	O	O
D	O	O
-	O	O
Hmp	O	O
(	O	O
1	O	O
)	O	O
-	O	O
L	O	O
-	O	O
MeVal	O	O
(	O	O
2	O	O
)	O	O
-	O	O
L	O	O
-	O	O
Phe	O	O
(	O	O
3	O	O
)	O	O
-	O	O
L	O	O
-	O	O
MePhe	O	O
(	O	O
4	O	O
)	O	O
-	O	O
L	O	O
-	O	O
Pro	O	O
(	O	O
5	O	O
)	O	O
-	O	O
L	O	O
-	O	O
aIle+	O	O
+	O	O
+	O	O
(	O	O
6	O	O
)	O	O
-	O	O
L	O	O
-	O	O
MeVal	O	O
(	O	O
7	O	O
)	O	O
-	O	O
L	O	O
-	O	O
Leu	O	O
(	O	O
8	O	O
)	O	O
-	O	O
L	O	O
-	O	O
betaHOMeVal	O	O
(	O	O
9	O	O
)	O	O
]	O	O
,	O	O
the	O	O
antifungal	O	O
antibiotic	O	O
aureobasidin	O	O
A	O	O
(	O	O
AbA	O	O
)	O	O
,	O	O
was	O	O
reported	O	O
to	O	O
interfere	O	O
with	O	O
ATP	O	O
-	O	O
binding	O	O
cassette	O	O
(	O	O
ABC	O	O
)	O	O
transporters	O	O
in	O	O
yeast	O	O
and	O	O
mammalian	O	O
cells	O	O
,	O	O
particularly	O	O
the	O	O
MDR1	O	O
P	O	O
-	O	O
glycoprotein	O	O
(	O	O
Pgp	O	O
)	O	O
,	O	O
a	O	O
transmembrane	O	O
phospholipid	O	O
flippase	O	O
or	O	O
"	O	O
hydrophobic	O	O
vacuum	O	O
cleaner	O	O
"	O	O
that	O	O
mediates	O	O
multidrug	O	O
resistance	O	O
(	O	O
MDR	O	O
)	O	O
of	O	O
cancer	O	O
cells	O	O
.	O	O
Alkylation	O	O
of	O	O
adenine	O	O
(	O	O
18	O	O
)	O	O
with	O	O
24	O	O
+	O	O
25	O	O
gave	O	O
(	O	B-PARTIUPAC
E	O	I-PARTIUPAC
)	O	I-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
(	O	B-IUPAC
Z	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
bromo	O	I-IUPAC
derivatives	O	B-MODIFIER
21	O	O
+	O	O
22	O	O
.	O	O
The	O	O
ethyl	O	O
esters	O	O
were	O	O
further	O	O
reacted	O	O
with	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
picolylamine	I-IUPAC	I-IUPAC
to	O	O
produce	O	O
corresponding	O	O
amides	O	O
.	O	O
Further	O	O
modifications	O	O
of	O	O
the	O	O
intermediate	O	O
led	O	O
to	O	O
the	O	O
syntheses	O	O
of	O	O
(	B-IUPAC	B-IUPAC
9R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
12,21	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
epoxyerythromycin	I-IUPAC	I-IUPAC
B	I-IUPAC	I-IUPAC
,	O	I-IUPAC
(	B-IUPAC	I-IUPAC
9R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
21	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyerythromycin	I-IUPAC	I-IUPAC
A	I-IUPAC	I-IUPAC
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
9R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
21	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyerythromycin	I-IUPAC	I-IUPAC
B	I-IUPAC	O
.	O	O
The	O	O
N	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
6	I-MODIFIER	I-MODIFIER
glycosylated	I-MODIFIER	I-MODIFIER
imidazo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isothiazoles	I-IUPAC	I-IUPAC
were	O	O
completely	O	O
inactive	O	O
up	O	O
to	O	O
the	O	O
highest	O	O
concentration	O	O
tested	O	O
.	O	O
Further	O	O
evaluation	O	O
of	O	O
the	O	O
mechanism	O	O
of	O	O
action	O	O
of	O	O
3	O	O
implicated	O	O
DHFR	O	O
as	O	O
its	O	O
primary	O	O
intracellular	O	O
target	O	O
.	O	O
Selected	O	O
derivatives	O	O
,	O	O
including	O	O
reversine	O	O
(	O	O
K	O	O
(	O	O
B	O	O
)	O	O
value	O	O
of	O	O
466	O	O
nM	O	O
via	O	O
Schild	O	O
analysis	O	O
)	O	O
,	O	O
competitively	O	O
antagonized	O	O
the	O	O
functional	O	O
effects	O	O
of	O	O
a	O	O
selective	O	O
A	O	O
(	O	O
3	O	O
)	O	O
AR	O	O
agonist	O	O
,	O	O
i.e.	O	O
,	O	O
inhibition	O	O
of	O	O
forskolin	O	O
-	O	O
stimulated	O	O
cAMP	O	O
production	O	O
in	O	O
stably	O	O
transfected	O	O
Chinese	O	O
hamster	O	O
ovary	O	O
(	O	O
CHO	O	O
)	O	O
cells	O	O
.	O	O
Nucleosides	O	O
5a	O	O
,	O	O
b	O	O
,	O	O
d	O	O
-	O	O
h	O	O
were	O	O
selectively	O	O
converted	O	O
to	O	O
the	O	O
corresponding	O	O
5'	O	B-IUPAC
-	O	I-IUPAC
monophosphates	O	I-IUPAC
6a	O	O
,	O	O
b	O	O
,	O	O
d	O	O
-	O	O
h	O	O
with	O	O
the	O	O
aid	O	O
of	O	O
the	O	O
wheat	O	O
shoot	O	O
phosphotransferase	O	O
system	O	O
.	O	O
Deprotection	O	O
with	O	O
hydrazine	O	O
or	O	O
by	O	O
alkaline	O	O
hydrolysis	O	O
gave	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
guanine	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
,	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminopurine	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
,	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoethoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethoxymethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
guanine	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
,	O	O
and	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
guanine	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
.	O	O
None	O	O
of	O	O
the	O	O
high	O	O
affinity	O	O
structures	O	O
described	O	O
here	O	O
showed	O	O
receptor	O	O
antagonism	O	O
.	O	O
The	O	O
substituted	O	O
estradiols	O	O
were	O	O
evaluated	O	O
for	O	O
estrogen	O	O
receptor	O	O
binding	O	O
activity	O	O
in	O	O
MCF	O	O
-	O	O
7	O	O
human	O	O
mammary	O	O
carcinoma	O	O
cells	O	O
,	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
estradiol	I-IUPAC	I-IUPAC
1	O	O
exhibited	O	O
the	O	O
highest	O	O
affinity	O	O
with	O	O
an	O	O
apparent	O	O
EC50	O	O
value	O	O
of	O	O
364	O	O
nM	O	O
.	O	O
Targets	O	O
14c	O	O
(	O	O
Z	O	O
-	O	O
isomer	O	O
)	O	O
and	O	O
15c	O	O
(	O	O
E	O	O
-	O	O
isomer	O	O
)	O	O
were	O	O
derived	O	O
,	O	O
in	O	O
turn	O	O
,	O	O
from	O	O
4,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanone	I-IUPAC	I-IUPAC
.	O	O
Particularly	O	O
,	O	O
the	O	O
bronchodilatory	O	O
effect	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethoxyethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylxanthine	I-IUPAC	I-IUPAC
was	O	O
much	O	O
stronger	O	O
and	O	O
more	O	O
continuous	O	O
than	O	O
those	O	O
of	O	O
theophylline	O	O
and	O	O
pentoxifylline	O	O
.	O	O
Although	O	O
their	O	O
in	O	O
vitro	O	O
antibacterial	O	O
activities	O	O
are	O	O
less	O	O
than	O	O
the	O	O
6,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
difluoro	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
,	O	O
the	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
quinolones	I-IUPAC	I-IUPAC
are	O	O
generally	O	O
equivalent	O	O
to	O	O
their	O	O
8H	O	O
analogues	O	O
.	O	O
These	O	O
compounds	O	O
were	O	O
prepared	O	O
by	O	O
modification	O	O
of	O	O
the	O	O
Corey	O	O
prostaglandin	O	O
synthesis	O	O
utilizing	O	O
as	O	O
a	O	O
key	O	O
step	O	O
condensation	O	O
of	O	O
known	O	O
hemiacetals	O	O
with	O	O
the	O	O
ylide	O	O
derived	O	O
from	O	O
the	O	O
requisite	O	O
substituted	O	O
phosphonium	O	O
salts	O	O
.	O	O
The	O	O
biological	O	O
properties	O	O
conferred	O	O
upon	O	O
norepinephrine	O	O
by	O	O
the	O	O
fluorine	O	O
substituents	O	O
in	O	O
peripheral	O	O
and	O	O
central	O	O
adrenergically	O	O
responsive	O	O
systems	O	O
clearly	O	O
demonstrate	O	O
that	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoronorepinephrine	I-IUPAC	I-IUPAC
is	O	O
a	O	O
nearly	O	O
a	O	O
pure	O	O
beta	O	O
-	O	O
adrenergic	O	O
agonist	O	O
,	O	O
while	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoronorepinephrine	I-IUPAC	I-IUPAC
is	O	O
an	O	O
alpha	O	O
-	O	O
adrenergic	O	O
agonist	O	O
.	O	O
Compounds	O	O
3	O	O
and	O	O
23	O	O
have	O	O
similar	O	O
affinities	O	O
to	O	O
5	O	O
-	O	O
HT1A	O	O
receptors	O	O
,	O	O
whereas	O	O
the	O	O
propyl	B-IUPAC	O
substituent	B-MODIFIER	O
of	O	O
2	O	O
not	O	O
only	O	O
enhances	O	O
the	O	O
selectivity	O	O
for	O	O
D2A	O	O
receptors	O	O
but	O	O
also	O	O
increases	O	O
the	O	O
D2A	O	O
affinity	O	O
.	O	O
Analogues	O	O
1	O	O
,	O	O
2	O	O
,	O	O
3	O	O
,	O	O
and	O	O
5	O	O
have	O	O
also	O	O
been	O	O
shown	O	O
to	O	O
antagonize	O	O
the	O	O
in	O	O
vivo	O	O
oxytocic	O	O
responses	O	O
to	O	O
oxytocin	O	O
.	O	O
alpha	O	O
-	O	O
Fluoromethyl	O	O
amino	O	O
acids	O	O
are	O	O
enzyme	O	O
-	O	O
activated	O	O
irreversible	O	O
inhibitors	O	O
of	O	O
amino	O	O
acid	O	O
decarboxylases	O	O
.	O	O
Our	O	O
investigation	O	O
of	O	O
the	O	O
permeability	O	O
-	O	O
enhancing	O	O
properties	O	O
of	O	O
the	O	O
AEL	O	O
molecules	O	O
imply	O	O
that	O	O
by	O	O
encapsulating	O	O
conventional	O	O
chemotherapeutic	O	O
drugs	O	O
,	O	O
such	O	O
as	O	O
doxorubicin	O	O
,	O	O
in	O	O
liposomes	O	O
consisting	O	O
of	O	O
proAELs	O	O
,	O	O
an	O	O
increased	O	O
effect	O	O
of	O	O
the	O	O
encapsulated	O	O
drug	O	O
might	O	O
be	O	O
achievable	O	O
due	O	O
to	O	O
an	O	O
enhanced	O	O
transmembrane	O	O
drug	O	O
diffusion	O	O
.	O	O
in	O	O
[	B-IUPAC	O
(	I-IUPAC	O
35	I-IUPAC	O
)	I-IUPAC	O
S	I-IUPAC	O
]	I-IUPAC	O
-	I-IUPAC	O
tert	I-IUPAC	O
-	I-IUPAC	O
butylbicyclophosphorothionate	I-IUPAC	O
binding	O	O
experiments	O	O
,	O	O
(	O	O
2	O	O
)	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
displayed	O	O
good	O	O
activity	O	O
against	O	O
intraperitoneally	O	O
implanted	O	O
P388	O	O
leukemia	O	O
in	O	O
mice	O	O
,	O	O
but	O	O
it	O	O
was	O	O
devoid	O	O
of	O	O
activity	O	O
against	O	O
M5076	O	O
sarcoma	O	O
,	O	O
amelanotic	O	O
(	O	O
LOX	O	O
)	O	O
melanoma	O	O
xenograft	O	O
,	O	O
and	O	O
subrenal	O	O
capsule	O	O
human	O	O
mammary	O	O
carcinoma	O	O
MX	O	O
-	O	O
1	O	O
xenograft	O	O
in	O	O
mice	O	O
.	O	O
We	O	O
prepared	O	O
six	O	O
pairs	O	O
of	O	O
alpha	B-IUPAC	O
-	I-IUPAC	O
heteroaromatic	I-IUPAC	O
aldoximes	I-IUPAC	O
,	O	O
RC	O	O
(	O	O
=	O	O
NOH	O	O
)	O	O
H	O	O
,	O	O
and	O	O
thiohydroximates	O	O
,	O	O
RC	O	O
(	O	O
=	O	O
NOH	O	O
)	O	O
S	O	O
-	O	O
(	O	O
CH2	O	O
)	O	O
2N	O	O
(	O	O
C2H5	O	O
)	O	O
2	O	O
,	O	O
where	O	O
R	O	O
represents	O	O
various	O	O
oxadiazole	O	O
and	O	O
thiadiazole	O	O
rings	O	O
.	O	O
N	O	O
-	O	O
Methylation	O	O
in	O	O
the	O	O
beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ionylideneacetamidobenzoate	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
(	O	O
10c	O	O
)	O	O
also	O	O
results	O	O
in	O	O
the	O	O
formation	O	O
of	O	O
a	O	O
cis	O	O
-	O	O
amide	O	O
bond	O	O
and	O	O
loss	O	O
of	O	O
activity	O	O
.	O	O
The	O	O
ring	O	O
size	O	O
,	O	O
bridgehead	O	O
amino	O	O
acid	O	O
chirality	O	O
,	O	O
and	O	O
side	O	O
-	O	O
chain	O	O
amide	O	O
bond	O	O
location	O	O
were	O	O
varied	O	O
in	O	O
this	O	O
partial	O	O
series	O	O
in	O	O
an	O	O
attempt	O	O
to	O	O
maximize	O	O
potency	O	O
.	O	O
Here	O	O
we	O	O
describe	O	O
the	O	O
synthesis	O	O
and	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
(	O	O
SAR	O	O
)	O	O
studies	O	O
of	O	O
two	O	O
new	O	O
series	O	O
of	O	O
LTB4	O	O
receptor	O	O
antagonists	O	O
in	O	O
which	O	O
the	O	O
phenyl	O	O
ring	O	O
of	O	O
this	O	O
receptor	O	O
binding	O	O
domain	O	O
is	O	O
replaced	O	O
with	O	O
indole	O	O
and	O	O
naphthalene	O	O
,	O	O
respectively	O	O
.	O	O
Two	O	O
9,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydrophenanthrenes	I-IUPAC	I-IUPAC
substituted	O	B-MODIFIER
with	O	O
quaternary	O	O
ammonium	O	O
salts	O	O
,	O	O
2d	O	O
and	O	O
3d	O	O
,	O	O
each	O	O
containing	O	O
a	O	O
reactive	O	O
benzylic	B-MODIFIER	O
dimethyl	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ammonio	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
,	O	O
were	O	O
found	O	O
to	O	O
be	O	O
10-20	O	O
times	O	O
more	O	O
potent	O	O
than	O	O
juncusol	O	O
(	O	O
1a	O	O
)	O	O
.	O	O
The	O	O
alkenylestradiols	O	O
were	O	O
obtained	O	O
via	O	O
a	O	O
Stille	O	O
cross	O	O
-	O	O
coupling	O	O
between	O	O
a	O	O
MOM	O	O
-	O	O
protected	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromoestradiol	I-IUPAC	I-IUPAC
and	O	O
an	O	O
alkenylstannane	O	O
.	O	O
In	O	O
a	O	O
previous	O	O
study	O	O
,	O	O
we	O	O
described	O	O
affinity	O	O
labeling	O	O
of	O	O
the	O	O
lamb	O	O
uterine	O	O
estrogen	O	O
receptor	O	O
by	O	O
17	B-IUPAC	B-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromoacetoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
alkynyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
estradiols	I-IUPAC	I-IUPAC
.	O	O
Compound	O	O
33	O	O
and	O	O
its	O	O
analogues	O	O
did	O	O
not	O	O
inhibit	O	O
AChE	O	O
.	O	O
Selective	O	O
N	O	O
-	O	O
acetylation	O	O
and	O	O
subsequent	O	O
Friedel	O	O
-	O	O
Crafts	O	O
acylation	O	O
with	O	O
phthalic	O	O
anhydride	O	O
produced	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azanaphthacene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
,	O	O
which	O	O
was	O	O
protected	O	O
as	O	O
its	O	O
dimethyl	O	O
ether	O	O
and	O	O
epoxidized	O	O
to	O	O
an	O	O
acylated	O	O
aza	O	O
Brigl	O	O
's	O	O
anhydride	O	O
.	O	O
Such	O	O
inhibitors	O	O
may	O	O
be	O	O
useful	O	O
in	O	O
elucidating	O	O
the	O	O
physiological	O	O
and	O	O
pathological	O	O
events	O	O
involving	O	O
these	O	O
proteases	O	O
and	O	O
may	O	O
become	O	O
possible	O	O
therapeutic	O	O
agents	O	O
.	O	O
Efforts	O	O
to	O	O
improve	O	O
the	O	O
potency	O	O
of	O	O
the	O	O
title	O	O
series	O	O
by	O	O
variation	O	O
of	O	O
the	O	O
amide	O	O
,	O	O
indole	O	O
,	O	O
or	O	O
sulfonamide	O	O
substituents	O	O
led	O	O
to	O	O
compounds	O	O
of	O	O
comparable	O	O
in	O	O
vitro	O	O
potency	O	O
to	O	O
ICI	O	O
204,219	O	O
,	O	O
but	O	O
of	O	O
somewhat	O	O
lower	O	O
oral	O	O
activity	O	O
.	O	O
Both	O	O
isomers	O	O
were	O	O
hydrolyzed	O	O
by	O	O
NTPDase	O	O
1	O	O
at	O	O
about	O	O
half	O	O
the	O	O
rate	O	O
of	O	O
ATP	O	O
hydrolysis	O	O
.	O	O
In	O	O
previous	O	O
studies	O	O
,	O	O
we	O	O
reported	O	O
that	O	O
certain	O	O
(	B-PARTIUPAC	O
1R	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
3	I-PARTIUPAC	O
beta	I-PARTIUPAC	O
-	I-PARTIUPAC	O
(	O	O
substituted	B-MODIFIER	B-MODIFIER
phenyl	B-IUPAC	B-IUPAC
)	O	I-IUPAC
nortropane	B-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
beta	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
carboxylic	I-PARTIUPAC	I-IUPAC
acid	I-PARTIUPAC	I-IUPAC
methyl	I-PARTIUPAC	I-IUPAC
esters	I-PARTIUPAC	I-IUPAC
(	O	O
2a	O	O
)	O	O
exhibited	O	O
high	O	O
affinity	O	O
and	O	O
reasonable	O	O
selectivity	O	O
for	O	O
the	O	O
serotonin	O	O
transporter	O	O
(	O	O
5	O	O
-	O	O
HTT	O	O
)	O	O
.	O	O
These	O	O
discrepancies	O	O
may	O	O
reflect	O	O
different	O	O
selectivities	O	O
among	O	O
delta	O	O
receptor	O	O
subtypes	O	O
for	O	O
the	O	O
analogues	O	O
or	O	O
may	O	O
represent	O	O
differing	O	O
efficacies	O	O
among	O	O
these	O	O
conformationally	O	O
restricted	O	O
peptides	O	O
.	O	O
The	O	O
configuration	O	O
at	O	O
the	O	O
C	O	O
-	O	O
5	O	O
and	O	O
C	O	O
-	O	O
6	O	O
positions	O	O
also	O	O
influenced	O	O
potency	O	O
where	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
5R	O	O
,	O	O
6R	O	O
-	O	O
diastereomer	O	O
was	O	O
generally	O	O
greater	O	O
than	O	O
that	O	O
of	O	O
the	O	O
corresponding	O	O
5S	O	O
,	O	O
6S	O	O
-	O	O
diastereomer	O	O
.	O	O
Interestingly	O	O
,	O	O
the	O	O
K	O	O
(	O	O
m	O	O
)	O	O
value	O	O
found	O	O
for	O	O
NOS	O	O
II	O	O
-	O	O
catalyzed	O	O
oxidation	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidine	I-IUPAC	I-IUPAC
was	O	O
25	O	O
microM	O	O
,	O	O
almost	O	O
identical	O	O
to	O	O
that	O	O
of	O	O
NOHA	O	O
.	O	O
This	O	O
paper	O	O
presents	O	O
the	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
leading	O	O
to	O	O
novel	O	O
tri	B-MODIFIER	O
-	I-MODIFIER	O
and	O	O
tetrasubstituted	B-MODIFIER	O
guanidines	B-IUPAC	O
,	O	O
which	O	O
exhibit	O	O
high	O	O
selectivity	O	O
for	O	O
NMDA	O	O
receptor	O	O
ion	O	O
channel	O	O
sites	O	O
and	O	O
weak	O	O
or	O	O
negligible	O	O
affinity	O	O
for	O	O
sigma	O	O
receptors	O	O
.	O	O
The	O	O
structures	O	O
of	O	O
the	O	O
new	O	O
analogues	O	O
are	O	O
as	O	O
follows	O	O
:	O	O
[	O	O
des	O	O
-	O	O
His1	O	O
,	O	O
des	O	O
-	O	O
Phe6	O	O
,	O	O
Glu9	O	O
]	O	O
glucagon	O	O
-	O	O
NH2	O	O
(	O	O
1	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
His1	O	O
,	O	O
Ala6	O	O
,	O	O
Glu9	O	O
]	O	O
glucagon	O	O
-	O	O
NH2	O	O
(	O	O
2	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
His1	O	O
,	O	O
Tyr6	O	O
,	O	O
Glu9	O	O
]	O	O
glucagon	O	O
-	O	O
NH2	O	O
(	O	O
3	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
His1	O	O
,	O	O
Trp6	O	O
,	O	O
Glu9	O	O
]	O	O
-	O	O
glucagon	O	O
-	O	O
NH2	O	O
(	O	O
4	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
His1	O	O
,	O	O
D	O	O
-	O	O
Phe6	O	O
,	O	O
Glu9	O	O
]	O	O
glucagon	O	O
-	O	O
NH2	O	O
(	O	O
5	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
His1	O	O
,	O	O
Nle6	O	O
,	O	O
Glu9	O	O
]	O	O
glucagon	O	O
-	O	O
NH2	O	O
(	O	O
6	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
His1	O	O
,	O	O
Asp6	O	O
,	O	O
Glu9	O	O
]	O	O
glucagon	O	O
-	O	O
NH2	O	O
(	O	O
7	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
His1	O	O
,	O	O
des	O	O
-	O	O
Gly4	O	O
,	O	O
Glu9	O	O
]	O	O
glucagon	O	O
-	O	O
NH2	O	O
(	O	O
8	O	O
)	O	O
;	O	O
[	O	O
desPhe6	O	O
,	O	O
-	O	O
Glu9	O	O
]	O	O
glucagon	O	O
-	O	O
NH2	O	O
(	O	O
9	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
Phe6	O	O
]	O	O
glucagon	O	O
-	O	O
NH2	O	O
(	O	O
10	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
His1	O	O
,	O	O
des	O	O
-	O	O
Phe6	O	O
]	O	O
glucagon	O	O
-	O	O
NH2	O	O
(	O	O
11	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
His1	O	O
,	O	O
des	O	O
-	O	O
Phe6	O	O
,	O	O
Glu9	O	O
]	O	O
glucagon	O	O
(	O	O
12	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
Phe6	O	O
,	O	O
Glu9	O	O
]	O	O
glucagon	O	O
(	O	O
13	O	O
)	O	O
;	O	O
[	O	O
des	O	O
-	O	O
Phe6	O	O
]	O	O
glucagon	O	O
(	O	O
14	O	O
)	O	O
;	O	O
and	O	O
[	O	O
des	O	O
-	O	O
His1	O	O
,	O	O
des	O	O
-	O	O
Phe6	O	O
]	O	O
glucagon	O	O
(	O	O
15	O	O
)	O	O
.	O	O
sigma	O	O
-	O	O
Receptor	O	O
binding	O	O
affinities	O	O
were	O	O
obtained	O	O
using	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentazocine	I-IUPAC	I-IUPAC
in	O	O
guinea	O	O
pig	O	O
brain	O	O
membrane	O	O
sigma	O	O
1	O	O
sites	O	O
.	O	O
Moderate	O	O
5-10	O	O
-	O	O
fold	O	O
selectivity	O	O
for	O	O
T	O	O
.	O	O
gondii	O	O
enzyme	O	O
relative	O	O
to	O	O
the	O	O
rat	O	O
liver	O	O
enzyme	O	O
.	O	O
The	O	O
distance	O	O
between	O	O
the	O	O
gem	O	B-IUPAC
-	O	I-IUPAC
dimethyl	O	I-IUPAC
group	O	B-MODIFIER
and	O	O
the	O	O
terminal	O	O
carboxylate	O	O
appears	O	O
to	O	O
be	O	O
too	O	O
short	O	O
to	O	O
activate	O	O
the	O	O
retinoid	O	O
receptor	O	O
.	O	O
The	O	O
sodium	O	O
salt	O	O
glycosylation	O	O
of	O	O
the	O	O
imidazo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isothiazoles	I-IUPAC	I-IUPAC
proceeded	O	O
smoothly	O	O
,	O	O
giving	O	O
mixtures	O	O
of	O	O
N	O	O
-	O	O
4	O	O
and	O	O
N	O	O
-	O	O
6	O	O
regioisomers	O	O
in	O	O
generally	O	O
good	O	O
yields	O	O
.	O	O
Addition	O	O
of	O	O
2	O	O
to	O	O
a	O	O
2	O	O
-	O	O
fold	O	O
excess	O	O
of	O	O
the	O	O
reaction	O	O
product	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridone	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
HOPO	O	O
-	O	O
C	O	O
)	O	O
and	O	O
1,1	B-IUPAC	B-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonyldiimidazole	I-IUPAC	I-IUPAC
(	O	O
CDI	O	O
)	O	O
in	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylformamide	I-IUPAC	I-IUPAC
(	O	O
DMF	O	O
)	O	O
and	O	O
deprotection	O	O
with	O	O
BBr3	O	O
gave	O	O
1,14	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxybenzoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridon	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,5,10,14	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetraaza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetradecane	I-IUPAC	I-IUPAC
[	O	O
3	O	O
,	O	O
3,4,3	O	O
-	O	O
LI	O	O
(	O	O
diCAM	O	O
-	O	O
diHOPO	O	O
)	O	O
]	O	O
in	O	O
5%	O	O
yield	O	O
.	O	O
4alpha	B-IUPAC	O
,	I-IUPAC	O
19	I-IUPAC	O
-	I-IUPAC	O
Diol	I-IUPAC	O
25	O	O
was	O	O
synthesized	O	O
from	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyldimethylsilyoxyandrost	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ene	I-IUPAC	I-IUPAC
steroid	B-MODIFIER	B-MODIFIER
(	O	O
9	O	O
)	O	O
through	O	O
its	O	O
OsO	O	O
(	O	O
4	O	O
)	O	O
oxidation	O	O
,	O	O
giving	O	O
the	O	O
4alpha	B-IUPAC	O
,	I-IUPAC	O
5alpha	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
12	O	O
,	O	O
as	O	O
a	O	O
key	O	O
reaction	O	O
.	O	O
The	O	O
electron	O	O
-	O	O
withdrawing	O	O
chloroethyl	B-IUPAC	O
group	B-MODIFIER	O
at	O	O
the	O	O
endocyclic	O	O
and	O	O
/	O	O
or	O	O
exocyclic	O	O
nitrogens	O	O
counteracts	O	O
the	O	O
endocyclic	O	O
P	O	O
-	O	O
N	O	O
bond	O	O
hydrolysis	O	O
.	O	O
Racemic	O	O
6	O	O
,	O	O
but	O	O
not	O	O
11	O	O
,	O	O
partially	O	O
substituted	O	O
for	O	O
LSD	O	O
.	O	O
Like	O	O
the	O	O
parent	O	O
compound	O	O
4a	O	O
(	O	O
IC50	O	O
=	O	O
0.18	O	O
microM	O	O
)	O	O
,	O	O
4c	O	O
(	O	O
IC50	O	O
=	O	O
0.18	O	O
microM	O	O
)	O	O
,	O	O
4e	O	O
(	O	O
IC50	O	O
=	O	O
0.14	O	O
microM	O	O
)	O	O
,	O	O
and	O	O
in	O	O
particular	O	O
4d	O	O
(	O	O
IC50	O	O
=	O	O
0.02	O	O
microM	O	O
)	O	O
were	O	O
effective	O	O
inhibitors	O	O
of	O	O
calcium	O	O
chloride	O	O
-	O	O
dependent	O	O
[	O	O
3H	O	O
]	O	O
glutamic	O	O
acid	O	O
binding	O	O
,	O	O
whereas	O	O
AMPA	O	O
is	O	O
inactive	O	O
(	O	O
IC50	O	O
greater	O	O
than	O	O
100	O	O
microM	O	O
)	O	O
in	O	O
this	O	O
binding	O	O
assay	O	O
.	O	O
Compound	O	O
9f	O	O
displayed	O	O
significant	O	O
activity	O	O
against	O	O
rhinovirus	O	O
type	O	O
34	O	O
grown	O	O
in	O	O
WISH	O	O
cells	O	O
.	O	O
Careful	O	O
analysis	O	O
of	O	O
the	O	O
NMR	O	O
structures	O	O
of	O	O
cyclo	O	O
(	O	O
4-10	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
Delta	O	O
(	O	O
3	O	O
)	O	O
Pro	O	O
(	O	O
1	O	O
)	O	O
,	O	O
DFpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DTrp	O	O
(	O	O
3	O	O
)	O	O
,	O	O
Asp	O	O
(	O	O
4	O	O
)	O	O
,	O	O
DNal	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Dpr	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
,	O	O
dicyclo	O	O
(	O	O
4-10/5-8	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DNal	O	O
(	O	O
1	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DTrp	O	O
(	O	O
3	O	O
)	O	O
,	O	O
Asp	O	O
(	O	O
4	O	O
)	O	O
,	O	O
Glu	O	O
(	O	O
5	O	O
)	O	O
,	O	O
DArg	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Lys	O	O
(	O	O
8	O	O
)	O	O
,	O	O
Dpr	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
,	O	O
and	O	O
dicyclo	O	O
(	O	O
4-10/5	O	O
,	O	O
5'	O	O
-	O	O
8	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DNal	O	O
(	O	O
1	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DPal	O	O
(	O	O
3	O	O
)	O	O
,	O	O
Asp	O	O
(	O	O
4	O	O
)	O	O
,	O	O
Glu	O	O
(	O	O
5	O	O
)	O	O
(	O	O
Gly	O	O
)	O	O
,	O	O
DArg	O	O
(	O	O
6	O	O
)	O	O
,	O	O
Dbu	O	O
(	O	O
8	O	O
)	O	O
,	O	O
Dpr	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
showed	O	O
that	O	O
,	O	O
in	O	O
the	O	O
N	O	B-IUPAC
-	O	I-IUPAC
terminal	O	I-IUPAC
tripeptide	O	I-IUPAC
,	O	O
a	O	O
type	O	O
II	O	O
beta	O	O
-	O	O
turn	O	O
around	O	O
residues	O	O
1	O	O
and	O	O
2	O	O
was	O	O
probable	O	O
along	O	O
with	O	O
a	O	O
gamma	O	O
-	O	O
turn	O	O
around	O	O
DTrp	O	O
(	O	O
3	O	O
)	O	O
/	O	O
DPal	O	O
(	O	O
3	O	O
)	O	O
.	O	O
The	O	O
ability	O	O
of	O	O
the	O	O
dihydrodiols	O	O
3a	O	O
-	O	O
c	O	O
and	O	O
the	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydrodiol	I-IUPAC	I-IUPAC
of	O	O
7,12	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylbenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthracene	I-IUPAC	I-IUPAC
(	O	O
3d	O	O
)	O	O
to	O	O
induce	O	O
chromosomal	O	O
aberrations	O	O
in	O	O
rat	O	O
bone	O	O
marrow	O	O
cells	O	O
was	O	O
also	O	O
examined	O	O
.	O	O
Side	O	O
-	O	O
chain	O	O
protection	O	O
of	O	O
Trp	O	O
by	O	O
the	O	O
Boc	O	O
group	O	O
was	O	O
found	O	O
to	O	O
preserve	O	O
Trp	O	O
integrity	O	O
during	O	O
Tl	O	O
(	O	O
Tfa	O	O
)	O	O
3	O	O
treatment	O	O
.	O	O
Analogues	O	O
1-9	O	O
and	O	O
14	O	O
are	O	O
potent	O	O
AVP	O	O
V1	O	O
antagonists	O	O
.	O	O
We	O	O
have	O	O
previously	O	O
described	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohepta	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
4	O	O
-	O	O
AHCP	O	O
)	O	O
as	O	O
a	O	O
highly	O	O
effective	O	O
agonist	O	O
at	O	O
non	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aspartate	I-IUPAC	I-IUPAC
(	O	O
non	O	O
-	O	O
NMDA	O	O
)	O	O
glutamate	O	O
(	O	O
Glu	O	O
)	O	O
receptors	O	O
in	O	O
vivo	O	O
,	O	O
which	O	O
is	O	O
more	O	O
potent	O	O
than	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
AMPA	O	O
)	O	O
but	O	O
inactive	O	O
at	O	O
NMDA	O	O
receptors	O	O
.	O	O
In	O	O
the	O	O
series	O	O
of	O	O
indoles	O	O
4	O	O
,	O	O
the	O	O
introduction	O	O
of	O	O
a	O	O
methyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
benzylic	O	O
carbon	O	O
with	O	O
the	O	O
R	O	O
configuration	O	O
improved	O	O
affinity	O	O
of	O	O
the	O	O
5	O	O
-	O	O
substituted	O	O
(	O	O
5	O	O
-	O	O
Cl	O	O
and	O	O
5	O	O
-	O	O
NO	O	O
(	O	O
2	O	O
)	O	O
)	O	O
derivatives	O	O
,	O	O
whereas	O	O
it	O	O
was	O	O
detrimental	O	O
for	O	O
their	O	O
5	O	O
-	O	O
unsubtituted	O	O
(	O	O
5	O	O
-	O	O
H	O	O
)	O	O
counterparts	O	O
.	O	O
A	O	O
series	O	O
of	O	O
complexes	O	O
of	O	O
the	O	O
general	O	O
formula	O	O
trans	O	O
-	O	O
[	O	O
PtCl2	O	O
(	O	O
Am	O	O
)	O	O
(	O	O
pip	O	O
-	O	O
pip	O	O
)	O	O
]	O	O
x	O	O
HCl	O	O
where	O	O
pip	O	O
-	O	O
pip	O	O
is	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
piperidinopiperidine	I-IUPAC	I-IUPAC
and	O	O
Am	O	O
is	O	O
NH3	O	O
,	O	O
methylamine	O	O
(	O	O
MA	O	O
)	O	O
,	O	O
dimethylamine	B-IUPAC	O
(	O	O
DMA	O	O
)	O	O
,	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propylamine	I-IUPAC	I-IUPAC
(	O	O
NPA	O	O
)	O	O
,	O	O
isopropylamine	O	O
(	O	O
IPA	O	O
)	O	O
,	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butylamine	I-IUPAC	I-IUPAC
(	O	O
NBA	O	O
)	O	O
,	O	O
or	O	O
cyclohexylamine	B-IUPAC	O
(	O	O
CHA	O	O
)	O	O
were	O	O
prepared	O	O
and	O	O
characterized	O	O
,	O	O
and	O	O
their	O	O
cytotoxic	O	O
properties	O	O
against	O	O
ovarian	O	O
and	O	O
colon	O	O
cancer	O	O
cells	O	O
were	O	O
evaluated	O	O
.	O	O
In	O	O
some	O	O
cases	O	O
,	O	O
the	O	O
positional	O	O
isomers	O	O
6	O	O
and	O	O
8	O	O
were	O	O
also	O	O
obtained	O	O
.	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Formyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
and	O	O
its	O	O
dithiolane	B-IUPAC	B-IUPAC
derivative	B-MODIFIER	B-MODIFIER
11	O	O
were	O	O
prepared	O	O
by	O	O
condensation	O	O
of	O	O
the	O	O
bis	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
trimethylsilyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
formyluracil	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
acetal	I-IUPAC	I-IUPAC
and	O	O
the	O	O
protected	O	O
chloro	O	O
sugar	O	O
followed	O	O
by	O	O
saponification	O	O
of	O	O
the	O	O
protective	O	O
groups	O	O
.	O	O
Scatchard	O	O
analyses	O	O
of	O	O
binding	O	O
to	O	O
brain	O	O
sections	O	O
revealed	O	O
heterogeneous	O	O
binding	O	O
profiles	O	O
for	O	O
both	O	O
antagonists	O	O
,	O	O
suggesting	O	O
the	O	O
presence	O	O
of	O	O
multiple	O	O
receptor	O	O
binding	O	O
sites	O	O
.	O	O
At	O	O
the	O	O
5	O	O
-	O	O
position	O	O
,	O	O
a	O	O
homologous	O	O
series	O	O
of	O	O
phenylalkyl	O	O
esters	O	O
and	O	O
a	O	O
series	O	O
of	O	O
substituted	B-MODIFIER	B-MODIFIER
benzyl	B-IUPAC	B-IUPAC
esters	I-IUPAC	I-IUPAC
were	O	O
prepared	O	O
and	O	O
tested	O	O
.	O	O
cis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpyrrolidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzamide	I-IUPAC	I-IUPAC
(	O	O
YM	O	O
-	O	O
09151-2	O	O
,	O	O
55	O	O
)	O	O
was	O	O
the	O	O
most	O	O
active	O	O
among	O	O
all	O	O
of	O	O
the	O	O
compounds	O	O
tested	O	O
,	O	O
being	O	O
13	O	O
and	O	O
408	O	O
times	O	O
more	O	O
potent	O	O
than	O	O
haloperidol	O	O
and	O	O
metoclopramide	O	O
,	O	O
respectively	O	O
.	O	O
In	O	O
this	O	O
displacement	O	O
assay	O	O
,	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentazocine	I-IUPAC	I-IUPAC
exhibited	O	O
a	O	O
Ki	O	O
of	O	O
3.1	O	O
nM	O	O
while	O	O
DTG	O	O
and	O	O
haloperidol	O	O
showed	O	O
Ki	O	O
values	O	O
of	O	O
27.7	O	O
and	O	O
3.7	O	O
nM	O	O
,	O	O
respectively	O	O
.	O	O
)	O	O
.	O	O
The	O	O
model	O	O
can	O	O
also	O	O
account	O	O
for	O	O
the	O	O
binding	O	O
of	O	O
quinoxaline	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diones	I-IUPAC	I-IUPAC
,	O	O
quinoxalic	B-IUPAC	O
acids	I-IUPAC	O
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxybenzimidazoles	I-IUPAC	I-IUPAC
.	O	O
The	O	O
(	O	O
1R	O	O
,	O	O
2R	O	O
)	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
enantiomer	O	O
,	O	O
(	O	O
+	O	O
)	O	O
-	O	O
2	O	O
,	O	O
had	O	O
low	O	O
affinity	O	O
for	O	O
both	O	O
kappa	O	O
and	O	O
sigma	O	O
receptors	O	O
,	O	O
exhibiting	O	O
Ki	O	O
values	O	O
of	O	O
1298	O	O
+	O	O
/	O	O
-	O	O
49	O	O
nM	O	O
at	O	O
kappa	O	O
(	O	O
[	O	O
3H	O	O
]	O	O
BREM	O	O
)	O	O
and	O	O
1270	O	O
+	O	O
/	O	O
-	O	O
168	O	O
nM	O	O
at	O	O
sigma	O	O
[	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
3	O	O
-	O	O
PPP	O	O
]	O	O
.	O	O
Appropriately	O	O
substituted	O	B-MODIFIER
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
9-12	O	O
and	O	O
18	O	O
were	O	O
considered	O	O
as	O	O
annulated	O	O
analogues	O	O
of	O	O
HEPT	O	O
(	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
)	O	I-IUPAC
,	O	O
and	O	O
some	O	O
of	O	O
these	O	O
compounds	O	O
were	O	O
also	O	O
found	O	O
active	O	O
against	O	O
HIV	O	O
-	O	O
1	O	O
,	O	O
the	O	O
most	O	O
active	O	O
one	O	O
being	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
10b	O	O
)	O	O
.	O	O
These	O	O
agents	O	O
were	O	O
evaluated	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
suppress	O	O
HMG	O	O
CoA	O	O
reductase	O	O
,	O	O
the	O	O
rate	O	O
-	O	O
limiting	O	O
enzyme	O	O
of	O	O
cholesterol	O	O
biosynthesis	O	O
.	O	O
Synthetic	O	O
yields	O	O
were	O	O
insufficient	O	O
for	O	O
chemical	O	O
investigations	O	O
or	O	O
evaluation	O	O
of	O	O
acute	O	O
toxicity	O	O
.	O	O
In	O	O
a	O	O
structure	O	O
-	O	O
activity	O	O
comparison	O	O
it	O	O
was	O	O
found	O	O
that	O	O
at	O	O
optimum	O	O
dose	O	O
all	O	O
compounds	O	O
containing	O	O
the	O	O
nitroxyl	O	B-IUPAC
radical	O	O
were	O	O
more	O	O
active	O	O
than	O	O
the	O	O
corresponding	O	O
hydroxylamine	O	O
derivatives	O	O
.	O	O
The	O	O
benzyl	B-IUPAC	O
ether	I-IUPAC	O
functions	B-MODIFIER	O
of	O	O
7	O	O
and	O	O
9	O	O
were	O	O
removed	O	O
with	O	O
boron	O	O
trichloride	O	O
to	O	O
afford	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arabinofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
and	O	O
its	O	O
3	O	O
-	O	O
bromo	O	O
analog	O	O
10	O	O
.	O	O
The	O	O
2'	O	O
-	O	O
substituent	O	O
was	O	O
also	O	O
a	O	O
determinant	O	O
of	O	O
cytotoxic	O	O
activity	O	O
in	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
(	O	O
11a	O	O
-	O	O
c	O	O
)	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
of	O	O
compounds	O	O
,	O	O
where	O	O
the	O	O
relative	O	O
activity	O	O
profile	O	O
was	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
greater	O	O
than	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
greater	O	O
than	O	O
uridine	B-IUPAC	O
(	O	O
11a	O	O
greater	O	O
than	O	O
11b	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
11c	O	O
;	O	O
12a	O	O
greater	O	O
than	O	O
12b	O	O
greater	O	O
than	O	O
12c	O	O
)	O	O
.	O	O
It	O	O
gave	O	O
100%	O	O
protection	O	O
against	O	O
PAF	O	O
-	O	O
induced	O	O
mortality	O	O
in	O	O
mice	O	O
7	O	O
h	O	O
after	O	O
i	O	O
.	O	O
Several	O	O
series	O	O
of	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4,5	I-IUPAC	I-IUPAC
-	O	I-IUPAC
trisubstituted	B-MODIFIER	I-IUPAC
-	O	I-IUPAC
3H	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
with	O	O
acidic	O	O
sulfonamide	O	O
replacements	O	O
of	O	O
tetrazole	O	O
at	O	O
the	O	O
2'	O	O
-	O	O
position	O	O
of	O	O
the	O	O
biphenyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
side	B-MODIFIER	B-MODIFIER
chain	I-MODIFIER	I-MODIFIER
at	O	O
N4	O	O
were	O	O
prepared	O	O
and	O	O
tested	O	O
as	O	O
angiotensin	O	O
II	O	O
(	O	O
AII	O	O
)	O	O
antagonists	O	O
.	O	O
Several	O	O
series	O	O
of	O	O
N6	O	O
-	O	O
or	O	O
8	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
derivatives	O	B-MODIFIER
of	O	O
adenosine	B-IUPAC	O
5'	I-IUPAC	O
-	I-IUPAC	O
triphosphate	I-IUPAC	O
(	O	O
ATP	O	O
)	O	O
were	O	O
synthesized	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indolone	I-IUPAC	I-IUPAC
was	O	O
the	O	O
most	O	O
potent	O	O
compound	O	O
(	O	O
ED50	O	O
=	O	O
2	O	O
+	O	O
/	O	O
-	O	O
0.3	O	O
nM	O	O
)	O	O
tested	O	O
,	O	O
while	O	O
the	O	O
related	O	O
secondary	O	O
amine	O	O
24	O	O
and	O	O
the	O	O
des	O	O
-	O	O
OH	O	O
derivatives	O	O
28	O	O
and	O	O
34	O	O
were	O	O
only	O	O
slightly	O	O
less	O	O
potent	O	O
.	O	O
The	O	O
interaction	O	O
of	O	O
indolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinolines	I-IUPAC	I-IUPAC
with	O	O
DNA	O	O
was	O	O
studied	O	O
by	O	O
measuring	O	O
the	O	O
increase	O	O
of	O	O
calf	O	O
thymus	O	O
DNA	O	O
denaturating	O	O
temperature	O	O
(	O	O
Tm	O	O
)	O	O
.	O	O
Analogously	O	O
,	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypyrimidine	I-IUPAC	I-IUPAC
gave	O	O
on	O	O
reaction	O	O
with	O	O
[	O	O
(	B-PARTIUPAC	O
R	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diisopropylphosphorylmethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	O	I-IUPAC
tosylate	B-MODIFIER	I-IUPAC
,	O	O
followed	O	O
by	O	O
deprotection	O	O
,	O	O
the	O	O
enantiomeric	O	B-MODIFIER
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phosphonomethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
.	O	O
None	O	O
of	O	O
the	O	O
indolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinolines	I-IUPAC	I-IUPAC
belonging	O	O
to	O	O
the	O	O
6H	O	O
series	O	O
,	O	O
i.e.	O	O
,	O	O
lacking	O	O
a	O	O
methyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
pyridine	O	O
nitrogen	O	O
,	O	O
was	O	O
active	O	O
in	O	O
analogous	O	O
tests	O	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanamido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
haloethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridines	I-IUPAC	I-IUPAC
(	O	O
4-6	O	O
)	O	O
all	O	O
were	O	O
approximately	O	O
equipotent	O	O
against	O	O
HSV	O	O
-	O	O
2	O	O
and	O	O
were	O	O
approximately	O	O
1.5	O	O
-	O	O
and	O	O
15	O	O
-	O	O
fold	O	O
less	O	O
inhibitory	O	O
for	O	O
HSV	O	O
-	O	O
2	O	O
than	O	O
EDU	O	O
and	O	O
acyclovir	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
activity	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethoxycarbonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiophene	I-IUPAC	I-IUPAC
,	O	O
10h	O	O
(	O	O
26%	O	O
)	O	O
,	O	O
is	O	O
an	O	O
exception	O	O
to	O	O
the	O	O
rule	O	O
that	O	O
a	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxycarbonyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
cannot	O	O
support	O	O
AE	O	O
activity	O	O
.	O	O
It	O	O
was	O	O
selected	O	O
from	O	O
a	O	O
large	O	O
series	O	O
of	O	O
(	B-PARTIUPAC	B-PARTIUPAC
2	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
piperidinyl	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
(	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethanones	I-IUPAC	I-IUPAC
synthesized	O	O
by	O	O
a	O	O
modified	O	O
Schopf	O	O
reaction	O	O
from	O	O
enolate	O	O
magnesium	O	O
salts	O	O
of	O	O
beta	O	O
-	O	O
keto	O	O
acids	O	O
and	O	O
2,3,4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyridine	I-IUPAC	I-IUPAC
trimer	B-MODIFIER	I-IUPAC
or	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrole	I-IUPAC	I-IUPAC
trimer	B-MODIFIER	B-MODIFIER
,	O	O
respectively	O	O
.	O	O
The	O	O
comparable	O	O
potency	O	O
and	O	O
spectrum	O	O
of	O	O
activity	O	O
of	O	O
juncusol	O	O
(	O	O
1a	O	O
)	O	O
,	O	O
desvinyljuncusol	O	O
(	O	O
2h	O	O
)	O	O
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydrophenanthrene	I-IUPAC	I-IUPAC
(	O	O
3h	O	O
)	O	O
suggest	O	O
that	O	O
the	O	O
agents	O	O
are	O	O
acting	O	O
as	O	O
simple	O	O
phenols	O	O
in	O	O
exerting	O	O
their	O	O
antimicrobial	O	O
and	O	O
cytotoxic	O	O
effects	O	O
.	O	O
An	O	O
enantiospecific	O	O
method	O	O
was	O	O
developed	O	O
for	O	O
the	O	O
synthesis	O	O
of	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
fluoromethyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
hydroxymethyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloromethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	O	I-IUPAC
substituted	B-MODIFIER	I-IUPAC
-	O	I-IUPAC
1,2,3,4	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinolines	I-IUPAC	I-IUPAC
(	O	O
THIQs	O	O
)	O	O
from	O	O
phenylalanine	O	O
.	O	O
In	O	O
the	O	O
ODC	O	O
assay	O	O
,	O	O
systems	O	O
1a	O	O
-	O	O
c	O	O
exhibited	O	O
strong	O	O
activity	O	O
(	O	O
within	O	O
10%	O	O
of	O	O
or	O	O
less	O	O
than	O	O
the	O	O
control	O	O
)	O	O
whereas	O	O
alcohols	O	O
2b	O	O
and	O	O
3a	O	O
showed	O	O
good	O	O
activity	O	O
(	O	O
within	O	O
50%	O	O
of	O	O
the	O	O
control	O	O
)	O	O
as	O	O
compared	O	O
to	O	O
either	O	O
13	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
retinoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
or	O	O
trans	B-IUPAC	O
-	I-IUPAC	O
retinoic	I-IUPAC	O
acid	I-IUPAC	O
.	O	O
Med.	O	O
Chem.	O	O
1998	O	O
,	O	O
41	O	O
,	O	O
1752	O	O
)	O	O
,	O	O
where	O	O
the	O	O
3	O	O
-	O	O
aza	O	O
and	O	O
2	O	O
-	O	O
NH	O	O
atoms	O	O
form	O	O
a	O	O
bidentate	O	O
H	O	O
-	O	O
bond	O	O
donor	O	O
-	O	O
acceptor	O	O
motif	O	O
that	O	O
interacts	O	O
with	O	O
Met341	O	O
and	O	O
the	O	O
1	O	B-IUPAC
-	O	I-IUPAC
aza	O	I-IUPAC
atom	O	O
is	O	O
not	O	O
involved	O	O
in	O	O
specific	O	O
binding	O	O
interactions	O	O
.	O	O
In	O	O
the	O	O
phototolerance	O	O
model	O	O
,	O	O
the	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
quinolones	I-IUPAC	I-IUPAC
are	O	O
comparable	O	O
to	O	O
the	O	O
8H	B-IUPAC	O
-	I-IUPAC	O
quinolones	I-IUPAC	O
.	O	O
A	O	O
detailed	O	O
NMR	O	O
analysis	O	O
with	O	O
restrained	O	O
and	O	O
free	O	O
molecular	O	O
dynamics	O	O
calculations	O	O
in	O	O
explicit	O	O
H	O	O
(	O	O
2	O	O
)	O	O
O	O	O
exhibits	O	O
a	O	O
well	O	O
-	O	O
defined	O	O
structure	O	O
with	O	O
characteristic	O	O
features	O	O
such	O	O
as	O	O
an	O	O
omega	O	O
-	O	O
loop	O	O
with	O	O
two	O	O
betaI	O	O
-	O	O
turns	O	O
about	O	O
Lys	O	O
(	O	O
3	O	O
)	O	O
,	O	O
Tyr	O	O
(	O	O
4	O	O
)	O	O
,	O	O
Ser	O	O
(	O	O
6	O	O
)	O	O
,	O	O
and	O	O
Asn	O	O
(	O	O
7	O	O
)	O	O
.	O	O
Cystazosin	O	O
(	O	O
3	O	O
)	O	O
,	O	O
bearing	O	O
a	O	O
cystamine	O	O
moiety	O	O
,	O	O
was	O	O
a	O	O
selective	O	O
alpha1D	O	O
-	O	O
adrenoreceptor	O	O
antagonist	O	O
being	O	O
1	O	O
order	O	O
of	O	O
magnitude	O	O
more	O	O
potent	O	O
at	O	O
alpha1D	O	O
-	O	O
adrenoreceptors	O	O
(	O	O
pA2	O	O
,	O	O
8.54	O	O
+	O	O
/	O	O
-	O	O
0.02	O	O
)	O	O
than	O	O
at	O	O
the	O	O
alpha1A	O	O
-	O	O
(	O	O
pA2	O	O
,	O	O
7.53	O	O
+	O	O
/	O	O
-	O	O
0.01	O	O
)	O	O
and	O	O
alpha1B	O	O
-	O	O
subtypes	O	O
(	O	O
pA2	O	O
,	O	O
7.49	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
In	O	O
order	O	O
to	O	O
explore	O	O
the	O	O
use	O	O
of	O	O
this	O	O
REV	O	O
to	O	O
account	O	O
for	O	O
the	O	O
activities	O	O
of	O	O
other	O	O
cannabinoids	O	O
,	O	O
the	O	O
minimally	O	O
active	O	O
classical	O	O
cannabinoid	O	O
(	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexahydrocannabinol	I-IUPAC	I-IUPAC
,	O	O
an	O	O
active	O	O
benzofuran	O	O
cannabinoid	O	O
,	O	O
and	O	O
the	O	O
active	O	O
nonclassical	O	O
cannabinoid	O	O
CP	O	O
-	O	O
47,497	O	O
were	O	O
then	O	O
studied	O	O
.	O	O
Sulfenylation	O	O
of	O	O
3	O	O
with	O	O
NPS	O	O
-	O	O
Cl	O	O
gave	O	O
Z	O	O
-	O	O
Lys	O	O
(	O	O
Z	O	O
)	O	O
-	O	O
Trp	O	O
(	O	O
NPS	O	O
)	O	O
-	O	O
OMe	O	O
,	O	O
which	O	O
,	O	O
on	O	O
catalytic	O	O
hydrogenation	O	O
of	O	O
the	O	O
nitro	O	O
group	O	O
using	O	O
10%	O	O
Pd	O	O
/	O	O
C	O	O
followed	O	O
by	O	O
acetylation	O	O
of	O	O
the	O	O
resulting	O	O
amino	O	O
function	O	O
and	O	O
removal	O	O
of	O	O
the	O	O
protecting	O	O
Z	O	O
groups	O	O
,	O	O
gave	O	O
17	O	O
.	O	O
The	O	O
final	O	O
products	O	O
were	O	O
tested	O	O
in	O	O
vitro	O	O
as	O	O
inhibitors	O	O
of	O	O
DHFR	O	O
from	O	O
Pneumocystis	O	O
carinii	O	O
,	O	O
Toxoplasma	O	O
gondii	O	O
,	O	O
rat	O	O
liver	O	O
,	O	O
beef	O	O
liver	O	O
,	O	O
and	O	O
Lactobacillus	O	O
casei	O	O
.	O	O
Although	O	O
analgesic	O	O
activities	O	O
of	O	O
sulfur	O	O
-	O	O
containing	O	O
benzazocines	O	O
decreased	O	O
compared	O	O
to	O	O
the	O	O
corresponding	O	O
hydroxy	O	O
compounds	O	O
,	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	O	B-IUPAC
S	O	I-IUPAC
-	O	I-IUPAC
metazocine	O	I-IUPAC
,	O	O
8	O	O
)	O	O
showed	O	O
potent	O	O
analgesic	O	O
activity	O	O
.	O	O
No	O	O
analgesia	O	O
was	O	O
however	O	O
found	O	O
with	O	O
the	O	O
phenylsulfenyl	O	B-IUPAC
or	O	O
acyclic	O	O
sulfenyl	O	O
substituted	O	O
dipeptides	O	O
9	O	O
,	O	O
11	O	O
,	O	O
and	O	O
17	O	O
or	O	O
13	O	O
,	O	O
23	O	O
,	O	O
and	O	O
24	O	O
.	O	O
Optimization	O	O
of	O	O
the	O	O
activity	O	O
in	O	O
this	O	O
series	O	O
resulted	O	O
in	O	O
the	O	O
development	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylcarboxamides	I-IUPAC	I-IUPAC
(	O	O
30	O	O
)	O	O
which	O	O
are	O	O
highly	O	O
potent	O	O
orally	O	O
active	O	O
NK1	O	O
antagonists	O	O
.	O	O
One	O	O
compound	O	O
(	O	O
5j	O	O
)	O	O
had	O	O
an	O	O
IC50	O	O
of	O	O
&	O	O
lt	O	O
;	O	O
0.01	O	O
microM	O	O
against	O	O
four	O	O
of	O	O
the	O	O
cell	O	O
lines	O	O
.	O	O
Several	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arylalkylpolyamines	I-IUPAC	I-IUPAC
containing	O	O
various	O	O
aromatic	O	O
ring	O	O
systems	O	O
were	O	O
synthesized	O	O
as	O	O
their	O	O
respective	O	O
HCl	O	O
salts	O	O
.	O	O
Several	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidines	I-IUPAC	I-IUPAC
bearing	O	O
a	O	O
relatively	O	O
small	O	O
,	O	O
electron	O	O
-	O	O
donating	O	O
para	O	O
subtituent	O	O
,	O	O
such	O	O
as	O	O
H	O	O
,	O	O
F	O	O
,	O	O
Cl	O	O
,	O	O
CH	O	O
(	O	O
3	O	O
)	O	O
,	O	O
OH	O	O
,	O	O
OCH	O	O
(	O	O
3	O	O
)	O	O
,	O	O
and	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
,	O	O
led	O	O
to	O	O
NO	O	O
formation	O	O
rates	O	O
between	O	O
8	O	O
and	O	O
41%	O	O
of	O	O
that	O	O
of	O	O
NO	O	O
formation	O	O
from	O	O
the	O	O
natural	O	O
NOS	O	O
substrate	O	O
,	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
omega	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arginine	I-IUPAC	I-IUPAC
(	O	O
NOHA	O	O
)	O	O
.	O	O
Qualitative	O	O
correlation	O	O
between	O	O
the	O	O
sigma	O	O
and	O	O
PCP	O	O
binding	O	O
data	O	O
suggests	O	O
some	O	O
similarities	O	O
between	O	O
these	O	O
binding	O	O
sites	O	O
.	O	O
The	O	O
affinities	O	O
and	O	O
the	O	O
GABA	O	O
ratios	O	O
of	O	O
selected	O	O
compounds	O	O
for	O	O
clonal	O	O
mammalian	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
beta	O	O
(	O	O
2	O	O
)	O	O
gamma	O	O
(	O	O
2	O	O
)	O	O
,	O	O
alpha	O	O
(	O	O
3	O	O
)	O	O
beta	O	O
(	O	O
2	O	O
)	O	O
gamma	O	O
(	O	O
2	O	O
)	O	O
,	O	O
and	O	O
alpha	O	O
(	O	O
5	O	O
)	O	O
beta	O	O
(	O	O
3	O	O
)	O	O
gamma	O	O
(	O	O
2	O	O
)	O	O
BzR	O	O
subtypes	O	O
were	O	O
also	O	O
determined	O	O
.	O	O
However	O	O
,	O	O
several	O	O
of	O	O
the	O	O
BTCP	O	O
-	O	O
related	O	O
derivatives	O	O
showed	O	O
greater	O	O
(	O	O
compared	O	O
with	O	O
BTCP	O	O
and	O	O
cocaine	O	O
)	O	O
ability	O	O
to	O	O
displace	O	O
[	O	O
3H	O	O
]	O	O
cocaine	O	O
.	O	O
Several	O	O
analogs	O	O
exhibited	O	O
moderate	O	O
to	O	O
very	O	O
good	O	O
growth	O	O
inhibitory	O	O
activities	O	O
against	O	O
cultured	O	O
L1210	O	O
leukemia	O	O
and	O	O
6410	O	O
human	O	O
leukemic	O	O
myeloblasts	O	O
.	O	O
(	O	O
125	O	O
)	O	O
Iodinated	O	O
19	O	O
selectively	O	O
binds	O	O
to	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
-	O	O
transfected	O	O
cells	O	O
but	O	O
not	O	O
to	O	O
sst	O	O
(	O	O
1-3	O	O
)	O	O
-	O	O
or	O	O
sst	O	O
(	O	O
5	O	O
)	O	O
-	O	O
transfected	O	O
cells	O	O
.	O	O
The	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazolidinone	I-IUPAC	I-IUPAC
has	O	O
high	O	O
affinity	O	O
for	O	O
5	O	O
-	O	O
HT2	O	O
receptors	O	O
(	O	O
IC50	O	O
=	O	O
3.4	O	O
nM	O	O
)	O	O
and	O	O
extremely	O	O
low	O	O
affinity	O	O
for	O	O
both	O	O
dopamine	O	O
D2	O	O
receptors	O	O
(	O	O
IC50	O	O
=	O	O
6900	O	O
nM	O	O
)	O	O
and	O	O
alpha	O	O
1	O	O
adrenoceptors	O	O
(	O	O
IC50	O	O
=	O	O
2300	O	O
nM	O	O
)	O	O
.	O	O
(	O	O
all	O	O
-	O	O
E	O	O
)	O	O
-	O	O
1	O	O
and	O	O
(	O	O
13Z	O	O
)	O	O
-	O	O
1	O	O
were	O	O
both	O	O
shown	O	O
to	O	O
be	O	O
equally	O	O
effective	O	O
as	O	O
(	B-IUPAC	B-IUPAC
13Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
retinoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
in	O	O
suppressing	O	O
the	O	O
proliferation	O	O
of	O	O
human	O	O
sebaceous	O	O
cells	O	O
in	O	O
vitro	O	O
.	O	O
Examination	O	O
of	O	O
initial	O	O
rate	O	O
kinetics	O	O
of	O	O
carbonic	O	O
anhydrase	O	O
catalyzed	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nitrophenyl	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
hydrolysis	O	O
showed	O	O
that	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylacetazolamide	I-IUPAC	I-IUPAC
was	O	O
a	O	O
competitive	O	O
inhibitor	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
noncompetitive	O	O
inhibition	O	O
seen	O	O
with	O	O
acetazolamide	O	O
and	O	O
other	O	O
primary	O	O
sulfonamide	O	O
inhibitors	O	O
.	O	O
On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
all	O	O
compounds	O	O
were	O	O
less	O	O
effective	O	O
than	O	O
DA	O	O
in	O	O
stimulation	O	O
of	O	O
adenylate	O	O
cyclase	O	O
activity	O	O
in	O	O
rat	O	O
striatal	O	O
homogenates	O	O
,	O	O
a	O	O
kind	O	O
of	O	O
effect	O	O
which	O	O
is	O	O
mediated	O	O
by	O	O
the	O	O
D	O	O
-	O	O
1	O	O
subtype	O	O
of	O	O
DA	O	O
receptors	O	O
.	O	O
;	O	O
et	O	O
al.	O	O
J	O	O
.	O	O
The	O	O
best	O	O
of	O	O
these	O	O
compounds	O	O
generally	O	O
had	O	O
a	O	O
methyl	O	B-IUPAC
group	O	B-MODIFIER
at	O	O
the	O	O
N1	O	O
position	O	O
,	O	O
a	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
cyclopentyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
or	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclopentylacetamido	I-IUPAC	I-IUPAC
or	O	O
N'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclopentylureido	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
at	O	O
the	O	O
C	O	O
-	O	O
5	O	O
position	O	O
,	O	O
and	O	O
an	O	O
arylsulfonyl	O	O
amide	O	O
group	O	O
as	O	O
part	O	O
of	O	O
the	O	O
acidic	O	O
chain	O	O
at	O	O
the	O	O
C	O	O
-	O	O
3	O	O
position	O	O
of	O	O
the	O	O
ring	O	O
.	O	O
This	O	O
article	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
(	O	O
SAR	O	O
)	O	O
concerning	O	O
beta	O	O
(	O	O
3	O	O
)	O	O
-	O	O
adrenoceptor	O	O
agonists	O	O
as	O	O
agents	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
urinary	O	O
frequency	O	O
and	O	O
incontinence	O	O
.	O	O
It	O	O
is	O	O
likely	O	O
that	O	O
they	O	O
exert	O	O
their	O	O
antiviral	O	O
effect	O	O
via	O	O
selective	O	O
inhibition	O	O
of	O	O
the	O	O
methyltransferases	O	O
which	O	O
are	O	O
required	O	O
for	O	O
the	O	O
maturation	O	O
of	O	O
viral	O	O
mRNAs	O	O
.	O	O
A	O	O
series	O	O
of	O	O
gallium	O	O
(	O	O
III	O	O
)	O	O
and	O	O
iron	O	O
(	O	O
III	O	O
)	O	O
complexes	O	O
with	O	O
five	O	O
different	O	O
4N	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
heterocyclic	I-IUPAC	I-IUPAC
thiosemicarbazones	I-IUPAC	I-IUPAC
,	O	O
viz	O	O
.	O	O
The	O	O
ratios	O	O
IC50	O	O
(	O	O
[	O	O
3H	O	O
]	O	O
cocaine	O	O
)	O	O
/	O	O
IC50	O	O
(	O	O
[	O	O
3H	O	O
]	O	O
BTCP	O	O
)	O	O
ranged	O	O
from	O	O
62	O	O
for	O	O
BTCP	O	O
to	O	O
1.5	O	O
for	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclopentylamine	I-IUPAC	I-IUPAC
(	O	O
17	O	O
)	O	O
;	O	O
cocaine	O	O
gave	O	O
a	O	O
ratio	O	O
of	O	O
0.6	O	O
.	O	O
gondii	O	O
tachyzoites	O	O
in	O	O
culture	O	O
and	O	O
were	O	O
found	O	O
to	O	O
have	O	O
a	O	O
potency	O	O
(	O	O
IC50	O	O
=	O	O
0.1-0.5	O	O
microM	O	O
)	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
pyrimethamine	O	O
(	O	O
IC50	O	O
=	O	O
0.69	O	O
microM	O	O
)	O	O
,	O	O
a	O	O
standard	O	O
clinical	O	O
agent	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
cerebral	O	O
toxoplasmosis	O	O
in	O	O
AIDS	O	O
patients	O	O
.	O	O
The	O	O
size	O	O
of	O	O
the	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arylalkyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
as	O	O
well	O	O
as	O	O
the	O	O
polyamine	O	O
sequence	O	O
used	O	O
had	O	O
direct	O	O
bearing	O	O
on	O	O
the	O	O
observed	O	O
cytotoxicity	O	O
profiles	O	O
.	O	O
E	O	O
.	O	O
[	O	B-IUPAC
1	O	I-IUPAC
-	O	I-IUPAC
N	O	I-IUPAC
-	O	I-IUPAC
Methylisoasparagine	O	I-IUPAC
,	O	I-IUPAC
8	O	I-IUPAC
-	O	I-IUPAC
isoleucine	O	I-IUPAC
]	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
I	O	I-IUPAC
)	O	I-IUPAC
,	O	I-IUPAC
[	B-PARTIUPAC	I-IUPAC
1	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
sarcosine	I-PARTIUPAC	I-IUPAC
,	I-PARTIUPAC	O
4	I-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
N	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methyltyrosine	I-PARTIUPAC	I-IUPAC
,	I-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
isoleucine	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	O	I-IUPAC
II	O	I-IUPAC
)	O	I-IUPAC
,	O	I-IUPAC
[	B-PARTIUPAC	I-IUPAC
1	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
sarcosine	I-PARTIUPAC	I-IUPAC
,	I-PARTIUPAC	O
5	I-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
N	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methylisoleucine	I-PARTIUPAC	I-IUPAC
,	I-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
isoleucine	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	O	I-IUPAC
III	O	I-IUPAC
)	O	I-IUPAC
,	O	I-IUPAC
[	B-PARTIUPAC	I-IUPAC
1	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
sarcosine	I-PARTIUPAC	I-IUPAC
,	I-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
N	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methylisoleucine	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	O	I-IUPAC
IV	O	I-IUPAC
)	O	I-IUPAC
,	O	I-IUPAC
[	B-PARTIUPAC	I-IUPAC
1	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
sarcosine8k	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
N	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methylisoleucine	I-PARTIUPAC	I-IUPAC
,	I-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
N	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methylisoleucine	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	O	I-IUPAC
V	O	I-IUPAC
)	O	I-IUPAC
,	O	I-IUPAC
[	B-PARTIUPAC	I-IUPAC
1	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
sarcosine	I-PARTIUPAC	I-IUPAC
,	I-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
O	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methylthreonine	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	O
-	I-PARTIUPAC	O
(	O	O
VI	O	O
)	O	O
,	O	O
[	B-PARTIUPAC	B-IUPAC
1	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
sarcosine	I-PARTIUPAC	I-IUPAC
,	I-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methionine	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	O
-	I-PARTIUPAC	O
(	O	O
VII	O	O
)	O	O
,	O	O
and	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sarcosine	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
serine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
angiotensin	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
(	O	O
VIII	O	O
)	O	O
,	O	O
synthesized	O	O
by	O	O
Merrifield	O	O
's	O	O
solid	O	O
-	O	O
phase	O	O
procedure	O	O
,	O	O
possess	O	O
respectively	O	O
0.8	O	O
,	O	O
0.3	O	O
,	O	O
0.5	O	O
,	O	O
1.0	O	O
,	O	O
0.0	O	O
,	O	O
0.5	O	O
,	O	O
3.7	O	O
,	O	O
and	O	O
0.7%	O	O
pressor	O	O
activity	O	O
of	O	O
angiotensin	O	O
II	O	O
(	O	O
vagotomized	O	O
,	O	O
ganglion	O	O
-	O	O
blocked	O	O
rats	O	O
)	O	O
.	O	O
Homo	O	O
-	O	O
AMPA	O	O
(	O	O
8	O	O
)	O	O
,	O	O
which	O	O
is	O	O
a	O	O
3	B-IUPAC	O
-	I-IUPAC	O
isoxazolol	I-IUPAC	O
bioisostere	B-MODIFIER	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminoadipic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
,	O	O
was	O	O
,	O	O
however	O	O
,	O	O
shown	O	O
to	O	O
be	O	O
a	O	O
specific	O	O
and	O	O
rather	O	O
potent	O	O
agonist	O	O
at	O	O
mGlu6	O	O
,	O	O
approximately	O	O
4	O	O
times	O	O
weaker	O	O
than	O	O
the	O	O
nonselective	O	O
excitatory	O	O
amino	O	O
acid	O	O
receptor	O	O
agonist	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
The	O	O
binding	O	O
affinities	O	O
of	O	O
21	O	O
at	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
-	O	O
adrenergic	O	O
receptors	O	O
(	O	O
[	B-IUPAC	O
(	I-IUPAC	O
3	I-IUPAC	O
)	I-IUPAC	O
H	I-IUPAC	O
]	I-IUPAC	O
prazosin	I-IUPAC	O
,	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.54	O	O
microM	O	O
)	O	O
and	O	O
dopamine	O	O
D2	O	O
receptors	O	O
(	O	O
[	B-IUPAC	O
(	I-IUPAC	O
3	I-IUPAC	O
)	I-IUPAC	O
H	I-IUPAC	O
]	I-IUPAC	O
raclopride	I-IUPAC	O
,	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.2	O	O
microM	O	O
)	O	O
are	O	O
reduced	O	O
by	O	O
incorporating	O	O
a	O	O
hydroxy	O	B-IUPAC
group	O	B-MODIFIER
onto	O	O
the	O	O
4	O	O
-	O	O
position	O	O
of	O	O
the	O	O
piperidine	O	O
ring	O	O
and	O	O
the	O	O
beta	O	O
-	O	O
carbon	O	O
of	O	O
the	O	O
N	O	O
-	O	O
alkyl	O	O
spacer	O	O
to	O	O
give	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
27	O	O
:	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
NR1A	O	O
/	O	O
2B	O	O
,	O	O
0.026	O	O
;	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
,	O	O
14	O	O
;	O	O
D2	O	O
,	O	O
105	O	O
microM	O	O
.	O	O
The	O	O
conformationally	O	O
free	O	O
parent	O	O
compound	O	O
1	O	O
exhibited	O	O
a	O	O
Ki	O	O
value	O	O
of	O	O
2.1	O	O
nM	O	O
.	O	O
Subsequent	O	O
modification	O	O
of	O	O
the	O	O
amino	O	O
terminal	O	O
into	O	O
N	B-IUPAC	B-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
threonine	I-IUPAC	I-IUPAC
led	O	O
to	O	O
the	O	O
most	O	O
potent	O	O
compound	O	O
,	O	O
N	B-IUPAC	B-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
threonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tryptophyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylalaninamide	I-IUPAC	I-IUPAC
[	O	O
Ac	O	O
-	O	O
Thr	O	O
-	O	O
D	O	O
-	O	O
Trp	O	O
(	O	O
CHO	O	O
)	O	O
-	O	O
Phe	O	O
-	O	O
NMeBzl	O	O
(	O	O
5a	O	O
,	O	O
FR113680	O	O
)	O	O
]	O	O
.	O	O
On	O	O
isolated	O	O
organs	O	O
pA2	O	O
values	O	O
(	O	O
rabbit	O	O
aortic	O	O
strips	O	O
)	O	O
of	O	O
8.74	O	O
,	O	O
7.44	O	O
,	O	O
7.64	O	O
,	O	O
7.85	O	O
,	O	O
7.89	O	O
,	O	O
8.76	O	O
,	O	O
8.63	O	O
,	O	O
and	O	O
8.08	O	O
,	O	O
and	O	O
pA2	O	O
values	O	O
(	O	O
cat	O	O
adrenal	O	O
medulla	O	O
of	O	O
8.16	O	O
,	O	O
9.16	O	O
,	O	O
9.31	O	O
,	O	O
8.00	O	O
,	O	O
8.00	O	O
,	O	O
7.00	O	O
,	O	O
9.16	O	O
,	O	O
and	O	O
9.33	O	O
were	O	O
obtained	O	O
.	O	O
A	O	O
dose	O	O
of	O	O
36	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
for	O	O
5	O	O
days	O	O
caused	O	O
no	O	O
toxic	O	O
deaths	O	O
while	O	O
the	O	O
average	O	O
tumor	O	O
volume	O	O
among	O	O
10	O	O
mice	O	O
was	O	O
reduced	O	O
to	O	O
8-9%	O	O
of	O	O
that	O	O
of	O	O
the	O	O
control	O	O
,	O	O
and	O	O
20%	O	O
of	O	O
the	O	O
test	O	O
animals	O	O
were	O	O
rendered	O	O
tumor	O	O
free	O	O
.	O	O
The	O	O
introduction	O	O
of	O	O
two	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
(	O	O
18a	O	O
)	O	O
on	O	O
the	O	O
nitrogen	O	O
atom	O	O
reduces	O	O
by	O	O
one	O	O
-	O	O
half	O	O
and	O	O
doubles	O	O
the	O	O
affinity	O	O
for	O	O
D	O	O
-	O	O
1	O	O
and	O	O
D	O	O
-	O	O
2	O	O
binding	O	O
sites	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
peptide	O	O
alpha	O	O
-	O	O
keto	O	O
amide	O	O
Z	O	O
-	O	O
Leu	O	O
-	O	O
Abu	O	O
-	O	O
CONH	O	O
-	O	O
(	O	O
CH2	O	O
)	O	O
2-3	O	O
-	O	O
indolyl	O	O
was	O	O
the	O	O
best	O	O
inhibitor	O	O
for	O	O
cathepsin	O	O
B	O	O
(	O	O
Ki	O	O
=	O	O
31	O	O
nM	O	O
)	O	O
.	O	O
In	O	O
a	O	O
continuing	O	O
effort	O	O
to	O	O
design	O	O
small	O	O
-	O	O
molecule	O	O
inhibitors	O	O
of	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
that	O	O
combine	O	O
the	O	O
enzyme	O	O
-	O	O
binding	O	O
selectivity	O	O
of	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trimethoxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
trimethoprim	O	O
,	O	O
TMP	O	O
)	O	O
with	O	O
the	O	O
potency	O	O
of	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
piritrexim	O	O
,	O	O
PTX	O	O
)	O	O
,	O	O
seven	O	O
previously	O	O
undescribed	O	O
2,4	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
diamino	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
2'	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methoxy	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
5'	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	O	I-IUPAC
substituted	B-MODIFIER	B-MODIFIER
benzyl	B-PARTIUPAC	B-IUPAC
)	O	I-IUPAC
]	B-PARTIUPAC	I-IUPAC
pyrimidines	I-PARTIUPAC	I-IUPAC
were	O	O
synthesized	O	O
in	O	O
which	O	O
the	O	O
substituent	O	O
at	O	O
the	O	O
5'	O	O
-	O	O
position	O	O
was	O	O
a	O	O
carboxyphenyl	B-IUPAC	O
group	B-MODIFIER	O
linked	O	O
to	O	O
the	O	O
benzyl	B-IUPAC	B-IUPAC
moiety	B-MODIFIER	B-MODIFIER
by	O	O
a	O	O
bridge	O	O
of	O	O
two	O	O
or	O	O
four	O	O
atoms	O	O
in	O	O
length	O	O
.	O	O
To	O	O
establish	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
physicochemical	O	O
and	O	O
biological	O	O
activities	O	O
of	O	O
indolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinolines	I-IUPAC	I-IUPAC
,	O	O
their	O	O
lipophilic	O	O
properties	O	O
,	O	O
cytotoxic	O	O
and	O	O
antimicrobial	O	O
activity	O	O
,	O	O
and	O	O
ability	O	O
to	O	O
induce	O	O
topoisomerase	O	O
II	O	O
dependent	O	O
pSP65	O	O
DNA	O	O
cleavage	O	O
in	O	O
vitro	O	O
were	O	O
investigated	O	O
.	O	O
The	O	O
multiple	O	O
-	O	O
alanine	O	O
-	O	O
substituted	O	O
peptides	O	O
[	O	O
MeTyr1	O	O
,	O	O
Ala15	O	O
,	O	O
22	O	O
,	O	O
Nle27	O	O
]	O	O
-	O	O
hGHRH	O	O
(	O	O
1-29	O	O
)	O	O
-	O	O
NH2	O	O
(	O	O
29	O	O
)	O	O
and	O	O
[	O	O
MeTyr1	O	O
,	O	O
Ala8	O	O
,	O	O
9,15,22,28	O	O
,	O	O
Nle	O	O
27	O	O
]	O	O
-	O	O
hGHRH	O	O
(	O	O
1-29	O	O
)	O	O
-	O	O
NH2	O	O
(	O	O
30	O	O
)	O	O
released	O	O
growth	O	O
hormone	O	O
26	O	O
and	O	O
11	O	O
times	O	O
,	O	O
respectively	O	O
,	O	O
more	O	O
effectively	O	O
than	O	O
the	O	O
standard	O	O
in	O	O
vitro	O	O
.	O	O
The	O	O
most	O	O
potent	O	O
inactivation	O	O
of	O	O
chymotrypsin	O	O
was	O	O
achieved	O	O
by	O	O
a	O	O
O'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
epoxybutyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tyrosine	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
.	O	O
The	O	O
thioanilide	O	O
side	O	O
chain	O	O
featured	O	O
in	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thioxoethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phthalazineacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
195	O	O
)	O	O
proved	O	O
to	O	O
be	O	O
an	O	O
effective	O	O
surrogate	O	O
for	O	O
benzothiazole	O	O
.	O	O
They	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
a	O	O
general	O	O
class	O	O
of	O	O
compounds	O	O
which	O	O
exhibit	O	O
A1	O	O
adenosine	O	O
receptor	O	O
affinity	O	O
.	O	O
This	O	O
is	O	O
of	O	O
interest	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
development	O	O
of	O	O
drugs	O	O
to	O	O
combat	O	O
resistance	O	O
mechanisms	O	O
which	O	O
arise	O	O
by	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
topo	O	O
II	O	O
beta	O	O
isozyme	O	O
.	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Hexadecyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arabino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexopyranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sn	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glycerol	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
was	O	O
more	O	O
effective	O	O
than	O	O
1	O	O
in	O	O
inhibiting	O	O
the	O	O
growth	O	O
of	O	O
MCF	O	O
-	O	O
7	O	O
(	O	O
human	O	O
breast	O	O
cancer	O	O
)	O	O
and	O	O
its	O	O
adriamycin	O	O
-	O	O
resistant	O	O
form	O	O
MCF	O	O
-	O	O
7	O	O
/	O	O
adriamycin	O	O
,	O	O
and	O	O
murine	O	O
Lewis	O	O
lung	O	O
cancer	O	O
cells	O	O
.	O	O
The	O	O
following	O	O
properties	O	O
were	O	O
measured	O	O
:	O	O
stability	O	O
in	O	O
tissue	O	O
culture	O	O
media	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
A549	O	O
lung	O	O
and	O	O
MCF	O	O
-	O	O
7	O	O
breast	O	O
tumor	O	O
cells	O	O
,	O	O
metabolic	O	O
stability	O	O
when	O	O
incubated	O	O
with	O	O
rat	O	O
liver	O	O
microsomes	O	O
,	O	O
and	O	O
rate	O	O
of	O	O
uptake	O	O
and	O	O
subcellular	O	O
location	O	O
in	O	O
A549	O	O
and	O	O
MCF	O	O
-	O	O
7	O	O
cells	O	O
.	O	O
The	O	O
present	O	O
studies	O	O
have	O	O
emphasized	O	O
that	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
heteroatom	O	O
in	O	O
the	O	O
2	O	O
-	O	O
position	O	O
of	O	O
the	O	O
heteroaryl	O	O
5	O	O
-	O	O
substituent	O	O
greatly	O	O
facilitates	O	O
AMPA	O	O
receptor	O	O
agonist	O	O
activity	O	O
.	O	O
Treatment	O	O
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxycinnamoylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propa	I-IUPAC	I-IUPAC
rgylur	I-IUPAC	O
acil	I-IUPAC	O
with	O	O
hexamethyldisilazane	O	O
at	O	O
high	O	O
temperature	O	O
resulted	O	O
in	O	O
higher	O	O
yields	O	O
of	O	O
the	O	O
target	O	O
xanthine	O	O
than	O	O
the	O	O
standard	O	O
ring	O	O
-	O	O
closure	O	O
procedure	O	O
using	O	O
sodium	O	O
hydroxide	O	O
.	O	O
Base	O	O
-	O	O
catalyzed	O	O
ring	O	O
closure	O	O
of	O	O
these	O	O
imidazole	O	O
nucleosides	O	O
gave	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deazaguanosine	I-IUPAC	I-IUPAC
(	O	O
29	O	O
)	O	O
,	O	O
the	O	O
alpha	O	O
-	O	O
anomer	O	O
28	O	O
,	O	O
and	O	O
the	O	O
corresponding	O	O
N	O	O
-	O	O
3	O	O
positional	O	O
isomers	O	O
27	O	O
and	O	O
26	O	O
.	O	O
New	O	O
nucleoside	O	O
analogues	O	O
14-17	O	O
based	O	O
on	O	O
a	O	O
methylenecyclopropane	O	O
structure	O	O
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
antiviral	O	O
activity	O	O
.	O	O
However	O	O
,	O	O
for	O	O
all	O	O
compounds	O	O
there	O	O
was	O	O
a	O	O
good	O	O
correlation	O	O
(	O	O
R	O	O
&	O	O
gt	O	O
;	O	O
0.97	O	O
)	O	O
between	O	O
the	O	O
differential	O	O
uptake	O	O
ratio	O	O
(	O	O
DUR	O	O
,	O	O
(	O	O
%	O	O
ID	O	O
/	O	O
g	O	O
)	O	O
x	O	O
body	O	O
weight	O	O
(	O	O
g	O	O
)	O	O
/	O	O
100	O	O
)	O	O
in	O	O
individual	O	O
rat	O	O
brain	O	O
regions	O	O
at	O	O
30	O	O
min	O	O
after	O	O
injection	O	O
and	O	O
the	O	O
concentration	O	O
of	O	O
receptors	O	O
as	O	O
determined	O	O
by	O	O
in	O	O
vitro	O	O
quantitative	O	O
autoradiography	O	O
in	O	O
rat	O	O
.	O	O
Hydrophobic	O	O
character	O	O
appeared	O	O
to	O	O
influence	O	O
the	O	O
activity	O	O
of	O	O
type	O	O
6	O	O
compounds	O	O
.	O	O
The	O	O
most	O	O
active	O	O
compound	O	O
was	O	O
dl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
erythro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzodioxan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
spiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoxazine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidin	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
,	O	O
and	O	O
various	O	O
modifications	O	O
of	O	O
this	O	O
compound	O	O
were	O	O
made	O	O
in	O	O
order	O	O
to	O	O
elucidate	O	O
the	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
in	O	O
the	O	O
series	O	O
.	O	O
Our	O	O
prior	O	O
publications	O	O
have	O	O
discussed	O	O
the	O	O
discovery	O	O
of	O	O
this	O	O
series	O	O
of	O	O
compounds	O	O
and	O	O
reported	O	O
some	O	O
preliminary	O	O
chemical	O	O
and	O	O
biological	O	O
studies	O	O
around	O	O
N	O	O
-	O	O
6	O	O
substitutions	O	O
and	O	O
5	O	O
-	O	O
membered	O	O
ring	O	O
variations	O	O
of	O	O
1	O	O
.	O	O
A	O	O
new	O	O
one	O	O
-	O	O
pot	O	O
procedure	O	O
is	O	O
described	O	O
for	O	O
the	O	O
preparation	O	O
of	O	O
6,19	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
epithioprogesterone	I-IUPAC	I-IUPAC
and	O	O
related	O	O
compounds	O	O
by	O	O
iodocyclization	O	O
of	O	O
a	O	O
19	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
sulfanylpregn	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ene	I-IUPAC	I-IUPAC
.	O	O
Structure	O	O
-	O	O
activity	O	O
relationships	O	O
are	O	O
discussed	O	O
.	O	O
None	O	O
of	O	O
the	O	O
amino	O	O
acids	O	O
4c	O	O
-	O	O
e	O	O
showed	O	O
detectable	O	O
affinity	O	O
for	O	O
[	O	O
3H	O	O
]	O	O
kainic	O	O
acid	O	O
binding	O	O
sites	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
its	O	O
4alpha	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
19	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
isomer	B-MODIFIER	B-MODIFIER
25	O	O
and	O	O
other	O	O
series	O	O
of	O	O
diol	O	O
compounds	O	O
,	O	O
6,19	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
en	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
steroids	B-MODIFIER	B-MODIFIER
,	O	O
were	O	O
moderate	O	O
to	O	O
poor	O	O
competitive	O	O
inhibitors	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
110-800	O	O
nM	O	O
)	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
relationships	O	O
were	O	O
also	O	O
discussed	O	O
.	O	O
In	O	O
vitro	O	O
calcium	O	O
channel	O	O
antagonist	O	O
and	O	O
agonist	O	O
activities	O	O
were	O	O
determined	O	O
using	O	O
guinea	O	O
pig	O	O
ileum	O	O
longitudinal	O	O
smooth	O	O
muscle	O	O
(	O	O
GPILSM	O	O
)	O	O
and	O	O
guinea	O	O
pig	O	O
left	O	O
atrium	O	O
(	O	O
GPLA	O	O
)	O	O
assays	O	O
,	O	O
respectively	O	O
.	O	O
Condensation	O	O
of	O	O
diethyl	B-IUPAC	O
L	I-IUPAC	O
-	I-IUPAC	O
glutamate	I-IUPAC	O
with	O	O
methyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrobenzoate	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
catalytic	O	O
reduction	O	O
of	O	O
the	O	O
nitro	O	O
group	O	O
,	O	O
reductive	O	O
coupling	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetamido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formylpyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
in	O	O
the	O	O
presence	O	O
of	O	O
dimethylaminoborane	O	O
,	O	O
and	O	O
acidolysis	O	O
with	O	O
HBr	O	O
/	O	O
AcOH	O	O
yielded	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetamido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoindolyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
glutaric	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
.	O	O
The	O	O
longer	O	O
analogues	O	O
PIP	O	O
(	O	O
5,4,5	O	O
)	O	O
and	O	O
PYR	O	O
(	O	O
5,4,5	O	O
)	O	O
are	O	O
very	O	O
similar	O	O
in	O	O
the	O	O
spacing	O	O
of	O	O
their	O	O
amino	O	O
groups	O	O
.	O	O
casei	O	O
.	O	O
Reaction	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carbomethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiophenoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butanone	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
with	O	O
hydroxylamine	O	O
under	O	O
carefully	O	O
controlled	O	O
conditions	O	O
gave	O	O
the	O	O
corresponding	O	O
oxime	O	O
33	O	O
.	O	O
The	O	O
binding	O	O
was	O	O
compared	O	O
with	O	O
that	O	O
of	O	O
PCP	O	O
and	O	O
contrasted	O	O
with	O	O
the	O	O
rigid	O	O
symmetrical	O	O
phencyclidine	O	B-IUPAC
derivatives	O	B-MODIFIER
cis	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bicyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3.1.0	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
hexyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
piperidines	I-IUPAC	I-IUPAC
(	O	O
6	O	O
and	O	O
7	O	O
)	O	O
.	O	O
The	O	O
rates	O	O
of	O	O
hydrolysis	O	O
of	O	O
the	O	O
corresponding	O	O
triphosphates	O	O
by	O	O
recombinant	O	O
rat	O	O
NTPDase1	O	O
and	O	O
2	O	O
were	O	O
studied	O	O
.	O	O
These	O	O
studies	O	O
suggest	O	O
that	O	O
[	O	O
18F	O	O
]	O	O
4c	O	O
should	O	O
be	O	O
a	O	O
useful	O	O
compound	O	O
to	O	O
assess	O	O
dynamic	O	O
changes	O	O
in	O	O
serotonin	O	O
levels	O	O
while	O	O
[	O	O
18F	O	O
]	O	O
4d	O	O
,	O	O
with	O	O
its	O	O
high	O	O
contrast	O	O
and	O	O
F	O	O
-	O	O
18	O	O
label	O	O
,	O	O
should	O	O
provide	O	O
better	O	O
statistics	O	O
and	O	O
quantification	O	O
for	O	O
static	O	O
measurement	O	O
of	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
distribution	O	O
.	O	O
Optimal	O	O
antitetrabenazine	O	O
activity	O	O
is	O	O
associated	O	O
with	O	O
the	O	O
cis	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
3'	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
phenyl	I-PARTIUPAC	I-PARTIUPAC
series	B-MODIFIER	B-MODIFIER
,	O	O
and	O	O
the	O	O
cis	O	O
secondary	O	O
amine	O	O
5a	O	O
is	O	O
approximately	O	O
twice	O	O
as	O	O
potent	O	O
as	O	O
the	O	O
cis	O	O
tertiary	O	O
amine	O	O
3a	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
most	O	O
of	O	O
the	O	O
reported	O	O
compounds	O	O
was	O	O
achieved	O	O
by	O	O
reaction	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nonanone	I-IUPAC	I-IUPAC
with	O	O
the	O	O
suitable	O	O
azole	O	O
followed	O	O
by	O	O
reduction	O	O
of	O	O
the	O	O
carbonyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
to	O	O
give	O	O
a	O	O
diastereoisomeric	O	O
mixture	O	O
of	O	O
N	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
(	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
azoles	I-IUPAC	I-IUPAC
.	O	O
Most	O	O
importantly	O	O
,	O	O
it	O	O
was	O	O
found	O	O
that	O	O
irreversible	O	O
inactivation	O	O
by	O	O
O'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
epoxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tyrosine	I-IUPAC	I-IUPAC
only	O	O
resulted	O	O
if	O	O
the	O	O
carboxy	O	O
terminus	O	O
was	O	O
a	O	O
substrate	O	O
(	O	O
i.e.	O	O
a	O	O
compound	O	O
with	O	O
free	O	O
carboxy	O	O
terminus	O	O
did	O	O
not	O	O
lead	O	O
to	O	O
inactivation	O	O
)	O	O
.	O	O
Evaluation	O	O
of	O	O
compounds	O	O
1	O	O
,	O	O
3-7	O	O
revealed	O	O
that	O	O
only	O	O
the	O	O
heterocycle	O	O
(	O	O
1	O	O
)	O	O
and	O	O
the	O	O
thiocarboxamide	O	O
acyclic	O	O
nucleoside	O	O
(	O	O
5	O	O
)	O	O
were	O	O
active	O	O
.	O	O
The	O	O
key	O	O
step	O	O
in	O	O
each	O	O
preparation	O	O
was	O	O
the	O	O
condensation	O	O
of	O	O
the	O	O
appropriate	O	O
chroman	B-IUPAC	O
-	O	O
,	O	O
thiochroman	B-IUPAC	O
-	I-IUPAC	O
,	O	O
or	O	O
benzothienyl	B-IUPAC	B-PARTIUPAC
-	I-IUPAC	O
substituted	B-MODIFIER	O
phosphorus	B-IUPAC	O
ylide	I-IUPAC	O
,	O	O
obtained	O	O
from	O	O
the	O	O
independent	O	O
synthesis	O	O
of	O	O
the	O	O
corresponding	O	O
phosphonium	O	O
salts	O	O
,	O	O
with	O	O
selected	O	O
polyene	B-IUPAC	O
-	O	O
substituted	B-MODIFIER	O
aldehyde	B-IUPAC	O
esters	I-IUPAC	O
.	O	O
The	O	O
anticonvulsant	O	O
activity	O	O
of	O	O
these	O	O
compounds	O	O
against	O	O
audiogenic	O	O
seizures	O	O
was	O	O
evaluated	O	O
in	O	O
DBA	O	O
/	O	O
2	O	O
mice	O	O
after	O	O
intraperitoneal	O	O
(	O	O
ip	O	O
)	O	O
injection	O	O
.	O	O
Compounds	O	O
synthesized	O	O
in	O	O
this	O	O
study	O	O
inhibited	O	O
HIV	O	O
-	O	O
1	O	O
replication	O	O
in	O	O
MT	O	O
-	O	O
4	O	O
cells	O	O
in	O	O
the	O	O
submicromolar	O	O
to	O	O
namomolar	O	O
concentration	O	O
range	O	O
.	O	O
Several	O	O
unsymmetrical	O	O
guanidines	O	O
containing	O	O
a	O	O
naphthalene	O	O
ring	O	O
on	O	O
one	O	O
nitrogen	O	O
atom	O	O
and	O	O
an	O	O
ortho	O	O
-	O	O
or	O	O
a	O	O
meta	O	O
-	O	O
substituted	O	B-MODIFIER
phenyl	O	B-IUPAC
ring	O	B-MODIFIER
on	O	O
the	O	O
second	O	O
nitrogen	O	O
atom	O	O
,	O	O
e.g.	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
guanidine	I-IUPAC	I-IUPAC
(	O	O
36	O	O
)	O	O
,	O	O
showed	O	O
a	O	O
3-5	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
affinity	O	O
for	O	O
the	O	O
NMDA	O	O
receptor	O	O
ion	O	O
channel	O	O
site	O	O
and	O	O
no	O	O
change	O	O
in	O	O
sigma	O	O
receptor	O	O
affinity	O	O
compared	O	O
to	O	O
the	O	O
respective	O	O
symmetrical	O	O
counterparts	O	O
.	O	O
Unexpectedly	O	O
,	O	O
[	O	O
Ala	O	O
(	O	O
7	O	O
)	O	O
]	O	O
-	O	O
2	O	O
(	O	O
10	O	O
)	O	O
and	O	O
[	O	O
Ala	O	O
(	O	O
7	O	O
)	O	O
]	O	O
-	O	O
3	O	O
(	O	O
11	O	O
)	O	O
have	O	O
very	O	O
high	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
affinity	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.84	O	O
and	O	O
0.98	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
selectivity	O	O
(	O	O
&	O	O
gt	O	O
;	O	O
600	O	O
-	O	O
and	O	O
200	O	O
-	O	O
fold	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxypyridine	I-IUPAC	I-IUPAC
was	O	O
converted	O	O
,	O	O
in	O	O
two	O	O
steps	O	O
,	O	O
to	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
.	O	O
The	O	O
most	O	O
potent	O	O
type	O	O
6	O	O
inhibitor	O	O
was	O	O
alpha	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butylcarbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperidino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
xylene	I-IUPAC	I-IUPAC
(	O	O
6i	O	O
)	O	O
.	O	O
The	O	O
novel	O	O
calcium	O	O
antagonists	O	O
3	B-MODIFIER	O
-	I-MODIFIER	O
N	I-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyrimidines	I-IUPAC	I-IUPAC
1	O	O
and	O	O
9	O	O
and	O	O
3	B-MODIFIER	B-IUPAC
-	I-MODIFIER	I-IUPAC
N	I-MODIFIER	I-IUPAC
-	I-MODIFIER	I-IUPAC
substituted	I-MODIFIER	I-IUPAC
-	O	I-IUPAC
dihydro	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
8	O	O
were	O	O
regioselectively	O	O
synthesized	O	O
in	O	O
good	O	O
yields	O	O
.	O	O
Initial	O	O
derivatives	O	O
of	O	O
these	O	O
series	O	O
(	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
cyclopentylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbamoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylindol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzamide	I-IUPAC	I-IUPAC
(	O	O
5a	O	O
)	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
cyclopentylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbamoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylindol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzamide	I-IUPAC	I-IUPAC
(	O	O
6a	O	O
)	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
when	O	O
compared	O	O
to	O	O
the	O	O
corresponding	O	O
indole	O	O
amides	O	O
(	O	O
e.g.	O	O
28	O	O
and	O	O
29	O	O
)	O	O
,	O	O
were	O	O
found	O	O
to	O	O
be	O	O
approximately	O	O
10	O	O
-	O	O
fold	O	O
less	O	O
potent	O	O
in	O	O
vitro	O	O
and	O	O
substantially	O	O
less	O	O
active	O	O
when	O	O
administered	O	O
orally	O	O
to	O	O
guinea	O	O
pigs	O	O
.	O	O
Attaching	O	O
the	O	O
ligand	O	O
to	O	O
a	O	O
polyamine	O	O
vector	O	O
had	O	O
a	O	O
profound	O	O
effect	O	O
on	O	O
increasing	O	O
the	O	O
iron	O	O
-	O	O
clearing	O	O
efficiency	O	O
of	O	O
this	O	O
chelator	O	O
relative	O	O
to	O	O
its	O	O
parent	O	O
drug	O	O
.	O	O
The	O	O
syntheses	O	O
and	O	O
antinociceptive	O	O
effects	O	O
of	O	O
these	O	O
analogues	O	O
of	O	O
general	O	O
formula	O	O
H	O	O
-	O	O
Lys	O	O
-	O	O
Trp	O	O
(	O	O
R	O	O
)	O	O
-	O	O
OMe	O	O
[	O	O
R	O	O
=	O	O
phenylsulfenyl	B-IUPAC	O
(	O	O
PS	O	O
)	O	O
(	O	O
9	O	O
)	O	O
;	O	O
R	O	O
=	O	O
(	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbomethyoxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfenyl	I-IUPAC	I-IUPAC
(	O	O
CmPS	O	O
)	O	O
(	O	O
10	O	O
)	O	O
;	O	O
R	O	O
=	O	O
(	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfenyl	I-IUPAC	I-IUPAC
(	O	O
pNPS	O	O
)	O	O
(	O	O
11	O	O
)	O	O
;	O	O
R	O	O
=	O	O
(	B-IUPAC	B-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dinitrophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfenyl	I-IUPAC	I-IUPAC
(	O	O
DNPS	O	O
)	O	O
(	O	O
12	O	O
)	O	O
;	O	O
R	O	O
=	O	O
[	B-IUPAC	O
2	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
acetylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbomethoxyethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
sulfenyl	I-IUPAC	I-IUPAC
(	O	O
AacCmES	O	O
)	O	O
(	O	O
13	O	O
)	O	O
;	O	O
R	O	O
=	O	O
[	B-IUPAC	O
2	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
acetylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
sulfenyl	I-IUPAC	I-IUPAC
(	O	O
AacPS	O	O
)	O	O
(	O	O
17	O	O
)	O	O
;	O	O
R	O	O
=	O	O
tert	B-IUPAC	O
-	I-IUPAC	O
butylsulfenyl	I-IUPAC	O
(	O	O
t	O	O
-	O	O
BuS	O	O
)	O	O
(	O	O
23	O	O
)	O	O
;	O	O
R	O	O
=	O	O
(	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbomethoxyethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfenyl	I-IUPAC	I-IUPAC
(	O	O
CmES	O	O
)	O	O
(	O	O
24	O	O
)	O	O
]	O	O
are	O	O
described	O	O
.	O	O
The	O	O
most	O	O
striking	O	O
divergence	O	O
of	O	O
this	O	O
correlation	O	O
was	O	O
the	O	O
high	O	O
potency	O	O
combined	O	O
with	O	O
a	O	O
high	O	O
stability	O	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetylamino	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	B-MODIFIER
derivative	I-MODIFIER	B-MODIFIER
11e	O	O
.	O	O
The	O	O
release	O	O
of	O	O
5	O	O
from	O	O
6	O	O
following	O	O
metabolism	O	O
was	O	O
confirmed	O	O
and	O	O
shown	O	O
by	O	O
use	O	O
of	O	O
the	O	O
bioassay	O	O
system	O	O
to	O	O
be	O	O
an	O	O
event	O	O
of	O	O
similar	O	O
toxicity	O	O
to	O	O
release	O	O
of	O	O
4	O	O
from	O	O
18	O	O
;	O	O
in	O	O
vivo	O	O
,	O	O
however	O	O
,	O	O
6	O	O
(	O	O
LD50	O	O
330	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
more	O	O
toxic	O	O
to	O	O
mice	O	O
than	O	O
18	O	O
(	O	O
LD50	O	O
greater	O	O
than	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O
The	O	O
utility	O	O
of	O	O
polyamines	O	O
as	O	O
vectors	O	O
for	O	O
the	O	O
intracellular	O	O
transport	O	O
of	O	O
iron	O	O
chelators	O	O
is	O	O
further	O	O
described	O	O
.	O	O
One	O	O
compound	O	O
,	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
10,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
azepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
23	O	O
)	O	O
,	O	O
was	O	O
selected	O	O
for	O	O
further	O	O
biological	O	O
investigations	O	O
and	O	O
showed	O	O
a	O	O
protective	O	O
index	O	O
comparable	O	O
to	O	O
or	O	O
slightly	O	O
better	O	O
than	O	O
that	O	O
of	O	O
the	O	O
recently	O	O
launched	O	O
anticonvulsant	O	O
product	O	O
5	O	O
(	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	O	O
.	O	O
A	O	O
novel	O	O
series	O	O
of	O	O
nonpeptide	O	O
CCK	O	O
(	O	O
2	O	O
)	O	O
receptor	O	O
antagonists	O	O
has	O	O
been	O	O
prepared	O	O
,	O	O
in	O	O
which	O	O
2,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dioxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3,4,5,6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
h	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diazonine	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
was	O	O
used	O	O
as	O	O
a	O	O
chemical	O	O
template	O	O
.	O	O
In	O	O
the	O	O
adenylate	O	O
cyclase	O	O
assay	O	O
,	O	O
the	O	O
compounds	O	O
behave	O	O
as	O	O
potent	O	O
D	O	O
-	O	O
2	O	O
agonists	O	O
.	O	O
The	O	O
high	O	O
potency	O	O
of	O	O
several	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
alkoxy	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
alkylthio	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sulfamoylbenzoic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
confirmed	O	O
previous	O	O
suggestions	O	O
that	O	O
the	O	O
apparent	O	O
diuretic	O	O
effect	O	O
of	O	O
4	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkylamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzisothiazole	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxides	I-IUPAC	I-IUPAC
originates	O	I-IUPAC
from	O	O
the	O	O
corresponding	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sulfamoylbenzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
due	O	O
to	O	O
an	O	O
existing	O	O
equilibrium	O	O
in	O	O
plasma	O	O
.	O	O
In	O	O
fact	O	O
,	O	O
[	O	O
Tyr	O	O
(	O	O
7	O	O
)	O	O
]	O	O
-	O	O
2	O	O
(	O	O
6	O	O
)	O	O
and	O	O
[	O	O
Tyr	O	O
(	O	O
7	O	O
)	O	O
]	O	O
-	O	O
3	O	O
(	O	O
7	O	O
)	O	O
show	O	O
ca.	O	O
5	O	O
-	O	O
fold	O	O
selectivity	O	O
for	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
,	O	O
and	O	O
[	O	O
Aph	O	O
(	O	O
7	O	O
)	O	O
]	O	O
-	O	O
2	O	O
(	O	O
8	O	O
)	O	O
and	O	O
[	O	O
Aph	O	O
(	O	O
7	O	O
)	O	O
]	O	O
-	O	O
3	O	O
(	O	O
9	O	O
)	O	O
have	O	O
high	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
affinity	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.2	O	O
and	O	O
0.88	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
selectivity	O	O
,	O	O
suggesting	O	O
that	O	O
indeed	O	O
an	O	O
l	O	O
-	O	O
residue	O	O
at	O	O
position	O	O
8	O	O
will	O	O
direct	O	O
selectivity	O	O
toward	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
.	O	O
Alkylation	O	O
of	O	O
7	O	O
by	O	O
13a	O	O
,	O	O
b	O	O
led	O	O
to	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propargyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deazaaminopterin	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propargyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deazaaminopterin	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
.	O	O
The	O	O
syntheses	O	O
of	O	O
(	B-IUPAC	B-IUPAC
3RS	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypiperidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
3RS	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5SR	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypiperidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
20	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
3RS	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4SR	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetamidopiperidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
3RS	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5SR	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetamidopiperidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
18	O	O
)	O	O
,	O	O
related	O	O
to	O	O
the	O	O
specific	O	O
gamma	B-IUPAC	O
-	I-IUPAC	O
aminobutyric	I-IUPAC	O
acid	I-IUPAC	O
(	O	O
GABA	O	O
)	O	O
uptake	O	O
inhibitors	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
nipecotic	O	O
acid	O	O
)	O	O
and	O	O
(	B-IUPAC	B-IUPAC
3RS	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4SR	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypiperidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
21	O	O
)	O	O
,	O	O
are	O	O
described	O	O
.	O	O
The	O	O
absolute	O	O
stereochemical	O	O
requirements	O	O
for	O	O
binding	O	O
were	O	O
found	O	O
to	O	O
be	O	O
2S	O	O
,	O	O
4R	O	O
,	O	O
showing	O	O
that	O	O
,	O	O
in	O	O
common	O	O
with	O	O
other	O	O
glycine	O	O
-	O	O
site	O	O
NMDA	O	O
receptor	O	O
ligands	O	O
,	O	O
the	O	O
unnatural	O	O
configuration	O	O
at	O	O
the	O	O
alpha	O	O
-	O	O
amino	O	O
acid	O	O
center	O	O
is	O	O
required	O	O
.	O	O
carinii	O	O
)	O	O
and	O	O
IC50	O	O
(	O	O
rat	O	O
)	O	O
/	O	O
IC50	O	O
(	O	O
T	O	O
.	O	O
A	O	O
diverse	O	O
range	O	O
of	O	O
chromen	B-IUPAC	O
-	I-IUPAC	O
2	I-IUPAC	O
-	I-IUPAC	O
one	I-IUPAC	O
,	O	O
chromen	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
and	O	O
pyrimidoisoquinolin	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
was	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
inhibitory	O	O
activity	O	O
against	O	O
the	O	O
DNA	O	O
repair	O	O
enzyme	O	O
DNA	O	O
-	O	O
dependent	O	O
protein	O	O
kinase	O	O
(	O	O
DNA	O	O
-	O	O
PK	O	O
)	O	O
,	O	O
with	O	O
a	O	O
view	O	O
to	O	O
elucidating	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
for	O	O
potency	O	O
and	O	O
kinase	O	O
selectivity	O	O
.	O	O
The	O	O
most	O	O
potent	O	O
alpha2	O	O
-	O	O
agonist	O	O
was	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazole	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
,	O	O
whose	O	O
key	O	O
pharmacophoric	O	O
features	O	O
closely	O	O
matched	O	O
those	O	O
found	O	O
in	O	O
the	O	O
alpha2	O	O
-	O	O
agonist	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
exo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylprop	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
exo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
norbornyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxazoline	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
.	O	O
The	O	O
optimal	O	O
compound	O	O
19	O	O
UR	O	O
-	O	O
12670	O	O
)	O	O
,	O	O
bearing	O	O
the	O	O
3,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diphenylpropanoyl	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
,	O	O
exhibited	O	O
very	O	O
high	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
potency	O	O
IC50	O	O
=	O	O
0.0076	O	O
microM	O	O
for	O	O
the	O	O
in	O	O
vitro	O	O
PAF	O	O
-	O	O
induced	O	O
platelet	O	O
aggregation	O	O
assay	O	O
,	O	O
ID50	O	O
=	O	O
0.0086	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
the	O	O
in	O	O
vivo	O	O
PAF	O	O
-	O	O
induced	O	O
hypotension	O	O
test	O	O
in	O	O
normotensive	O	O
rats	O	O
,	O	O
and	O	O
ID50	O	O
=	O	O
0.092	O	O
mg	O	O
/	O	O
kg	O	O
po	O	O
and	O	O
0.0008	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O
Equally	O	O
effective	O	O
was	O	O
an	O	O
[	O	O
i	O	O
-	O	O
(	O	O
i	O	O
+	O	O
3	O	O
)	O	O
]	O	O
constraint	O	O
yielding	O	O
the	O	O
18	O	O
-	O	O
membered	O	O
ring	O	O
cyclo	O	O
(	O	O
25-28	O	O
)	O	O
[	O	O
MeTyr1	O	O
,	O	O
Ala15	O	O
,	O	O
Glu25	O	O
,	O	O
Nle	O	O
,	O	O
27Lys28	O	O
]	O	O
-	O	O
hGHRH	O	O
-	O	O
(	O	O
1-29	O	O
)	O	O
-	O	O
NH2	O	O
(	O	O
51	O	O
)	O	O
which	O	O
was	O	O
14	O	O
times	O	O
more	O	O
potent	O	O
than	O	O
the	O	O
standard	O	O
.	O	O
Rat	O	O
brain	O	O
monoamine	O	O
levels	O	O
were	O	O
unaltered	O	O
1	O	O
week	O	O
following	O	O
a	O	O
single	O	O
high	O	O
dose	O	O
(	O	O
10	O	O
or	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
sc	O	O
)	O	O
of	O	O
6	O	O
or	O	O
11	O	O
,	O	O
or	O	O
two	O	O
weeks	O	O
following	O	O
a	O	O
subacute	O	O
dosing	O	O
regimen	O	O
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
sc	O	O
,	O	O
twice	O	O
a	O	O
day	O	O
for	O	O
4	O	O
days	O	O
)	O	O
.	O	O
The	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thienylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiazoles	I-IUPAC	I-IUPAC
were	O	O
more	O	O
potent	O	O
in	O	O
mammalian	O	O
than	O	O
in	O	O
nematode	O	O
mitochondria	O	O
and	O	O
had	O	O
an	O	O
average	O	O
titer	O	O
of	O	O
0.11	O	O
mM	O	O
for	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiazole	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
.	O	O
The	O	O
aim	O	O
of	O	O
the	O	O
current	O	O
study	O	O
concerns	O	O
the	O	O
synthesis	O	O
of	O	O
amantidine	O	O
analogues	O	O
by	O	O
appending	O	O
primary	O	O
amines	O	O
to	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
boraadamantane	I-IUPAC	I-IUPAC
to	O	O
evaluate	O	O
such	O	O
compounds	O	O
for	O	O
CD81	O	O
-	O	O
dependent	O	O
antiproliferation	O	O
of	O	O
CD81	O	O
-	O	O
enriched	O	O
cell	O	O
lines	O	O
(	O	O
astrocyte	O	O
)	O	O
vs	O	O
CD81	O	O
-	O	O
deficient	O	O
cell	O	O
lines	O	O
(	O	O
C6	O	O
glioma	O	O
)	O	O
.	O	O
Structure	O	O
proof	O	O
of	O	O
target	O	O
nucleosides	O	O
was	O	O
provided	O	O
by	O	O
independent	O	O
synthesis	O	O
,	O	O
1H	O	O
NMR	O	O
,	O	O
and	O	O
UV	O	O
.	O	O
Contrary	O	O
to	O	O
the	O	O
literature	O	O
reports	O	O
,	O	O
no	O	O
enhancement	O	O
in	O	O
activity	O	O
due	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
hydroxy	O	O
group	O	O
was	O	O
found	O	O
when	O	O
the	O	O
cytotoxicity	O	O
of	O	O
furanones	O	O
13a	O	O
,	O	O
b	O	O
,	O	O
d	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenedihydrofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
6a	O	O
,	O	O
b	O	O
,	O	O
d	O	O
was	O	O
compared	O	O
.	O	O
In	O	O
the	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxydopamine	I-IUPAC	I-IUPAC
-	O	O
lesioned	O	O
rat	O	O
model	O	O
,	O	O
this	O	O
compound	O	O
was	O	O
also	O	O
quite	O	O
effective	O	O
,	O	O
with	O	O
a	O	O
minimum	O	O
effective	O	O
dose	O	O
of	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
po	O	O
.	O	O
Their	O	O
affinity	O	O
to	O	O
beta	O	O
1	O	O
-	O	O
and	O	O
beta	O	B-IUPAC
-	O	I-IUPAC
2	O	I-IUPAC
-	O	I-IUPAC
adrenoceptors	O	I-IUPAC
was	O	O
determined	O	O
and	O	O
compared	O	O
with	O	O
the	O	O
affinity	O	O
of	O	O
known	O	O
beta	O	O
-	O	O
blockers	O	O
.	O	O
With	O	O
an	O	O
in	O	O
vitro	O	O
pA2	O	O
(	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
Mg2+	O	O
)	O	O
=	O	O
9.12	O	O
+	O	O
/	O	O
-	O	O
0.09	O	O
,	O	O
dP	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
]	O	O
AVT	O	O
is	O	O
(	O	O
7	O	O
)	O	O
one	O	O
of	O	O
the	O	O
most	O	O
potent	O	O
in	O	O
vitro	O	O
oxytocin	O	O
antagonists	O	O
reported	O	O
to	O	O
date	O	O
.	O	O
5	O	O
-	O	O
Bromo	O	O
-	O	O
dUMP	O	O
and	O	O
5	O	O
-	O	O
iodo	O	O
-	O	O
dUMP	O	O
showed	O	O
substrate	O	O
activity	O	O
independent	O	O
of	O	O
N	B-IUPAC	O
(	I-IUPAC	O
5	I-IUPAC	O
)	I-IUPAC	O
,	I-IUPAC	O
N	I-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenetetrahydrofolate	I-IUPAC	I-IUPAC
in	O	O
the	O	O
thymidylate	O	O
synthase	O	O
-	O	O
catalyzed	O	O
dehalogenation	O	O
reaction	O	O
.	O	O
3,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
isopropyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylflavone	I-IUPAC	I-IUPAC
,	O	O
11e	O	O
,	O	O
was	O	O
both	O	O
potent	O	O
and	O	O
highly	O	O
selective	O	O
(	O	O
approximately	O	O
200	O	O
-	O	O
fold	O	O
)	O	O
for	O	O
human	O	O
A3	O	O
receptors	O	O
(	O	O
Ki	O	O
=	O	O
0.56	O	O
microM	O	O
)	O	O
.	O	O
Incorporation	O	O
of	O	O
substituted	B-MODIFIER	B-MODIFIER
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylidene	I-IUPAC	I-IUPAC
moieties	B-MODIFIER	B-MODIFIER
onto	O	O
the	O	O
7	O	O
-	O	O
keto	O	O
precursor	O	O
of	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
morphan	I-IUPAC	I-IUPAC
,	O	O
(	O	O
+	O	O
)	O	O
-	O	O
1	O	O
,	O	O
produces	O	O
compounds	O	O
(	O	O
-	O	O
)	O	O
-	O	O
2	O	O
through	O	O
(	O	O
-	O	O
)	O	O
-	O	O
7	O	O
(	O	O
5.8-32.0	O	O
nM	O	O
,	O	O
sigma	O	O
1	O	O
)	O	O
,	O	O
which	O	O
have	O	O
between	O	O
a	O	O
25	O	O
-	O	O
and	O	O
131	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
affinity	O	O
for	O	O
the	O	O
sigma	O	O
1	O	O
receptor	O	O
subtype	O	O
relative	O	O
to	O	O
the	O	O
keto	O	O
precursor	O	O
(	O	O
+	O	O
)	O	O
-	O	O
1	O	O
(	O	O
Ki	O	O
=	O	O
762	O	O
nM	O	O
,	O	O
sigma	O	O
1	O	O
)	O	O
.	O	O
In	O	O
the	O	O
series	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
thienylvinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
imidazothiazoles	I-IUPAC	I-IUPAC
,	O	O
the	O	O
hydrobromide	B-MODIFIER	O
of	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thienylvinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiazole	I-IUPAC	I-IUPAC
(	O	O
E	O	O
-	O	O
5	O	O
.	O	O
Competition	O	O
binding	O	O
in	O	O
cells	O	O
stably	O	O
expressing	O	O
the	O	O
transfected	O	O
human	O	O
SERT	O	O
,	O	O
dopamine	O	O
transporter	O	O
(	O	O
DAT	O	O
)	O	O
,	O	O
and	O	O
norepinephrine	O	O
transporter	O	O
(	O	O
NET	O	O
)	O	O
using	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
citalopram	O	O
,	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
WIN	O	O
35,428	O	O
,	O	O
and	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
nisoxetine	O	O
,	O	O
respectively	O	O
,	O	O
demonstrated	O	O
the	O	O
following	O	O
order	O	O
of	O	O
SERT	O	O
affinity	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
in	O	O
nM	O	O
)	O	O
:	O	O
ZIENT	O	O
(	O	O
0.05	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
nor	O	O
-	O	O
CIT	O	O
(	O	O
0.12	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
&	O	O
gt	O	O
;	O	O
EIENT	O	O
(	O	O
1.15	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
fluvoxamine	O	O
(	O	O
1.46	O	O
)	O	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azidovinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
9a	O	O
-	O	O
c	O	O
were	O	O
found	O	O
to	O	O
exhibit	O	O
potent	O	O
and	O	O
selective	O	O
in	O	O
vitro	O	O
anti	O	O
-	O	O
HBV	O	O
activity	O	O
against	O	O
duck	O	O
hepatitis	O	O
B	O	O
virus	O	O
(	O	O
DHBV	O	O
)	O	O
infected	O	O
primary	O	O
duck	O	O
hepatocytes	O	O
at	O	O
low	O	O
concentrations	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.01-0.1	O	O
microg	O	O
/	O	O
mL	O	O
range	O	O
)	O	O
.	O	O
Attachment	O	O
of	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
sulfonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolidinedione	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
to	O	O
the	O	O
2	O	O
-	O	O
naphthalene	O	O
position	O	O
led	O	O
to	O	O
optimum	O	O
activity	O	O
.	O	O
The	O	O
most	O	O
selective	O	O
A	O	O
(	O	O
3	O	O
)	O	O
AR	O	O
antagonist	O	O
(	O	O
&	O	O
gt	O	O
;	O	O
200	O	O
-	O	O
fold	O	O
)	O	O
was	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexyladenine	I-IUPAC	I-IUPAC
(	O	O
22	O	O
)	O	O
.	O	O
Med.	O	O
Chem.	O	O
1993	O	O
,	O	O
36	O	O
,	O	O
801-810	O	O
)	O	O
.	O	O
Potencies	O	O
at	O	O
central	O	O
pre	O	O
-	O	O
(	O	O
auto	O	O
-	O	O
)	O	O
and	O	O
postsynaptic	O	O
DA	O	O
receptors	O	O
were	O	O
determined	O	O
by	O	O
a	O	O
biochemical	O	O
and	O	O
a	O	O
behavioral	O	O
method	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
2	B-IUPAC	O
-	I-IUPAC	O
phenyl	I-IUPAC	O
residue	B-MODIFIER	O
in	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylpyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amine	I-IUPAC	I-IUPAC
(	O	O
ADPEP	O	O
,	O	O
1	O	O
)	O	O
and	O	O
in	O	O
the	O	O
corresponding	O	O
pyrimido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indole	I-IUPAC	I-IUPAC
(	O	O
APEPI	O	O
,	O	O
3	O	O
)	O	O
could	O	O
be	O	O
bioisosterically	O	O
replaced	O	O
by	O	O
heterocyclic	O	O
rings	O	O
,	O	O
such	O	O
as	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
.	O	O
Preliminary	O	O
findings	O	O
on	O	O
the	O	O
acute	O	O
toxicity	O	O
of	O	O
the	O	O
poly	O	O
(	O	O
HOPO	O	O
)	O	O
ligands	O	O
and	O	O
HOPO	O	O
monomers	O	O
are	O	O
presented	O	O
in	O	O
an	O	O
appendix	O	O
.	O	O
The	O	O
triethyl	O	O
and	O	O
tripropyl	O	B-IUPAC
ether	O	I-IUPAC
derivatives	O	B-MODIFIER
of	O	O
the	O	O
flavonol	O	O
galangin	O	O
,	O	O
4	O	O
,	O	O
had	O	O
Ki	O	O
values	O	O
of	O	O
0.3	O	O
-	O	O
0.4	O	O
microM	O	O
at	O	O
human	O	O
A3	O	O
receptors	O	O
.	O	O
For	O	O
each	O	O
compound	O	O
,	O	O
the	O	O
corresponding	O	O
carboxylic	O	O
acid	O	O
was	O	O
identified	O	O
as	O	O
a	O	O
major	O	O
metabolite	O	O
in	O	O
blood	O	O
.	O	O
(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O
The	O	O
synthesis	O	O
and	O	O
sigma	O	O
receptor	O	O
affinity	O	O
of	O	O
a	O	O
series	O	O
of	O	O
conformationally	O	O
restricted	O	O
derivatives	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylethylenedi	I-IUPAC	I-IUPAC
amine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
is	O	O
described	O	O
.	O	O
On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
(	O	O
R	O	O
)	O	O
-	O	O
APPA	O	O
(	O	O
3	O	O
)	O	O
and	O	O
(	O	O
R	O	O
)	O	O
-	O	O
2	O	O
-	O	O
Py	O	O
-	O	O
AMPA	O	O
(	O	O
6	O	O
)	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
weak	O	O
AMPA	O	O
antagonists	O	O
.	O	O
The	O	O
combination	O	O
of	O	O
the	O	O
2,2,4,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetramethylthiochroman	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
and	O	O
the	O	O
benzoic	O	O
acid	O	O
(	O	O
or	O	O
ester	O	O
)	O	O
terminal	O	O
group	O	O
seemed	O	O
to	O	O
enhance	O	O
the	O	O
biological	O	O
action	O	O
which	O	O
resembles	O	O
that	O	O
found	O	O
with	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5,6,7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,5,8,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetramethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthalenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
TTNPB	O	O
,	O	O
6b	O	O
)	O	O
,	O	O
a	O	O
well	O	O
-	O	O
known	O	O
model	O	O
system	O	O
.	O	O
The	O	O
intravenous	O	O
administration	O	O
of	O	O
3h	O	O
significantly	O	O
reduced	O	O
the	O	O
urinary	O	O
bladder	O	O
pressure	O	O
in	O	O
anesthetized	O	O
male	O	O
rats	O	O
(	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
=	O	O
48	O	O
microg	O	O
/	O	O
kg	O	O
)	O	O
without	O	O
cardiovascular	O	O
side	O	O
effects	O	O
.	O	O
Both	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,2,5	O	O
)	O	O
-	O	O
[	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
,	O	O
Tyr	O	O
(	O	O
11	O	O
)	O	O
]	O	O
-	O	O
Cbm	O	O
-	O	O
SRIF	O	O
(	O	O
27	O	O
)	O	O
and	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,2,5	O	O
)	O	O
-	O	O
[	O	O
DCys	O	O
(	O	O
3	O	O
)	O	O
,	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
,	O	O
Tyr	O	O
(	O	O
11	O	O
)	O	O
]	O	O
-	O	O
Cbm	O	O
-	O	O
SRIF	O	O
(	O	O
29	O	O
)	O	O
show	O	O
agonistic	O	O
activity	O	O
in	O	O
a	O	O
cAMP	O	O
assay	O	O
;	O	O
therefore	O	O
,	O	O
the	O	O
structural	O	O
basis	O	O
for	O	O
the	O	O
agonist	O	O
property	O	O
of	O	O
this	O	O
family	O	O
of	O	O
analogues	O	O
is	O	O
not	O	O
contingent	O	O
upon	O	O
the	O	O
chirality	O	O
of	O	O
the	O	O
Cys	O	O
residue	O	O
at	O	O
position	O	O
3	O	O
as	O	O
shown	O	O
to	O	O
be	O	O
the	O	O
case	O	O
in	O	O
18	O	O
-	O	O
membered	O	O
ring	O	O
SRIF	O	O
octapeptides	O	O
.	O	O
The	O	O
same	O	O
sequence	O	O
of	O	O
reactions	O	O
starting	O	O
with	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
omega	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
N6	O	O
-	O	O
CH3	O	O
-	O	O
AMP	O	O
gave	O	O
N6	O	O
-	O	O
CH3	O	O
,	O	O
N6	O	O
-	O	O
(	O	O
CH2	O	O
)	O	O
nH	O	O
(	O	O
CH3	O	O
)	O	O
CO	O	O
(	O	O
CH2	O	O
)	O	O
mNHCOCH2I	O	O
derivatives	O	O
of	O	O
ATP	O	O
(	O	O
n	O	O
=	O	O
4	O	O
,	O	O
m	O	O
=	O	O
3	O	O
,	O	O
5	O	O
or	O	O
6	O	O
;	O	O
n	O	O
=	O	O
6	O	O
,	O	O
m	O	O
=	O	O
5	O	O
or	O	O
6	O	O
)	O	O
.	O	O
The	O	O
inhibitory	O	O
action	O	O
of	O	O
E	O	O
-	O	O
5	O	O
.	O	O
A	O	O
convenient	O	O
synthesis	O	O
of	O	O
8	O	B-IUPAC
-	O	I-IUPAC
azapurine	O	I-IUPAC
ribonucleosides	O	I-IUPAC
substituted	O	B-MODIFIER
at	O	O
the	O	O
6	O	O
position	O	O
with	O	O
thio	B-IUPAC	O
,	O	O
alkylthio	B-IUPAC	O
,	O	O
alkoxy	B-IUPAC	O
,	O	O
amino	B-IUPAC	O
,	O	O
and	O	O
alkylamino	B-IUPAC	O
groups	B-MODIFIER	O
is	O	O
described	O	O
.	O	O
Since	O	O
hypoxic	O	O
cells	O	O
remote	O	O
from	O	O
the	O	O
tumor	O	O
blood	O	O
supply	O	O
may	O	O
have	O	O
a	O	O
greater	O	O
capacity	O	O
for	O	O
reductive	O	O
reactions	O	O
than	O	O
well	O	O
-	O	O
oxygenated	O	O
cells	O	O
,	O	O
we	O	O
have	O	O
prepared	O	O
a	O	O
series	O	O
of	O	O
anthraquinone	O	O
prodrugs	O	O
which	O	O
may	O	O
be	O	O
capable	O	O
of	O	O
generating	O	O
a	O	O
reactive	O	O
quinonemethide	O	O
species	O	O
following	O	O
enzymatic	O	O
reduction	O	O
to	O	O
the	O	O
hydroquinone	O	O
and	O	O
loss	O	O
of	O	O
the	O	O
substituent	O	O
on	O	O
the	O	O
methylene	O	O
group	O	O
in	O	O
the	O	O
2	O	O
position	O	O
.	O	O
Seven	O	O
compounds	O	O
strongly	O	O
inhibited	O	O
tubulin	O	O
polymerization	O	O
with	O	O
activities	O	O
higher	O	O
or	O	O
comparable	O	O
to	O	O
those	O	O
of	O	O
the	O	O
reference	O	O
compounds	O	O
such	O	O
as	O	O
colchicine	O	O
,	O	O
podophyllotoxin	O	O
,	O	O
and	O	O
nocodazole	O	O
.	O	O
An	O	O
increase	O	O
in	O	O
the	O	O
size	O	O
of	O	O
the	O	O
4	O	O
substitutent	O	O
of	O	O
the	O	O
3	O	B-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
aryloxy	O	I-IUPAC
)	O	I-IUPAC
moiety	O	B-MODIFIER
to	O	O
caproamido	O	O
leads	O	O
to	O	O
a	O	O
substantially	O	O
higher	O	O
affinity	O	O
for	O	O
the	O	O
beta	O	O
1	O	O
-	O	O
-	O	O
adrenoceptor	O	O
of	O	O
rat	O	O
ventricular	O	O
muscle	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxyphenethyl	I-IUPAC	I-IUPAC
than	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenethyl	I-IUPAC	I-IUPAC
or	O	O
isopropyl	O	B-IUPAC
group	O	B-MODIFIER
;	O	O
this	O	O
combination	O	O
also	O	O
gave	O	O
the	O	O
highest	O	O
cardioselectivity	O	O
.	O	O
In	O	O
particular	O	O
,	O	O
compounds	O	O
37	O	O
and	O	O
47	O	O
proved	O	O
lethal	O	O
at	O	O
100	O	O
micrograms	O	O
/	O	O
mL	O	O
after	O	O
an	O	O
exposure	O	O
of	O	O
only	O	O
1	O	O
h	O	O
.	O	O
Analogs	O	O
with	O	O
dihydroxy	B-IUPAC	O
substituents	B-MODIFIER	O
(	O	O
catechols	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
nitrogen	O	O
substituents	O	O
larger	O	O
than	O	O
methyl	O	O
,	O	O
had	O	O
little	O	O
affinity	O	O
for	O	O
[	O	O
3H	O	O
]	O	O
4	O	O
binding	O	O
sites	O	O
and	O	O
did	O	O
not	O	O
significantly	O	O
affect	O	O
TH	O	O
activity	O	O
.	O	O
Several	O	O
compounds	O	O
demonstrated	O	O
moderate	O	O
to	O	O
high	O	O
affinity	O	O
for	O	O
the	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
binding	O	O
site	O	O
,	O	O
with	O	O
compounds	O	O
37	O	O
and	O	O
38	O	O
containing	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidinylpiperazinyl	I-IUPAC	I-IUPAC
and	O	O
[	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
piperazinyl	I-IUPAC	I-IUPAC
moieties	B-MODIFIER	B-MODIFIER
and	O	O
compound	O	O
47	O	O
containing	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyrazinylpiperazinyl	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
displaying	O	O
the	O	O
highest	O	O
affinity	O	O
(	O	O
Ki	O	O
values	O	O
of	O	O
10	O	O
,	O	O
4	O	O
,	O	O
and	O	O
9	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
brucei	O	O
parasite	O	O
growth	O	O
in	O	O
vitro	O	O
at	O	O
&	O	O
lt	O	O
;	O	O
1	O	O
microM	O	O
.	O	O
Compounds	O	O
14	O	O
+	O	O
16	O	O
were	O	O
converted	O	O
to	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methylene	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
28	O	O
and	O	O
29	O	O
which	O	O
were	O	O
separated	O	O
and	O	O
deprotected	O	O
to	O	O
give	O	O
14	O	O
and	O	O
16	O	O
.	O	O
Introduction	O	O
of	O	O
a	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
at	O	O
the	O	O
indole	O	O
nitrogen	O	O
atom	O	O
rendered	O	O
very	O	O
selective	O	O
sigma	O	O
2	O	O
ligands	O	O
with	O	O
subnanomolar	O	O
affinity	O	O
for	O	O
the	O	O
sigma	O	O
2	O	O
binding	O	O
site	O	O
.	O	O
Their	O	O
protected	O	O
precursors	O	O
were	O	O
synthesized	O	O
either	O	O
entirely	O	O
by	O	O
the	O	O
solid	O	O
-	O	O
phase	O	O
method	O	O
or	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
solid	O	O
-	O	O
phase	O	O
and	O	O
solution	O	O
methods	O	O
(	O	O
1	O	O
+	O	O
8	O	O
or	O	O
8	O	O
+	O	O
1	O	O
couplings	O	O
)	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
prepared	O	O
by	O	O
nucleophilic	O	O
displacement	O	O
of	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
chloromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
furo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
with	O	O
the	O	O
appropriate	O	O
thiol	O	O
,	O	O
amine	O	O
,	O	O
or	O	O
naphthol	O	O
.	O	O
The	O	O
low	O	O
adrenomedullary	O	O
affinity	O	O
observed	O	O
with	O	O
[	B-IUPAC	B-IUPAC
14C	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
guanidine	I-IUPAC	I-IUPAC
and	O	O
m	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
125I	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
iodobenzylamine	I-IUPAC	I-IUPAC
demonstrates	O	O
the	O	O
uniqueness	O	O
of	O	O
the	O	O
aralkylguanidine	O	O
structure	O	O
.	O	O
In	O	O
addition	O	O
5a	O	O
exhibited	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
contraction	O	O
induced	O	O
by	O	O
histamine	O	O
or	O	O
acetylcholine	O	O
.	O	O
The	O	O
higher	O	O
[	O	O
ST	O	O
-	O	O
CB	O	O
]	O	O
/	O	O
CB	O	O
ratio	O	O
observed	O	O
for	O	O
2B	O	O
was	O	O
corroborated	O	O
by	O	O
the	O	O
results	O	O
of	O	O
an	O	O
in	O	O
vitro	O	O
binding	O	O
assay	O	O
.	O	O
A	O	O
series	O	O
of	O	O
four	O	O
halogenated	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
of	O	O
L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fucose	I-IUPAC	I-IUPAC
(	O	O
4	O	O
,	O	O
X	O	O
=	O	O
F	O	O
,	O	O
Cl	O	O
,	O	O
Br	O	O
,	O	O
and	O	O
I	O	O
)	O	O
have	O	O
been	O	O
obtained	O	O
starting	O	O
from	O	O
1,2	B-IUPAC	B-IUPAC
:	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropylidene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
galactose	I-IUPAC	I-IUPAC
.	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
hydroxyl	O	B-IUPAC
group	O	B-MODIFIER
of	O	O
7	O	O
functions	O	O
as	O	O
an	O	O
H	O	O
-	O	O
bond	O	O
acceptor	O	O
,	O	O
rather	O	O
than	O	O
a	O	O
donor	O	O
,	O	O
and	O	O
that	O	O
on	O	O
interaction	O	O
of	O	O
7	O	O
,	O	O
and	O	O
the	O	O
pyrido	O	B-IUPAC
analogues	O	B-MODIFIER
9	O	O
,	O	O
with	O	O
a	O	O
common	O	O
receptor	O	O
,	O	O
an	O	O
orbital	O	O
occupied	O	O
by	O	O
one	O	O
of	O	O
the	O	O
oxygen	O	O
lone	O	O
pair	O	O
electrons	O	O
of	O	O
7	O	O
must	O	O
assume	O	O
the	O	O
same	O	O
orientation	O	O
as	O	O
the	O	O
orbital	O	O
occupied	O	O
by	O	O
the	O	O
pyridine	O	O
nitrogen	O	O
lone	O	O
pair	O	O
.	O	O
The	O	O
gamma	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
methylene	I-PARTIUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
MTX	O	O
and	O	O
AMT	O	O
are	O	O
attractive	O	O
because	O	O
of	O	O
their	O	O
potential	O	O
to	O	O
act	O	O
as	O	O
Michael	O	O
acceptors	O	O
within	O	O
the	O	O
DHFR	O	O
active	O	O
site	O	O
.	O	O
In	O	O
a	O	O
preliminary	O	O
study	O	O
,	O	O
a	O	O
series	O	O
of	O	O
N	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
14	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
C	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
ethylpiperidin	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
yl	I-PARTIUPAC	I-IUPAC
or	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
ylmethanol	I-PARTIUPAC	I-IUPAC
esters	I-PARTIUPAC	I-IUPAC
(	O	O
acetyl	O	O
and	O	O
propionyl	O	O
esters	O	O
)	O	O
were	O	O
newly	O	O
designed	O	O
and	O	O
evaluated	O	O
in	O	O
vitro	O	O
regarding	O	O
the	O	O
reactivity	O	O
with	O	O
and	O	O
specificity	O	O
to	O	O
AChE	O	O
using	O	O
purified	O	O
human	O	O
enzymes	O	O
,	O	O
leading	O	O
to	O	O
a	O	O
novel	O	O
(	O	O
18	O	O
)	O	O
F	O	O
-	O	O
labeled	O	O
acetylcholine	O	O
analogue	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
18	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
F	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
fluoroethylpiperidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
.	O	O
They	O	O
displayed	O	O
high	O	O
potency	O	O
on	O	O
all	O	O
the	O	O
assays	O	O
and	O	O
some	O	O
selectivity	O	O
for	O	O
alpha1a	O	O
and	O	O
alpha1d	O	O
subtypes	O	O
.	O	O
The	O	O
present	O	O
work	O	O
explored	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkylamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzothiadiazine	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxides	I-IUPAC	I-IUPAC
diversely	O	O
substituted	O	O
in	O	O
the	O	O
7	O	O
-	O	O
position	O	O
.	O	O
A	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylacetyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
,	O	O
12	O	O
,	O	O
was	O	O
470	O	O
-	O	O
fold	O	O
selective	O	O
for	O	O
human	O	O
A3	O	O
vs	O	O
rat	O	O
A1	O	O
receptors	O	O
with	O	O
a	O	O
Ki	O	O
value	O	O
of	O	O
0.65	O	O
nM	O	O
.	O	O
Biological	O	O
evaluation	O	O
in	O	O
Limulus	O	O
photoreceptors	O	O
showed	O	O
that	O	O
1L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
myo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
1,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trisphosphate	I-IUPAC	I-IUPAC
was	O	O
much	O	O
more	O	O
active	O	O
than	O	O
the	O	O
D	O	O
-	O	O
enantiomer	O	O
,	O	O
producing	O	O
repetitive	O	O
bursts	O	O
of	O	O
depolarization	O	O
due	O	O
to	O	O
mobilization	O	O
of	O	O
intracellular	O	O
calcium	O	O
.	O	O
In	O	O
conclusion	O	O
,	O	O
small	O	O
cyclic	O	O
peptides	O	O
were	O	O
created	O	O
,	O	O
which	O	O
mimic	O	O
the	O	O
structure	O	O
and	O	O
activity	O	O
of	O	O
the	O	O
binding	O	O
epitope	O	O
of	O	O
uPA	O	O
to	O	O
uPAR	O	O
and	O	O
which	O	O
may	O	O
serve	O	O
as	O	O
novel	O	O
therapeutic	O	O
agents	O	O
in	O	O
cancer	O	O
metastasis	O	O
.	O	O
The	O	O
syntheses	O	O
of	O	O
the	O	O
fixed	O	O
Northern	O	O
conformers	O	O
1-5	O	O
were	O	O
performed	O	O
by	O	O
Mitsunobu	O	O
coupling	O	O
of	O	O
the	O	O
heterocyclic	O	O
bases	O	O
with	O	O
the	O	O
chiral	O	O
carbocyclic	O	O
alcohol	O	O
6	O	O
[	O	O
(	B-IUPAC	O
1R	I-IUPAC	O
,	I-IUPAC	O
2S	I-IUPAC	O
,	I-IUPAC	O
4R	I-IUPAC	O
,	I-IUPAC	O
5S	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
1	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydrox	I-IUPAC	I-IUPAC
ybicyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3.1.0	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
hexane	I-IUPAC	I-IUPAC
]	O	I-IUPAC
,	O	O
while	O	O
the	O	O
synthesis	O	O
of	O	O
the	O	O
Southern	O	O
conformer	O	O
,	O	O
(	O	B-IUPAC
S	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
methanocarba	O	I-IUPAC
-	O	I-IUPAC
T	O	I-IUPAC
(	O	O
12	O	O
)	O	O
,	O	O
was	O	O
reported	O	O
earlier	O	O
.	O	O
Previously	O	O
we	O	O
have	O	O
reported	O	O
the	O	O
discovery	O	O
of	O	O
ABT	O	O
-	O	O
627	O	O
(	O	O
1	O	O
,	O	O
A	O	O
-	O	O
147627	O	O
,	O	O
active	O	O
enantiomer	O	O
of	O	O
A	O	O
-	O	O
127722	O	O
)	O	O
,	O	O
a	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaryl	I-IUPAC	I-IUPAC
substituted	B-MODIFIER	B-MODIFIER
pyrrolidine	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
based	O	O
endothelin	O	O
receptor	O	O
-	O	O
A	O	O
antagonist	O	O
.	O	O
Of	O	O
particular	O	O
interest	O	O
are	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methoxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diphenylhydantoin	I-IUPAC	I-IUPAC
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetoxymethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylhydantoin	I-IUPAC	I-IUPAC
,	O	O
which	O	O
show	O	O
good	O	O
activity	O	O
against	O	O
maximal	O	O
electroshock	O	O
seizures	O	O
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxymethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylhydantoin	I-IUPAC	I-IUPAC
,	O	O
which	O	O
is	O	O
effective	O	O
against	O	O
both	O	O
maximal	O	O
electroshock	O	O
and	O	O
pentylenetetrazole	B-IUPAC	O
.	O	O
Herein	O	O
we	O	O
report	O	O
the	O	O
effects	O	O
of	O	O
varying	O	O
stereochemistry	O	O
around	O	O
the	O	O
hydroisoquinoline	O	O
ring	O	O
;	O	O
of	O	O
tetrahydro	O	O
-	O	O
versus	O	O
decahydroisoquinoline	O	O
;	O	O
of	O	O
having	O	O
the	O	O
carboxylic	O	O
acid	O	O
at	O	O
C	O	O
-	O	O
1	O	O
versus	O	O
C	O	O
-	O	O
3	O	O
;	O	O
of	O	O
varying	O	O
the	O	O
length	O	O
of	O	O
the	O	O
carbon	O	O
chain	O	O
connecting	O	O
a	O	O
tetrazole	O	O
to	O	O
the	O	O
bicyclic	O	O
nucleus	O	O
;	O	O
and	O	O
of	O	O
holding	O	O
the	O	O
connecting	O	O
chain	O	O
constant	O	O
at	O	O
two	O	O
atoms	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
heteroatom	O	O
substitution	O	O
in	O	O
the	O	O
position	O	O
adjacent	O	O
to	O	O
the	O	O
bicyclic	O	O
nucleus	O	O
and	O	O
substitution	O	O
with	O	O
methyl	O	O
or	O	O
phenyl	O	O
on	O	O
the	O	O
chain	O	O
.	O	O
(	B-IUPAC	O
6R	I-IUPAC	O
,	I-IUPAC	O
6S	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
5	I-IUPAC	O
-	I-IUPAC	O
Deazatetrahydrofolate	I-IUPAC	O
,	O	O
in	O	O
which	O	O
the	O	O
side	O	O
chain	O	O
is	O	O
free	O	O
to	O	O
rotate	O	O
,	O	O
was	O	O
rapidly	O	O
converted	O	O
to	O	O
long	O	O
-	O	O
chain	O	O
polyglutamates	O	O
.	O	O
A	O	O
trace	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorouracil	I-IUPAC	I-IUPAC
(	O	O
3	O	O
-	O	O
Thf	O	O
-	O	O
FU	O	O
,	O	O
5	O	O
)	O	O
was	O	O
formed	O	O
in	O	O
these	O	O
reactions	O	O
.	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Deaza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propargylfolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
,	O	O
an	O	O
analogue	O	O
of	O	O
the	O	O
thymidylate	O	O
synthase	O	O
(	O	O
TS	O	O
)	O	O
inhibitor	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propargyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideazafolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
PDDF	O	O
,	O	O
1	O	O
)	O	O
,	O	O
was	O	O
prepared	O	O
via	O	O
alkylation	O	O
of	O	O
diethyl	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
propargylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamate	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
by	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidinone	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
.	O	O
The	O	O
enantiomer	O	O
of	O	O
11a	O	O
,	O	O
i.e.	O	O
,	O	O
ent	O	O
-	O	O
11a	O	O
,	O	O
with	O	O
the	O	O
(	B-IUPAC	B-IUPAC
1S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclopropane	I-IUPAC	I-IUPAC
structure	B-MODIFIER	B-MODIFIER
turned	O	O
out	O	O
to	O	O
be	O	O
a	O	O
highly	O	O
potent	O	O
and	O	O
selective	O	O
H3	O	O
receptor	O	O
antagonist	O	O
with	O	O
a	O	O
Ki	O	O
of	O	O
3.6	O	O
nM	O	O
.	O	O
Methylation	O	O
of	O	O
4	O	O
with	O	O
CH2N2	O	O
and	O	O
subsequent	O	O
removal	O	O
of	O	O
the	O	O
benzyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
by	O	O
catalytic	O	O
hydrogenation	O	O
provided	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylpyrazofurin	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
.	O	O
Insight	O	O
into	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
(	O	O
SAR	O	O
)	O	O
for	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamides	I-IUPAC	I-IUPAC
has	O	O
been	O	O
enhanced	O	O
by	O	O
studying	O	O
the	O	O
complex	O	O
formed	O	O
between	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
44	O	O
,	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
6	O	O
nM	O	O
)	O	O
and	O	O
the	O	O
catalytic	O	O
domain	O	O
of	O	O
chicken	O	O
PARP	O	O
.	O	O
In	O	O
a	O	O
sequence	O	O
of	O	O
reactions	O	O
,	O	O
methyl	O	B-IUPAC
mesopyropheophorbide	O	I-IUPAC
a	O	I-IUPAC
,	O	I-IUPAC
mesochlorin	B-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
trimethyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
,	O	O
mesochlorin	B-IUPAC	O
p	I-IUPAC	O
(	I-IUPAC	O
6	I-IUPAC	O
)	I-IUPAC	O
trimethyl	I-IUPAC	O
ester	I-IUPAC	O
,	O	O
mesopurpurin	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
18	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexylimide	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
,	O	O
and	O	O
mesopurpurin	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
18	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzylimide	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
from	O	O
chlorophyll	O	O
-	O	O
a	O	O
.	O	O
The	O	O
N3	O	O
-	O	O
substituted	O	B-MODIFIER
derivatives	O	B-MODIFIER
were	O	O
heated	O	O
with	O	O
a	O	O
mixture	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylaniline	I-IUPAC	I-IUPAC
and	O	O
its	O	O
hydrochloride	O	O
to	O	O
effect	O	O
displacement	O	O
of	O	O
the	O	O
6	O	B-IUPAC
-	O	I-IUPAC
amino	O	I-IUPAC
group	O	B-MODIFIER
and	O	O
simultaneous	O	O
demethylation	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
to	O	O
yield	O	O
target	O	O
compounds	O	O
in	O	O
good	O	O
yields	O	O
.	O	O
Thus	O	O
,	O	O
unlike	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxazolidinediones	I-IUPAC	I-IUPAC
,	O	O
N3	O	O
-	O	O
alkylation	O	O
of	O	O
hydantoins	O	O
dramatically	O	O
decreases	O	O
sodium	O	O
channel	O	O
-	O	O
binding	O	O
activity	O	O
.	O	O
Inhibitory	O	O
activity	O	O
of	O	O
cytosine	O	O
derivative	O	O
9c	O	O
is	O	O
reversed	O	O
with	O	O
uridine	O	O
and	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
but	O	O
not	O	O
with	O	O
the	O	O
corresponding	O	O
cytosine	O	O
nucleosides	O	O
.	O	O
The	O	O
synthesis	O	O
and	O	O
sigma	O	O
1	O	O
and	O	O
sigma	O	O
2	O	O
binding	O	O
properties	O	O
of	O	O
several	O	O
(	B-PARTIUPAC	O
+	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
(	B-PARTIUPAC	O
-	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	B-PARTIUPAC
2	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
benzyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylallyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
substituted	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,9	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzomorphans	I-IUPAC	I-IUPAC
(	O	O
3	O	O
and	O	O
4	O	O
)	O	O
are	O	O
presented	O	O
.	O	O
High	O	O
DAT	O	O
affinity	O	O
and	O	O
selectivity	O	O
,	O	O
increased	O	O
locomotor	O	O
activity	O	O
with	O	O
slow	O	O
onset	O	O
and	O	O
long	O	O
duration	O	O
of	O	O
action	O	O
,	O	O
and	O	O
generalization	O	O
to	O	O
cocaine	O	O
shown	O	O
by	O	O
the	O	O
3beta	B-PARTIUPAC	O
-	I-PARTIUPAC	O
(	O	O
substituted	B-MODIFIER	B-MODIFIER
phenyl	B-PARTIUPAC	B-PARTIUPAC
)	O	O
-	I-PARTIUPAC	B-PARTIUPAC
2beta	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
3	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
isoxazol	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tropanes	I-IUPAC	I-IUPAC
are	O	O
properties	O	O
thought	O	O
necessary	O	O
for	O	O
a	O	O
pharmacotherapy	O	O
for	O	O
treating	O	O
cocaine	O	O
abuse	O	O
.	O	O
Preparation	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkyloxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
(	O	O
2-4	O	O
)	O	O
derivatives	B-MODIFIER	O
was	O	O
carried	O	O
out	O	O
based	O	O
on	O	O
alkylation	O	O
of	O	O
HEPT	O	O
with	O	O
primary	O	O
alkyl	O	O
halides	O	O
.	O	O
All	O	O
three	O	O
compounds	O	O
retained	O	O
antibacterial	O	O
activity	O	O
against	O	O
several	O	O
organisms	O	O
normally	O	O
susceptible	O	O
to	O	O
(	B-IUPAC	B-IUPAC
9R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
erythromycin	I-IUPAC	I-IUPAC
A	I-IUPAC	O
.	O	O
This	O	O
process	O	O
is	O	O
characterized	O	O
by	O	O
a	O	O
transformation	O	O
of	O	O
the	O	O
conformation	O	O
of	O	O
lowest	O	O
potential	O	O
energy	O	O
to	O	O
one	O	O
with	O	O
an	O	O
energy	O	O
content	O	O
above	O	O
the	O	O
minimum	O	O
.	O	O
Compound	O	O
7	O	O
also	O	O
was	O	O
the	O	O
only	O	O
compound	O	O
which	O	O
demonstrated	O	O
significant	O	O
in	O	O
vivo	O	O
antifilarial	O	O
activity	O	O
against	O	O
the	O	O
adult	O	O
worms	O	O
of	O	O
Acanthocheilonema	O	O
viteae	O	O
in	O	O
experimentally	O	O
infected	O	O
jirds	O	O
.	O	O
Unlike	O	O
the	O	O
hydroxylated	O	O
DENSPM	O	O
compounds	O	O
,	O	O
both	O	O
cyclopropyl	O	O
norspermines	O	O
substantially	O	O
upregulated	O	O
spermidine	O	O
/	O	O
spermine	O	B-IUPAC
N	O	I-IUPAC
(	O	I-IUPAC
1	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
acetyltransferase	O	I-IUPAC
.	O	O
The	O	O
potency	O	O
of	O	O
iodoproxyfan	O	O
is	O	O
more	O	O
than	O	O
300	O	O
times	O	O
lower	O	O
at	O	O
H1	O	O
,	O	O
H2	O	O
,	O	O
alpha1	O	O
,	O	O
alpha2	O	O
,	O	O
beta1	O	O
,	O	O
5	O	O
-	O	O
HT2A	O	O
,	O	O
5	O	O
-	O	O
HT3	O	O
,	O	O
and	O	O
M3	O	O
receptors	O	O
than	O	O
at	O	O
histamine	O	O
H3	O	O
receptors	O	O
.	O	O
Debromination	O	O
of	O	O
3a	O	O
-	O	O
k	O	O
,	O	O
via	O	O
catalytic	O	O
hydrogenation	O	O
,	O	O
gave	O	O
the	O	O
corresponding	O	O
7	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonitrile	I-IUPAC	I-IUPAC
analogs	B-MODIFIER	B-MODIFIER
4a	O	O
-	O	O
j	O	O
,	O	O
l	O	O
.	O	O
Among	O	O
the	O	O
compounds	O	O
synthesized	O	O
,	O	O
N	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
3,5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
bis	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
trifluoromethyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
benzyl	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
7,8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
dihydro	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
N	I-PARTIUPAC	I-IUPAC
,	I-PARTIUPAC	I-IUPAC
7	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
dimethyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
oxo	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
substituted	B-MODIFIER	B-MODIFIER
phenyl	B-IUPAC	B-IUPAC
)	B-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
6	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
pyrido	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
3,4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
b	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
pyridinecarboxamides	I-PARTIUPAC	I-IUPAC
(	O	O
30a	O	O
,	O	O
f	O	O
,	O	O
g	O	O
)	O	O
showed	O	O
excellent	O	O
antagonist	O	O
activities	O	O
with	O	O
IC50	O	O
values	O	O
(	O	O
in	O	O
vitro	O	O
inhibition	O	O
of	O	O
[	O	O
125I	O	O
]	O	O
-	O	O
BH	O	O
-	O	O
SP	O	O
binding	O	O
in	O	O
human	O	O
IM	O	O
-	O	O
9	O	O
cells	O	O
)	O	O
of	O	O
0.21-0.34	O	O
nM	O	O
and	O	O
ED50	O	O
values	O	O
(	O	O
in	O	O
vivo	O	O
inhibition	O	O
of	O	O
capsaicin	O	O
-	O	O
induced	O	O
plasma	O	O
extravasation	O	O
in	O	O
guinea	O	O
-	O	O
pig	O	O
trachea	O	O
,	O	O
iv	O	O
)	O	O
of	O	O
0.017-0.030	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
The	O	O
inhibition	O	O
of	O	O
the	O	O
growth	O	O
of	O	O
leukemia	O	O
CCRF	O	O
-	O	O
CEM	O	O
cells	O	O
by	O	O
both	O	O
compounds	O	O
parallels	O	O
their	O	O
inhibition	O	O
of	O	O
CCRF	O	O
-	O	O
CEM	O	O
DHFR	O	O
.	O	O
On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
enantiomers	O	O
(	O	O
+	O	O
)	O	O
-	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
14b	O	O
,	O	O
(	O	O
+	O	O
)	O	O
-	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
15b	O	O
displayed	O	O
high	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
the	O	O
D1	O	O
receptor	O	O
.	O	O
Am.	O	O
Chem.	O	O
Soc	O	O
.	O	O
[	O	O
18F	O	O
]	O	O
4c	O	O
was	O	O
superior	O	O
to	O	O
[	O	O
18F	O	O
]	O	O
4b	O	O
since	O	O
its	O	O
specific	O	O
binding	O	O
was	O	O
more	O	O
readily	O	O
blocked	O	O
by	O	O
4a	O	O
.	O	O
These	O	O
nucleosides	O	O
were	O	O
evaluated	O	O
for	O	O
in	O	O
vitro	O	O
cytotoxicity	O	O
to	O	O
human	O	O
prostate	O	O
cancer	O	O
(	O	O
HTB	O	O
-	O	O
81	O	O
)	O	O
and	O	O
mouse	O	O
melanoma	O	O
(	O	O
B16	O	O
)	O	O
cells	O	O
as	O	O
well	O	O
as	O	O
normal	O	O
human	O	O
fibroblasts	O	O
(	O	O
NHF	O	O
)	O	O
.	O	O
Alkylation	O	O
of	O	O
cytosine	O	O
with	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butene	I-IUPAC	I-IUPAC
gave	O	O
chloro	O	O
derivative	O	O
2f	O	O
,	O	O
which	O	O
was	O	O
hydrolyzed	O	O
to	O	O
alcohol	O	O
2h	O	O
.	O	O
One	O	O
of	O	O
the	O	O
most	O	O
potent	O	O
DNA	O	O
-	O	O
PK	O	O
inhibitors	O	O
identified	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
morpholin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
16	O	O
;	O	O
DNA	O	O
-	O	O
PK	O	O
;	O	O
IC50	O	O
=	O	O
220	O	O
nM	O	O
)	O	O
effectively	O	O
sensitized	O	O
HeLa	O	O
cells	O	O
to	O	O
the	O	O
topoisomerase	O	O
II	O	O
inhibitor	O	O
etoposide	O	O
in	O	O
vitro	O	O
.	O	O
The	O	O
results	O	O
of	O	O
the	O	O
enzymatic	O	O
test	O	O
indicate	O	O
that	O	O
the	O	O
nitrogen	O	O
in	O	O
the	O	O
3	O	O
-	O	O
position	O	O
,	O	O
and	O	O
secondly	O	O
,	O	O
the	O	O
nitrogen	O	O
in	O	O
the	O	O
5	O	O
-	O	O
position	O	O
are	O	O
very	O	O
important	O	O
for	O	O
the	O	O
interaction	O	O
of	O	O
the	O	O
azole	O	O
ring	O	O
with	O	O
the	O	O
inhibitory	O	O
site	O	O
on	O	O
the	O	O
enzyme	O	O
.	O	O
Amidification	O	O
was	O	O
successfully	O	O
carried	O	O
out	O	O
by	O	O
condensation	O	O
of	O	O
the	O	O
corresponding	O	O
acids	O	O
or	O	O
their	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
with	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopyridine	I-IUPAC	I-IUPAC
promoted	O	O
by	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpyridinium	I-IUPAC	I-IUPAC
iodide	I-IUPAC	I-IUPAC
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Phenylethynyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyridine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
are	O	O
selective	O	O
antagonists	O	O
at	O	O
human	O	O
A3	O	O
adenosine	O	O
receptors	O	O
,	O	O
with	O	O
Ki	O	O
values	O	O
in	O	O
a	O	O
radioligand	O	O
binding	O	O
assay	O	O
vs	O	O
[	O	O
125I	O	O
]	O	O
AB	O	O
-	O	O
MECA	O	O
(	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylcarbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
)	O	O
in	O	O
the	O	O
submicromolar	O	O
range	O	O
.	O	O
We	O	O
have	O	O
now	O	O
combined	O	O
the	O	O
ring	O	O
-	O	O
constrained	O	O
(	O	O
N	O	O
)	O	O
-	O	O
methanocarba	O	O
modification	O	O
of	O	O
adenine	O	O
nucleotides	O	O
with	O	O
other	O	O
functionalities	O	O
known	O	O
to	O	O
enhance	O	O
potency	O	O
at	O	O
P2	O	O
receptors	O	O
.	O	O
The	O	O
key	O	O
intermediate	O	O
8	O	O
was	O	O
synthesized	O	O
starting	O	O
from	O	O
L	O	O
-	O	O
gulose	O	O
via	O	O
1,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thioanhydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
gulopyranose	I-IUPAC	I-IUPAC
.	O	O
In	O	O
general	O	O
,	O	O
the	O	O
vinyl	O	O
and	O	O
ethylene	O	O
bridges	O	O
yielded	O	O
the	O	O
most	O	O
potent	O	O
analogs	O	O
while	O	O
the	O	O
propylene	O	O
-	O	O
bridged	O	O
analogs	O	O
were	O	O
among	O	O
the	O	O
least	O	O
potent	O	O
compounds	O	O
.	O	O
Rearrangement	O	O
of	O	O
the	O	O
4	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
picoline	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxides	I-IUPAC	I-IUPAC
with	O	O
Ac2O	O	O
yielded	O	O
respective	O	O
methyl	O	B-IUPAC
acetates	O	I-IUPAC
,	O	O
which	O	O
upon	O	O
acid	O	O
hydrolysis	O	O
,	O	O
MnO2	O	O
oxidation	O	O
,	O	O
and	O	O
reaction	O	O
with	O	O
thiosemicarbazide	O	O
resulted	O	O
in	O	O
the	O	O
desired	O	O
compounds	O	O
.	O	O
However	O	O
,	O	O
the	O	O
most	O	O
selective	O	O
sigma	O	O
2	O	O
versus	O	O
sigma	O	O
1	O	O
ligand	O	O
was	O	O
the	O	O
tropane	O	B-IUPAC
derivative	O	B-MODIFIER
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azabicyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3.2.1	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oct	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
en	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indole	I-IUPAC	I-IUPAC
,	O	O
15a	O	O
.	O	O
New	O	O
compounds	O	O
of	O	O
the	O	O
nitroimidazole	O	O
series	O	O
have	O	O
been	O	O
synthesized	O	O
as	O	O
radiosensitizers	O	O
which	O	O
selectively	O	O
sensitize	O	O
hypoxic	O	O
cells	O	O
to	O	O
the	O	O
lethal	O	O
effect	O	O
of	O	O
radiation	O	O
.	O	O
Compound	O	O
3	O	O
was	O	O
obtained	O	O
via	O	O
a	O	O
Wittig	O	O
reaction	O	O
of	O	O
the	O	O
tributylphosphonium	O	O
salt	O	O
of	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
chloromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
furo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
and	O	O
methyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formylbenzoate	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
followed	O	O
by	O	O
reduction	O	O
and	O	O
coupling	O	O
with	O	O
the	O	O
diethyl	O	O
ester	O	O
of	O	O
L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
Each	O	O
isomer	O	O
afforded	O	O
high	O	O
yields	O	O
of	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloromethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthracene	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
on	O	O
treatment	O	O
with	O	O
hydrogen	O	O
chloride	O	O
in	O	O
ethyl	O	O
acetate	O	O
.	O	O
A	O	O
series	O	O
of	O	O
polyamines	O	O
based	O	O
on	O	O
the	O	O
high	O	O
affinity	O	O
sigma	O	O
receptor	O	O
ligand	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethylamine	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
were	O	O
developed	O	O
and	O	O
evaluated	O	O
for	O	O
their	O	O
binding	O	O
characteristics	O	O
at	O	O
sigma	O	O
-	O	O
1	O	O
and	O	O
sigma	O	O
-	O	O
2	O	O
receptor	O	O
subtypes	O	O
.	O	O
It	O	O
is	O	O
highly	O	O
likely	O	O
that	O	O
nitrogen	O	O
lone	O	O
pair	O	O
orientations	O	O
and	O	O
steric	O	O
factors	O	O
on	O	O
the	O	O
aliphatic	O	O
portions	O	O
of	O	O
these	O	O
ligands	O	O
play	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
sigma	O	O
receptor	O	O
binding	O	O
of	O	O
this	O	O
pharmacophore	O	O
.	O	O
Whereas	O	O
the	O	O
classical	O	O
GABA	O	O
uptake	O	O
inhibitor	O	O
,	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nipecotic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
nonselectively	O	O
inhibits	O	O
neuronal	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
12	O	O
microM	O	O
)	O	O
and	O	O
glial	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
16	O	O
microM	O	O
)	O	O
GABA	O	O
uptake	O	O
and	O	O
4,5,6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoxazolo	I-IUPAC	I-IUPAC
\C2	I-IUPAC	I-IUPAC
\BF	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cpyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ol	I-IUPAC	I-IUPAC
(	O	O
1	O	O
,	O	O
THPO	O	O
)	O	O
shows	O	O
some	O	O
selectivity	O	O
for	O	O
glial	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
268	O	O
microM	O	O
)	O	O
versus	O	O
neuronal	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
530	O	O
microM	O	O
)	O	O
GABA	O	O
uptake	O	O
,	O	O
exo	O	O
-	O	O
THPO	O	O
(	O	O
8	O	O
)	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
more	O	O
potent	O	O
as	O	O
an	O	O
inhibitor	O	O
of	O	O
glial	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
200	O	O
microM	O	O
)	O	O
rather	O	O
than	O	O
neuronal	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
900	O	O
microM	O	O
)	O	O
GABA	O	O
uptake	O	O
.	O	O
Carbamoylation	O	O
of	O	O
the	O	O
N	O	O
-	O	O
terminus	O	O
of	O	O
most	O	O
of	O	O
these	O	O
analogues	O	O
resulted	O	O
in	O	O
slightly	O	O
improved	O	O
affinity	O	O
,	O	O
selectivity	O	O
,	O	O
or	O	O
both	O	O
.	O	O
Synthesis	O	O
of	O	O
the	O	O
bay	O	O
region	O	O
anti	O	O
-	O	O
diol	O	O
epoxide	O	O
derivative	O	O
of	O	O
cholanthrene	O	O
,	O	O
its	O	O
putative	O	O
ultimate	O	O
carcinogenic	O	O
metabolite	O	O
,	O	O
is	O	O
also	O	O
described	O	O
.	O	O
In	O	O
the	O	O
cyclic	O	O
series	O	O
,	O	O
particularly	O	O
among	O	O
the	O	O
benzamides	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopyrrolidine	I-IUPAC	I-IUPAC
,	O	O
most	O	O
of	O	O
the	O	O
compounds	O	O
tested	O	O
were	O	O
more	O	O
active	O	O
than	O	O
the	O	O
corresponding	O	O
linear	O	O
benzamides	O	O
.	O	O
A	O	O
release	O	O
study	O	O
,	O	O
employing	O	O
calcein	O	O
encapsulated	O	O
in	O	O
non	O	B-IUPAC
-	O	I-IUPAC
hydrolyzable	O	I-IUPAC
1,2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
octadecyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sn	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glycero	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphocholine	I-IUPAC	I-IUPAC
(	O	O
D	O	O
-	O	O
O	O	O
-	O	O
SPC	O	O
)	O	O
liposomes	O	O
,	O	O
showed	O	O
that	O	O
proAELs	O	O
,	O	O
activated	O	O
by	O	O
sPLA	O	O
(	O	O
2	O	O
)	O	O
,	O	O
perturb	O	O
membranes	O	O
because	O	O
of	O	O
the	O	O
detergent	O	O
-	O	O
like	O	O
properties	O	O
of	O	O
the	O	O
released	O	O
hydrolysis	O	O
products	O	O
.	O	O
The	O	O
chlorine	O	O
-	O	O
substituted	O	O
derivatives	O	O
3f	O	O
-	O	O
i	O	O
exhibited	O	O
potent	O	O
beta	O	O
(	O	O
3	O	O
)	O	O
-	O	O
adrenoceptor	O	O
-	O	O
mediated	O	O
relaxation	O	O
of	O	O
ferret	O	O
detrusor	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.93	O	O
,	O	O
11	O	O
,	O	O
14	O	O
,	O	O
and	O	O
160	O	O
nM	O	O
)	O	O
and	O	O
higher	O	O
potency	O	O
at	O	O
beta	O	O
(	O	O
3	O	O
)	O	O
-	O	O
adrenoceptors	O	O
than	O	O
at	O	O
beta	O	O
(	O	O
1	O	O
)	O	O
or	O	O
beta	O	O
(	O	O
2	O	O
)	O	O
.	O	O
These	O	O
compounds	O	O
are	O	O
the	O	O
most	O	O
potent	O	O
inhibitors	O	O
of	O	O
the	O	O
kynurenine	O	O
-	O	O
3	O	O
-	O	O
hydroxylase	O	O
enzyme	O	O
so	O	O
far	O	O
disclosed	O	O
.	O	O
The	O	O
most	O	O
potent	O	O
compounds	O	O
were	O	O
oxidized	O	O
to	O	O
the	O	O
paramagnetic	O	O
nitroxides	O	O
and	O	O
the	O	O
latter	O	O
were	O	O
reduced	O	O
to	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
;	O	O
these	O	O
products	O	O
had	O	O
no	O	O
or	O	O
only	O	O
decreased	O	O
antiarrhythmic	O	O
effect	O	O
.	O	O
A	O	O
significant	O	O
finding	O	O
was	O	O
that	O	O
monocyclic	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxazolidinediones	I-IUPAC	I-IUPAC
provided	O	O
relatively	O	O
potent	O	O
,	O	O
nontoxic	O	O
,	O	O
broad	O	O
-	O	O
spectrum	O	O
anticonvulsants	O	O
.	O	O
After	O	O
our	O	O
discovery	O	O
that	O	O
H	O	O
-	O	O
c	O	O
[	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
Phe	O	O
-	O	O
DNal	O	O
-	O	O
Lys	O	O
-	O	O
Thr	O	O
-	O	O
Phe	O	O
-	O	O
Cys	O	O
]	O	O
-	O	O
OH	O	O
(	O	O
ODN	O	O
-	O	O
8	O	O
)	O	O
had	O	O
high	O	O
affinity	O	O
and	O	O
marginal	O	O
selectivity	O	O
for	O	O
human	O	O
sst	O	O
(	O	O
3	O	O
)	O	O
(	O	O
part	O	O
2	O	O
of	O	O
this	O	O
series	O	O
:	O	O
Erchegyi	O	O
et	O	O
al.	O	O
J	O	O
.	O	O
All	O	O
compounds	O	O
were	O	O
tested	O	O
for	O	O
their	O	O
H3	O	O
receptor	O	O
antagonist	O	O
activity	O	O
in	O	O
a	O	O
[	O	B-IUPAC
3H	O	I-IUPAC
]	O	I-IUPAC
-	O	I-IUPAC
histamine	O	I-IUPAC
-	O	O
release	O	O
assay	O	O
with	O	O
synaptosomes	O	O
from	O	O
rat	O	O
cerebral	O	O
cortex	O	O
.	O	O
Med.	O	O
Chem.	O	O
,	O	O
preceding	O	O
paper	O	O
in	O	O
this	O	O
issue	O	O
)	O	O
(	O	O
11	O	O
)	O	O
and	O	O
that	O	O
H	O	O
-	O	O
c	O	O
[	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
Phe	O	O
-	O	O
DTrp	O	O
-	O	O
Lys	O	O
-	O	O
Thr	O	O
-	O	O
Phe	O	O
-	O	O
Cys	O	O
]	O	O
-	O	O
OH	O	O
(	O	O
ODT	O	O
-	O	O
8	O	O
,	O	O
3	O	O
)	O	O
had	O	O
high	O	O
affinity	O	O
and	O	O
marginal	O	O
selectivity	O	O
for	O	O
human	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
,	O	O
that	O	O
H	O	O
-	O	O
c	O	O
[	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
Tyr	O	O
-	O	O
D	O	O
-	O	O
threo	O	O
-	O	O
beta	O	O
-	O	O
Me2Nal	O	O
-	O	O
Lys	O	O
-	O	O
Thr	O	O
-	O	O
Phe	O	O
-	O	O
Cys	O	O
]	O	O
-	O	O
OH	O	O
had	O	O
high	O	O
affinity	O	O
for	O	O
all	O	O
sst	O	O
's	O	O
except	O	O
for	O	O
sst	O	O
(	O	O
1	O	O
)	O	O
,	O	O
and	O	O
that	O	O
H	O	O
-	O	O
c	O	O
[	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
Tyr	O	O
-	O	O
L	O	O
-	O	O
threo	O	O
-	O	O
beta	O	O
-	O	O
Me2Nal	O	O
-	O	O
Lys	O	O
-	O	O
Thr	O	O
-	O	O
Phe	O	O
-	O	O
Cys	O	O
]	O	O
-	O	O
OH	O	O
had	O	O
high	O	O
affinity	O	O
for	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
2.1	O	O
nM	O	O
)	O	O
,	O	O
with	O	O
more	O	O
than	O	O
50	O	O
-	O	O
fold	O	O
selectivity	O	O
toward	O	O
the	O	O
other	O	O
receptors	O	O
(	O	O
parts	O	O
1	O	O
and	O	O
2	O	O
of	O	O
this	O	O
series	O	O
:	O	O
Rivier	O	O
et	O	O
al.	O	O
and	O	O
Erchegyi	O	O
et	O	O
al.	O	O
J	O	O
.	O	O
mol	O	O
-	O	O
1	O	O
)	O	O
between	O	O
the	O	O
most	O	O
and	O	O
the	O	O
least	O	O
favorable	O	O
conformations	O	O
.	O	O
In	O	O
the	O	O
current	O	O
study	O	O
,	O	O
a	O	O
similar	O	O
approach	O	O
was	O	O
applied	O	O
to	O	O
the	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxymethyloxyphenylalanyl	I-IUPAC	I-IUPAC
-	O	O
containing	O	O
peptide	O	O
,	O	O
which	O	O
led	O	O
to	O	O
the	O	O
preparation	O	O
of	O	O
monomeric	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxymethyloxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
900	O	O
microM	O	O
)	O	O
.	O	O
cruzi	O	O
,	O	O
with	O	O
either	O	O
trypanothione	O	O
disulfide	O	O
or	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyloxycarbonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cysteinylglycyl	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylaminopropylamide	I-IUPAC	I-IUPAC
disulfide	I-IUPAC	I-IUPAC
as	O	O
substrate	O	O
.	O	O
The	O	O
m	O	B-IUPAC
-	O	I-IUPAC
fluorophenylalanine	O	I-IUPAC
analog	O	B-MODIFIER
demonstrated	O	O
the	O	O
best	O	O
delta	O	O
binding	O	O
of	O	O
the	O	O
group	O	O
,	O	O
with	O	O
a	O	O
Ki	O	O
of	O	O
4.79	O	O
nM	O	O
.	O	O
Both	O	O
the	O	O
t	O	O
-	O	O
Hpp1	O	O
and	O	O
c	O	O
-	O	O
Hpp1	O	O
analogues	O	O
displayed	O	O
delta	O	O
receptor	O	O
binding	O	O
affinity	O	O
similar	O	O
to	O	O
the	O	O
parent	O	O
Tyr1	O	O
-	O	O
containing	O	O
peptide	O	O
,	O	O
while	O	O
the	O	O
D	O	O
-	O	O
Hat1	O	O
,	O	O
L	O	O
-	O	O
Hat1	O	O
,	O	O
and	O	O
L	O	O
-	O	O
Hai1	O	O
analogues	O	O
exhibited	O	O
somewhat	O	O
lower	O	O
affinity	O	O
.	O	O
In	O	O
fact	O	O
,	O	O
the	O	O
pyrazole	O	O
and	O	O
the	O	O
2	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
1,2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
triazole	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
(	O	O
10	O	O
and	O	O
15	O	O
,	O	O
respectively	O	O
)	O	O
are	O	O
nearly	O	O
inactive	O	O
,	O	O
whereas	O	O
the	O	O
erythro	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazole	I-IUPAC	I-IUPAC
(	O	O
18e	O	O
)	O	O
was	O	O
the	O	O
most	O	O
potent	O	O
ADA	O	O
inhibitor	O	O
in	O	O
the	O	O
series	O	O
with	O	O
Ki	O	O
=	O	O
0.3	O	O
microM	O	O
.	O	O
THMNDs	O	O
were	O	O
prepared	O	O
via	O	O
a	O	O
Diels	O	O
-	O	O
Alder	O	O
reaction	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzoquinone	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
or	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzoquinone	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
and	O	O
substituted	B-MODIFIER	B-MODIFIER
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butadienes	I-IUPAC	I-IUPAC
.	O	O
The	O	O
present	O	O
work	O	O
reports	O	O
the	O	O
synthesis	O	O
of	O	O
enantiomeric	O	O
pairs	O	O
of	O	O
the	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indene	I-IUPAC	I-IUPAC
[	O	O
(	O	O
+	O	O
)	O	O
-	O	O
14a	O	O
,	O	O
(	O	O
-	O	O
)	O	O
-	O	O
14a	O	O
]	O	O
and	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indene	I-IUPAC	I-IUPAC
[	O	O
(	O	O
+	O	O
)	O	O
-	O	O
14b	O	O
,	O	O
(	O	O
-	O	O
)	O	O
-	O	O
14b	O	O
]	O	O
and	O	O
their	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
[	O	B-PARTIUPAC
(	O	I-PARTIUPAC
+	O	I-PARTIUPAC
)	O	I-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
15a	O	O
,	O	O
b	O	O
]	O	O
,	O	O
N	B-IUPAC	B-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
methyl	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
N	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
allyl	I-IUPAC	I-PARTIUPAC
[	O	I-PARTIUPAC
(	O	I-PARTIUPAC
+	O	I-PARTIUPAC
)	O	I-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
16a	O	O
,	O	O
b	O	O
]	O	O
,	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
[	O	O
(	O	O
+	O	O
)	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
17a	O	O
,	O	O
b	O	O
]	O	O
derivatives	B-MODIFIER	O
obtained	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
stereospecific	O	O
reactions	O	O
and	O	O
optical	O	O
resolution	O	O
.	O	O
Methylation	O	O
of	O	O
the	O	O
hydroxyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
HEPT	O	O
did	O	O
not	O	O
affect	O	O
the	O	O
anti	O	O
-	O	O
HIV	O	O
-	O	O
1	O	O
activity	O	O
of	O	O
HEPT	O	O
.	O	O
As	O	O
a	O	O
continuation	O	O
of	O	O
our	O	O
earlier	O	O
study	O	O
(	O	O
J	O	O
.	O	O
The	O	O
metabolic	O	O
fate	O	O
of	O	O
tolazamide	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hexahydroazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tolylsulfonylurea	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
,	O	O
was	O	O
studied	O	O
in	O	O
man	O	O
and	O	O
in	O	O
the	O	O
rat	O	O
using	O	O
tritium	O	O
-	O	O
labeled	O	O
1	O	O
.	O	O
Condensation	O	O
of	O	O
compounds	O	O
32	O	O
and	O	O
39	O	O
with	O	O
thiosemicarbazide	O	O
afforded	O	O
the	O	O
respective	O	O
4	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
5	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
acetoxy	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	O
5	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
4	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
methyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
thiosemicarbazones	I-PARTIUPAC	I-IUPAC
33	O	O
and	O	O
40	O	O
,	O	O
which	O	O
were	O	O
then	O	O
converted	O	O
to	O	O
their	O	O
respective	O	O
4	O	O
-	O	O
and	O	O
5	O	B-IUPAC
-	O	I-IUPAC
hydroxy	O	I-IUPAC
derivatives	O	B-MODIFIER
34	O	O
and	O	O
41	O	O
by	O	O
acid	O	O
hydrolysis	O	O
.	O	O
Its	O	O
efficiency	O	O
in	O	O
inhibition	O	O
of	O	O
microvascular	O	O
permeability	O	O
was	O	O
assessed	O	O
in	O	O
two	O	O
rhinitis	O	O
models	O	O
;	O	O
ovalbumin	O	O
and	O	O
capsaicin	O	O
-	O	O
induced	O	O
rhinorrhea	O	O
could	O	O
be	O	O
prevented	O	O
after	O	O
topical	O	O
application	O	O
of	O	O
submicromolar	O	O
concentrations	O	O
of	O	O
45	O	O
(	O	O
IC50	O	O
=	O	O
0.25	O	O
and	O	O
0.30	O	O
microM	O	O
)	O	O
;	O	O
and	O	O
it	O	O
also	O	O
exerted	O	O
significant	O	O
inhibitory	O	O
effect	O	O
in	O	O
the	O	O
first	O	O
test	O	O
after	O	O
iv	O	O
and	O	O
oral	O	O
administration	O	O
,	O	O
with	O	O
ID50	O	O
=	O	O
0.005	O	O
and	O	O
0.46	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
The	O	O
three	O	O
compounds	O	O
AMPA	O	O
,	O	O
ATPA	O	O
,	O	O
and	O	O
ABPA	O	O
are	O	O
agonists	O	O
at	O	O
the	O	O
class	O	O
of	O	O
receptors	O	O
assumed	O	O
to	O	O
represent	O	O
a	O	O
subtype	O	O
of	O	O
physiological	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
Glu	O	O
)	O	O
receptors	O	O
.	O	O
Several	O	O
of	O	O
these	O	O
compounds	O	O
,	O	O
such	O	O
as	O	O
6b	O	O
,	O	O
e	O	O
,	O	O
were	O	O
particularly	O	O
interesting	O	O
inhibitors	O	O
of	O	O
HCMV	O	O
with	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
's	O	O
ranging	O	O
from	O	O
0.1	O	O
to	O	O
1.3	O	O
muM	O	O
.	O	O
The	O	O
structural	O	O
features	O	O
of	O	O
5	O	O
may	O	O
well	O	O
reflect	O	O
optimal	O	O
agonist	O	O
interaction	O	O
at	O	O
the	O	O
NMDA	O	O
receptor	O	O
site	O	O
.	O	O
They	O	O
inhibited	O	O
the	O	O
growth	O	O
of	O	O
Gram	O	O
-	O	O
positive	O	O
bacteria	O	O
and	O	O
pathogenic	O	O
fungi	O	O
at	O	O
MIC	O	O
range	O	O
3	O	O
x	O	O
10	O	O
(	O	O
-	O	O
2	O	O
)	O	O
to	O	O
2.5	O	O
x	O	O
10	O	O
(	O	O
-	O	O
1	O	O
)	O	O
mumol	O	O
/	O	O
mL	O	O
,	O	O
displayed	O	O
cytotoxicity	O	O
against	O	O
KB	O	O
cells	O	O
ID50	O	O
in	O	O
the	O	O
range	O	O
2	O	O
x	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
to	O	O
9	O	O
x	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
mumol	O	O
/	O	O
mL	O	O
,	O	O
and	O	O
stimulated	O	O
the	O	O
formation	O	O
of	O	O
calf	O	O
thymus	O	O
topoisomerase	O	O
II	O	O
mediated	O	O
DNA	O	O
cleavage	O	O
at	O	O
concentration	O	O
between	O	O
0.4	O	O
and	O	O
10	O	O
microM	O	O
.	O	O
Nineteen	O	O
previously	O	O
undescribed	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6,7	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroquinazolines	I-IUPAC	I-IUPAC
(	O	O
5a	O	O
-	O	O
m	O	O
,	O	O
10-12	O	O
)	O	O
were	O	O
synthesized	O	O
as	O	O
part	O	O
of	O	O
a	O	O
larger	O	O
effort	O	O
to	O	O
assess	O	O
the	O	O
therapeutic	O	O
potential	O	O
of	O	O
lipophilic	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
inhibitors	O	O
against	O	O
opportunistic	O	O
infections	O	O
of	O	O
AIDS	O	O
.	O	O
Following	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
and	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxyl	I-IUPAC	I-IUPAC
deprotections	B-MODIFIER	B-MODIFIER
of	O	O
11	O	O
and	O	O
12	O	O
,	O	O
EEDQ	O	O
[	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroquinoline	I-IUPAC	I-IUPAC
]	O	O
mediated	O	O
peptide	O	O
coupling	O	O
and	O	O
final	O	O
deprotection	O	O
provided	O	O
amino	O	O
acid	O	O
1	O	O
and	O	O
six	O	O
albomycin	O	O
-	O	O
like	O	O
peptides	O	O
(	O	O
20	O	O
,	O	O
23	O	O
,	O	O
25	O	O
,	O	O
28	O	O
,	O	O
35	O	O
,	O	O
and	O	O
36	O	O
)	O	O
.	O	O
It	O	O
is	O	O
known	O	O
that	O	O
the	O	O
HCV	O	O
-	O	O
E2	O	O
envelope	O	O
glycoprotein	O	O
binds	O	O
to	O	O
the	O	O
CD81	O	O
protein	O	O
.	O	O
With	O	O
a	O	O
benzoic	O	O
acid	O	O
group	O	O
as	O	O
part	O	O
of	O	O
the	O	O
structure	O	O
attached	O	O
to	O	O
the	O	O
thiochroman	O	O
unit	O	O
,	O	O
the	O	O
ODC	O	O
activity	O	O
was	O	O
enhanced	O	O
as	O	O
shown	O	O
in	O	O
10	O	O
and	O	O
11	O	O
.	O	O
CD81	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
tetraspanin	O	O
family	O	O
of	O	O
membrane	O	O
proteins	O	O
found	O	O
in	O	O
all	O	O
cell	O	O
lineages	O	O
in	O	O
the	O	O
liver	O	O
.	O	O
The	O	O
conformational	O	O
properties	O	O
of	O	O
the	O	O
parent	O	O
tetrapeptide	O	O
and	O	O
the	O	O
residue	O	O
1	O	O
-	O	O
modified	O	O
analogues	O	O
were	O	O
studied	O	O
by	O	O
molecular	O	O
mechanics	O	O
computations	O	O
.	O	O
As	O	O
part	O	O
of	O	O
an	O	O
effort	O	O
to	O	O
develop	O	O
a	O	O
new	O	O
class	O	O
of	O	O
subtype	O	O
selective	O	O
nicotine	O	O
agonists	O	O
,	O	O
we	O	O
have	O	O
synthesized	O	O
and	O	O
tested	O	O
a	O	O
group	O	O
of	O	O
12	O	B-PARTIUPAC
hydroxylated	O	I-PARTIUPAC
2	B-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
2	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
piperidyl	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
chromans	I-IUPAC	I-IUPAC
.	O	O
Compound	O	O
48	O	O
sensitized	O	O
the	O	O
HeLa	O	O
human	O	O
tumor	O	O
cell	O	O
line	O	O
to	O	O
the	O	O
cytotoxic	O	O
effects	O	O
of	O	O
ionizing	O	O
radiation	O	O
in	O	O
vitro	O	O
,	O	O
a	O	O
dose	O	O
modification	O	O
factor	O	O
of	O	O
2.3	O	O
at	O	O
10%	O	O
survival	O	O
being	O	O
observed	O	O
with	O	O
an	O	O
inhibitor	O	O
concentration	O	O
of	O	O
5	O	O
microM	O	O
.	O	O
Based	O	O
on	O	O
these	O	O
studies	O	O
,	O	O
one	O	O
compound	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
65	O	O
)	O	O
,	O	O
was	O	O
selected	O	O
for	O	O
preclinical	O	O
toxicity	O	O
evaluation	O	O
.	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbamyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
norapocodeine	I-IUPAC	I-IUPAC
(	O	O
1g	O	O
)	O	O
and	O	O
its	O	O
11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbamyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	O	O
1h	O	O
)	O	O
were	O	O
also	O	O
prepared	O	O
.	O	O
To	O	O
provide	O	O
a	O	O
direct	O	O
and	O	O
quantitative	O	O
assessment	O	O
of	O	O
the	O	O
contributions	O	O
of	O	O
several	O	O
conserved	O	O
residues	O	O
around	O	O
the	O	O
binding	O	O
site	O	O
to	O	O
PKC	O	O
-	O	O
ligand	O	O
binding	O	O
,	O	O
we	O	O
have	O	O
made	O	O
11	O	O
mutations	O	O
and	O	O
measured	O	O
the	O	O
binding	O	O
affinities	O	O
of	O	O
the	O	O
high	O	O
-	O	O
affinity	O	O
PKC	O	O
ligands	O	O
to	O	O
these	O	O
mutants	O	O
.	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyamidino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nicotinamidine	I-IUPAC	I-IUPAC
(	O	O
6a	O	O
)	O	O
was	O	O
prepared	O	O
via	O	O
methylation	O	O
of	O	O
the	O	O
respective	O	O
diamidoxime	O	O
5a	O	O
with	O	O
dimethylsulfate	O	O
.	O	O
Each	O	O
target	O	O
compound	O	O
was	O	O
obtained	O	O
in	O	O
five	O	O
steps	O	O
starting	O	O
from	O	O
cyclopent	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enone	I-IUPAC	I-IUPAC
.	O	O
;	O	O
Hurley	O	O
,	O	O
L	O	O
.	O	O
The	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoromuscarines	I-IUPAC	I-IUPAC
display	O	O
a	O	O
similar	O	O
trend	O	O
of	O	O
potency	O	O
as	O	O
the	O	O
corresponding	O	O
muscarines	O	O
and	O	O
compound	O	O
1a	O	O
shows	O	O
differences	O	O
in	O	O
the	O	O
affinity	O	O
constants	O	O
among	O	O
the	O	O
studied	O	O
tissues	O	O
.	O	O
The	O	O
unselective	O	O
excitatory	O	O
amino	O	O
acid	O	O
activity	O	O
of	O	O
21	O	O
is	O	O
comparable	O	O
with	O	O
6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinoxaline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
and	O	O
6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloroquinoxalic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
and	O	O
this	O	O
suggests	O	O
similarities	O	O
in	O	O
their	O	O
modes	O	O
of	O	O
binding	O	O
to	O	O
excitatory	O	O
amino	O	O
acid	O	O
receptors	O	O
.	O	O
The	O	O
effectiveness	O	O
of	O	O
inhibition	O	O
was	O	O
reduced	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
size	O	O
of	O	O
the	O	O
halogen	O	O
atom	O	O
.	O	O
The	O	O
2	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
histamine	O	B-IUPAC
analogues	O	B-MODIFIER
were	O	O
partial	O	O
H1	O	O
receptor	O	O
agonists	O	O
on	O	O
the	O	O
endothelium	O	O
-	O	O
denuded	O	O
isolated	O	O
guinea	O	O
pig	O	O
aorta	O	O
with	O	O
pEC50	O	O
values	O	O
generally	O	O
smaller	O	O
than	O	O
observed	O	O
on	O	O
the	O	O
guinea	O	O
pig	O	O
ileum	O	O
,	O	O
but	O	O
the	O	O
rank	O	O
order	O	O
of	O	O
potency	O	O
was	O	O
found	O	O
to	O	O
be	O	O
similar	O	O
.	O	O
Affinities	O	O
ranged	O	O
from	O	O
582	O	O
nM	O	O
[	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
9	O	O
]	O	O
to	O	O
29,000	O	O
nM	O	O
[	O	O
(	O	O
+	O	O
)	O	O
-	O	O
8	O	O
]	O	O
at	O	O
PCP	O	O
binding	O	O
sites	O	O
and	O	O
from	O	O
1130	O	O
nM	O	O
[	O	O
(	O	O
-	O	O
)	O	O
-	O	O
8	O	O
]	O	O
to	O	O
16,300	O	O
nM	O	O
(	O	O
7	O	O
)	O	O
at	O	O
sigma	O	O
sites	O	O
.	O	O
As	O	O
far	O	O
as	O	O
the	O	O
potency	O	O
at	O	O
the	O	O
A	O	O
(	O	O
2B	O	O
)	O	O
receptor	O	O
,	O	O
the	O	O
type	O	O
of	O	O
2	O	B-IUPAC
-	O	I-IUPAC
alkynyl	O	I-IUPAC
chain	O	B-MODIFIER
and	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
ethylcarboxamido	O	O
group	O	O
on	O	O
the	O	O
sugar	O	O
seem	O	O
to	O	O
be	O	O
very	O	O
important	O	O
;	O	O
in	O	O
fact	O	O
,	O	O
the	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylhydroxypropynyl	I-IUPAC	I-IUPAC
NECA	O	O
[	O	O
(	O	O
S	O	O
)	O	O
-	O	O
PHPNECA	O	O
,	O	O
1e	O	O
,	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
(	O	O
A	O	O
(	O	O
2B	O	O
)	O	O
)	O	O
=	O	O
0.22	O	O
microM	O	O
]	O	O
proved	O	O
to	O	O
be	O	O
one	O	O
of	O	O
the	O	O
most	O	O
potent	O	O
A	O	O
(	O	O
2B	O	O
)	O	O
agonist	O	O
reported	O	O
so	O	O
far	O	O
.	O	O
The	O	O
compounds	O	O
also	O	O
were	O	O
less	O	O
active	O	O
against	O	O
human	O	O
cytomegalovirus	O	O
(	O	O
HCMV	O	O
)	O	O
and	O	O
herpes	O	O
simplex	O	O
virus	O	O
type	O	O
1	O	O
(	O	O
HSV	O	O
-	O	O
1	O	O
)	O	O
.	O	O
Alternatively	O	O
,	O	O
the	O	O
above	O	O
-	O	O
indicated	O	O
compounds	O	O
were	O	O
prepared	O	O
from	O	O
amines	O	O
and	O	O
17	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
keto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azasteroids	I-IUPAC	I-IUPAC
to	O	O
form	O	O
imines	O	O
,	O	O
which	O	O
were	O	O
then	O	O
reduced	O	O
with	O	O
NaBH4	O	O
.	O	O
Certain	O	O
novel	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydronaphthalenes	I-IUPAC	I-IUPAC
(	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminotetralins	I-IUPAC	I-IUPAC
,	O	O
PATs	O	O
)	O	O
produced	O	O
stimulation	O	O
(	O	O
ca.	O	O
30%	O	O
above	O	O
basal	O	O
levels	O	O
)	O	O
of	O	O
tyrosine	O	O
hydroxylase	O	O
(	O	O
TH	O	O
)	O	O
activity	O	O
at	O	O
0.1	O	O
microM	O	O
concentrations	O	O
in	O	O
rodent	O	O
brain	O	O
tissue	O	O
.	O	O
A	O	O
library	O	O
of	O	O
compounds	O	O
were	O	O
prepared	O	O
by	O	O
reacting	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzisothiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxide	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
with	O	O
commercially	O	O
available	O	O
carboxylic	O	O
acids	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
potassium	O	O
carbonate	O	O
or	O	O
a	O	O
tertiary	O	O
amine	O	O
base	O	O
.	O	O
In	O	O
order	O	O
to	O	O
selectively	O	O
determine	O	O
affinities	O	O
for	O	O
the	O	O
high	O	O
-	O	O
affinity	O	O
agonist	O	O
binding	O	O
site	O	O
at	O	O
DA	O	O
D2	O	O
receptors	O	O
,	O	O
the	O	O
agonist	O	O
[	O	O
3H	O	O
]	O	O
quinpirole	O	O
was	O	O
used	O	O
.	O	O
In	O	O
this	O	O
case	O	O
,	O	O
highest	O	O
inhibitory	O	O
activity	O	O
was	O	O
obtained	O	O
by	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
decyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylpropanamid	I-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
(	O	O
65	O	O
)	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
aralkyl	B-IUPAC	O
,	O	O
alkyl	B-IUPAC	O
,	O	O
and	O	O
cycloalkyl	B-IUPAC	O
carboxylates	B-IUPAC	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
piperidinol	I-IUPAC	I-IUPAC
system	B-MODIFIER	B-MODIFIER
and	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxybenzoates	I-IUPAC	I-IUPAC
of	O	O
isomeric	O	O
piperidinols	O	O
(	O	O
24-26	O	O
)	O	O
were	O	O
synthesized	O	O
.	O	O
The	O	O
toxicity	O	O
of	O	O
2,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylacetaminophen	I-IUPAC	I-IUPAC
and	O	O
3,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylacetaminophen	I-IUPAC	I-IUPAC
was	O	O
examined	O	O
histologically	O	O
in	O	O
mice	O	O
and	O	O
rats	O	O
.	O	O
In	O	O
the	O	O
new	O	O
orientation	O	O
,	O	O
the	O	O
naphthyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
,	O	O
and	O	O
not	O	O
the	O	O
o	B-IUPAC	O
-	I-IUPAC	O
carboxy	I-IUPAC	O
carboxymethyloxy	I-IUPAC	O
groups	B-MODIFIER	O
,	O	O
mimics	O	O
a	O	O
phosphoryl	O	O
group	O	O
.	O	O
By	O	O
contrast	O	O
,	O	O
compound	O	O
17	O	O
might	O	O
be	O	O
partial	O	O
agonist	O	O
at	O	O
the	O	O
purinergic	O	O
inhibitory	O	O
(	O	O
A1	O	O
)	O	O
receptor	O	O
.	O	O
administration	O	O
of	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
and	O	O
also	O	O
provided	O	O
100%	O	O
inhibition	O	O
of	O	O
PAF	O	O
-	O	O
induced	O	O
aggregation	O	O
in	O	O
dog	O	O
whole	O	O
blood	O	O
6	O	O
h	O	O
after	O	O
i	O	O
.	O	O
A	O	O
number	O	O
of	O	O
N	B-IUPAC	O
,	I-IUPAC	O
N	I-IUPAC	O
:	I-IUPAC	O
N'	I-IUPAC	O
,	I-IUPAC	O
N'	I-IUPAC	O
:	I-IUPAC	O
N	I-IUPAC	O
"	I-IUPAC	O
,	I-IUPAC	O
N	I-IUPAC	B-IUPAC
"	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethanediylphosphoric	I-IUPAC	I-IUPAC
triamide	I-IUPAC	I-IUPAC
(	O	O
TEPA	O	O
)	O	O
and	O	O
N	B-IUPAC	O
,	I-IUPAC	O
N	I-IUPAC	O
:	I-IUPAC	O
N'	I-IUPAC	O
,	I-IUPAC	O
N'	I-IUPAC	O
:	I-IUPAC	O
N	I-IUPAC	O
"	I-IUPAC	O
,	I-IUPAC	O
N	I-IUPAC	B-IUPAC
"	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethanediylphosphorothioic	I-IUPAC	I-IUPAC
triamide	I-IUPAC	I-IUPAC
(	O	O
thio	O	O
-	O	O
TEPA	O	O
)	O	O
derivatives	O	O
containing	O	O
either	O	O
two	O	O
aziridine	B-IUPAC	O
moieties	B-MODIFIER	O
(	O	O
1a	O	O
)	O	O
or	O	O
two	O	B-IUPAC
(	B-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
functions	B-MODIFIER	B-MODIFIER
(	O	O
1b	O	O
)	O	O
and	O	O
either	O	O
a	O	O
2,2,6,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetramethylpiperidine	I-IUPAC	I-IUPAC
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,2,6,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetramethylpiperidine	I-IUPAC	I-IUPAC
or	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,2,6,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetramethylpiperidine	I-IUPAC	I-IUPAC
component	B-MODIFIER	B-MODIFIER
were	O	O
synthesized	O	O
and	O	O
tested	O	O
against	O	O
lymphocytic	O	O
leukemia	O	O
P388	O	O
in	O	O
mice	O	O
.	O	O
A	O	O
broad	O	O
screening	O	O
of	O	O
phytochemicals	O	O
has	O	O
demonstrated	O	O
that	O	O
certain	O	O
flavone	O	O
and	O	O
flavonol	O	O
derivatives	O	O
have	O	O
a	O	O
relatively	O	O
high	O	O
affinity	O	O
at	O	O
A3	O	O
adenosine	O	O
receptors	O	O
,	O	O
with	O	O
Ki	O	O
values	O	O
of	O	O
&	O	O
gt	O	O
;	O	O
or	O	O
=	O	O
1	O	O
microM	O	O
(	O	O
Ji	O	O
et	O	O
al.	O	O
J	O	O
.	O	O
Compound	O	O
139	O	O
,	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxadiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phthalazineacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
with	O	O
IC50	O	O
less	O	O
than	O	O
1.0	O	O
x	O	O
10	O	O
(	O	O
-	O	O
8	O	O
)	O	O
M	O	O
,	O	O
caused	O	O
a	O	O
69%	O	O
reduction	O	O
in	O	O
sorbitol	O	O
accumulation	O	O
in	O	O
rat	O	O
sciatic	O	O
nerve	O	O
at	O	O
an	O	O
oral	O	O
dose	O	O
of	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
Acta	O	O
1972	O	O
,	O	O
284	O	O
,	O	O
427-434	O	O
.	O	O
The	O	O
inactive	O	O
isomeric	O	O
indolones	O	O
38	O	O
,	O	O
39	O	O
,	O	O
and	O	O
41	O	O
were	O	O
derived	O	O
from	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nitrobenzeneethanamine	I-IUPAC	I-IUPAC
and	O	O
from	O	O
indolone	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
High	O	O
-	O	O
affinity	O	O
compounds	O	O
with	O	O
high	O	O
selectivity	O	O
for	O	O
the	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
were	O	O
found	O	O
among	O	O
structures	O	O
substituted	O	O
with	O	O
carboxylate	O	O
esters	O	O
,	O	O
amides	O	O
,	O	O
and	O	O
ketones	O	O
in	O	O
the	O	O
5	O	O
-	O	O
position	O	O
.	O	O
Saturation	O	O
of	O	O
the	O	O
double	O	O
bond	O	O
of	O	O
some	O	O
pyrroline	B-IUPAC	O
derivatives	B-MODIFIER	O
furnished	O	O
the	O	O
pyrrolidinecarboxamides	O	O
.	O	O
It	O	O
decreased	O	O
the	O	O
basal	O	O
[	O	O
35S	O	O
]	O	O
GTP	O	O
gamma	O	O
S	O	O
binding	O	O
and	O	O
potently	O	O
inhibited	O	O
the	O	O
DA	O	O
-	O	O
stimulated	O	O
[	O	O
35S	O	O
]	O	O
GTP	O	O
gamma	O	O
S	O	O
binding	O	O
.	O	O
Crystallization	O	O
of	O	O
the	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mandelate	I-IUPAC	I-IUPAC
salt	I-IUPAC	O
afforded	O	O
(	O	O
1R	O	O
,	O	O
2R	O	O
,	O	O
5S	O	O
)	O	O
-	O	O
(	O	O
-	O	O
)	O	O
-	O	O
16	O	O
,	O	O
whereas	O	O
the	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mandelate	I-IUPAC	I-IUPAC
salt	I-IUPAC	O
afforded	O	O
(	O	O
1S	O	O
,	O	O
2S	O	O
,	O	O
5R	O	O
)	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
16	O	O
;	O	O
the	O	O
absolute	O	O
configuration	O	O
was	O	O
determined	O	O
by	O	O
single	O	O
-	O	O
crystal	O	O
X	O	O
-	O	O
ray	O	O
analysis	O	O
of	O	O
(	B-IUPAC	O
-	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
16	I-IUPAC	O
.	I-IUPAC	O
For	O	O
example	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylguanidine	I-IUPAC	I-IUPAC
(	O	O
40	O	O
)	O	O
showed	O	O
high	O	O
affinity	O	O
for	O	O
the	O	O
NMDA	O	O
receptor	O	O
ion	O	O
channel	O	O
site	O	O
(	O	O
IC50	O	O
=	O	O
36	O	O
nM	O	O
vs	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
3	O	O
)	O	O
and	O	O
low	O	O
affinity	O	O
for	O	O
sigma	O	O
receptors	O	O
(	O	O
IC50	O	O
=	O	O
2540	O	O
nM	O	O
vs	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
5	O	O
)	O	O
.	O	O
2	B-PARTIUPAC	O
-	I-PARTIUPAC	O
Fluoro	I-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
5	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
fluoro	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorodimethoxybenzaldehydes	I-IUPAC	I-IUPAC
were	O	O
prepared	O	O
by	O	O
photochemical	O	O
decomposition	O	O
of	O	O
the	O	O
corresponding	O	O
diazonium	O	O
fluoroborates	O	O
.	O	O
The	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
compounds	B-MODIFIER	B-MODIFIER
5	O	O
and	O	O
6	O	O
were	O	O
as	O	O
potent	O	O
inhibitors	O	O
of	O	O
DHFR	O	O
from	O	O
L1210	O	O
cells	O	O
as	O	O
MTX	O	O
and	O	O
7	O	O
-	O	O
and	O	O
35	O	O
-	O	O
fold	O	O
,	O	O
respectively	O	O
,	O	O
more	O	O
inhibitory	O	O
than	O	O
MTX	O	O
toward	O	O
L1210	O	O
cell	O	O
growth	O	O
.	O	O
The	O	O
introduction	O	O
of	O	O
a	O	O
cycloaliphatic	O	O
five	O	O
-	O	O
or	O	O
six	O	O
-	O	O
membered	O	O
ring	O	O
fused	O	O
at	O	O
the	O	O
thiophene	O	O
was	O	O
favorable	O	O
for	O	O
CEase	O	O
inhibition	O	O
.	O	O
N	B-IUPAC	O
-	I-IUPAC	O
Bromosuccinimide	I-IUPAC	O
treatment	O	O
of	O	O
13	O	O
,	O	O
20	O	O
,	O	O
and	O	O
25	O	O
afforded	O	O
the	O	O
3	B-IUPAC	O
-	I-IUPAC	O
bromo	I-IUPAC	O
derivatives	B-MODIFIER	O
15	O	O
,	O	O
21	O	O
,	O	O
and	O	O
25	O	O
.	O	O

